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ABSTRACT 
 
 
Introduction: Breast cancer is the leading cancer in women in South Africa (SA). Triple 
negative breast cancer (TNBC) is clinically characterised by the lack of expression of 
estrogen, progesterone and HER2/NEU receptors. These breast cancers occur frequently in 
young African women and are associated with aggressive disease progression, poor prognosis 
and BRCA1 mutations. TN patients with operable tumours may undergo surgery under 
general anaesthetics. Treatment of TNBC poses a clinical challenge as these tumours are 
unresponsive to hormonal or HER2 targeted therapy. Defects in BRCA1 and other DNA repair 
genes contribute to chromosomal instability and radiosensitivity and cause irregularities in the 
cell cycle checkpoints in the S/G2 phase.  
Studies have shown the overlap of breast cancer susceptibility genes and Fanconi Anaemia 
(FA) genes. FA is an autosomal recessive disorder defined by cellular hypersensitivity to 
DNA cross-linking agents such as mitomycin C (MMC) and defects in DNA repair genes. FA 
patients are known to be radiosensitive and have defects with DNA repair. These patients are 
at high risk to develop leukaemia and solid tumours that may require radiotherapy. Diagnosis 
of FA patients often includes detecting chromosomal aberrations induced by a cross-linking 
agent. Molecular tests are also conducted to identify mutations in FA genes. It has previously 
been shown that FA patients undergoing radiotherapy display increased clinical 
radiosensitivity. Evidence suggests that FA patients are chromosomally radiosensitive to 
ionising radiation (IR).  
Chromosomal radiosensitivity can be evaluated using the cytokinesis-block micronucleus 
(CBMN) assay in different phases of the cell cycle. Micronuclei (MNi) serve as biomarkers 
for radiation-induced DNA damage repair and defects in DNA repair mechanisms can be 
reflected in chromosomal radiosensitivity. A number of factors could influence the MNi yield 
such as storage time and temperature, and cytotoxic agents such as anaesthetics. As 
radiotherapy is considered a principle treatment in the management of TNBC, it is important 
to investigate in vitro chromosomal radiosensitivity of South African TN breast cancer 
patients. Chromosomal instability and radiosensitivity of FA patients has previously not been 
investigated in SA. The overall aim of this study was to investigate chromosomal instability 
and radiosensitivity of lymphocytes in South African breast cancer patients, FA patients and 
parents compared to healthy individuals using the G0 and S/G2 CBMN assay. The effect of 
age, ethnicity and mutations in breast cancer susceptibility genes was also investigated. 
Furthermore, storage time and effect of anaesthetics on MNi yield was investigated. 
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Methods: For the G0 MN assay, heparinised blood in culture medium was irradiated at 0Gy 
(Baseline), 2 and 4 Gy followed by the immediate stimulation of lymphocytes using 
phytohaemagglutinin (PHA). Cytochalasin B was added 23 hours later to inhibit cell division. 
The S/G2 MN assay is a modified version of the G0 MN assay. In this assay, the cultures are 
first stimulated with PHA and irradiated 72 hours post stimulation. Eight hours post 
irradiation cells were fixed. The Mitomycin C (MMC) MN assay is similar to the G0 MN 
assay except the DNA damage is induced using MMC. 
 
Results: Chromosomal instability is significantly elevated in TNBC, young and older breast 
cancer patients. Radiation-induced MN values in the G0 MN assay are significantly enhanced 
in a total unselected group of breast cancer patients compared to healthy individuals. 
However, when subdividing the breast cancer patients in a TNBC group, the enhanced 
radiation-induced MNi are not observed. We cannot demonstrate a correlation between the 
age of the patients and chromosomal radiosensitivity but an effect of ethnicity is noted in our 
breast cancer population. In the S/G2 MN assay, TNBC patients continued to exhibit a 
decreased chromosomal radiosensitivity. We also demonstrated that increased storage time 
can influence MNi yields in patients and controls; anaesthetics influenced spontaneous MNi 
yields. 
The FA patients in our study demonstrate higher MNi when compared to parents and controls 
indicating chromosomal instability and chromosomal radiosensitivity in the G0 as well as in 
the S/G2 phase of the cell cycle. This is not seen in the FA heterozygotes. With the MMC 
assay, the detection of significantly higher MN is noted in as well the FA patients as well as 
the FA carriers. 
 
Conclusions: Chromosomal instability and radiosensitivity of breast cancer and FA patients 
are notably higher when compared to healthy individuals. The association of BRCA 
mutations in TN and young patients highlight the importance of radiosensitivity information 
in the understudied SA population. FA carriers can be at risk for breast cancer with mutations 
associated with breast cancer susceptibility genes. As a functional assay, the MMC MN assay 
will be useful in the identification of FA carriers who may be at risk of breast cancer. Data on 
radiosensitivity of patients with defects in DNA repair genes could provide important 
information for radiotherapy management of cancer.  
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1. Breast cancer 
 
Breast cancer is a heterogeneous and multifactorial disease. It can be attributed to various 
alterations in the genome, including amplification or deletions of genes, insertions, translocation 
and chromosomal aberrations. Such genetic alterations contribute to the inactivation of tumour 
suppressor genes and amplification of oncogenic genes.  When assembled in a single breast cell, 
an accumulation of a large number of individual genetic mutations disrupts the control system to 
the extent that the cell functions autonomously in an erratic and irregular manner. Such corrupted 
cells may start forming colonies of abnormal cells that may accumulate other aberrant mutations 
to eventually initiate cancer (Stephens et al., 2009).  
 
1.1 Incidence and mortality of breast cancer 
 
On a global scale, breast cancer is the most common cancer amongst women.  In 2012, the 
International Agency for Research on Cancer (IARC) estimated newly diagnosed breast cancer 
cases to be 1.67 million (Figure 1) and the number of deaths reported were 522,000 (Globocan, 
2012).  
 
Figure 1: Worldwide breast cancer incidence in women. The estimated age-standardised 
breast cancer incidence rate per 100, 000 worldwide as reported by the IARC in 2012 
(Globocan, 2012). 
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Although the incidence of breast cancer remains high in developed nations, the incidence of 
breast cancer in underdeveloped regions is increasing and has a slightly higher mortality rate 
than developed regions (Tfayli et al., 2010). The incidence rate is increasing owing to 
urbanisation and change in lifestyle. South African women are highly likely to present with late 
stage disease as compared to only 5% of American women that present with late stage disease 
(Kuo et al., 2011). Lack of awareness, limited access to diagnostic centres in rural areas for early 
detection, and lower standards of healthcare facilities attributed to this trend leading to higher 
mortality rates in less developed nations (Vorobiof et al., 2001). 
 
In South Africa (SA), breast cancer is the leading cancer in women and the second cause of death 
(Globocan, 2012). The lifetime risk of breast cancer for women in SA has been estimated to 1 in 
28 by the National Cancer registry with 1/51 in black women, 1/11 in white women, 1/19 in 
Asian women and 1/20 in coloured women (NCR, 2013). 
 
1.2 Breast cancer risk factors 
1.2.1. Environmental and lifestyle risk 
 
Multiple factors influence risk of developing breast cancer risk such as lifestyle changes that 
include change in diet, obesity, increased smoking and hormonal factors. Reproductive factors 
such as early menarche, late menopause, delayed and decreased parity, and absence of breast 
feeding are also associated with increased risk (Porter, 2009). These reproductive factors are 
correlated with exposure to estrogen. Long term exposure of estrogen has been shown to elevate 
risk; however, decreasing exposure to estrogen has a protective function against breast cancer. 
For instance, absence of early full-term pregnancy is associated with increased breast cancer risk 
(Britt et al., 2007, Martin and Weber, 2000).   
 
Young women diagnosed with Hodgkin’s lymphoma are often treated with chest radiotherapy 
and have increased incidence of breast cancer. Breast cancer risk and dose of radiation used are 
directly proportional. The observed risk primarily prevails in younger women when compared to 
older women. Consequently, radiotherapy is a factor that plays a role in breast cancer risk (Hill et 
al., 2005, Travis et al., 2005, van Leeuwen et al., 2003). 
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The association of breast density with breast cancer risk is evident in literature (Titus-Ernstoff et 
al., 2006, Boyd et al., 2011, Yaghjyan et al., 2015, Byrne et al., 1995). The risk increases by 4-6 
fold in women with dense breast tissue which is often noted in young women (McCormack and 
dos Santos Silva, 2006). The features of breast tissue can be assessed by mammography. Apart 
from breast density, obesity is linked with increased breast cancer risk. An alarming 20% of 
breast cancers result from obesity and lifestyle factors that affect body mass index. However, 
obesity-related cancers are more prevalent in postmenopausal women (De Pergola and Silvestris, 
2013).  
 
Gender is a key factor that influences breast cancer risk. Women are at higher risk of breast 
cancer than men. Young and older women are both highly likely to be diagnosed with breast 
cancer. Men are often older at diagnosis with larger and late stage tumours. The occurrence of 
breast cancer in men is prevalent in the African population (Greif et al., 2012). Only about 1% of 
all breast cancers in Europe are men. Hereditary causes are the primary reason of male breast 
cancer (section below) (Fentiman et al., 2006). 
 
1.2.2. Hereditary breast cancer and family history 
 
The occurrence of breast cancer can be either sporadic or hereditary/familial. About 10% of all 
breast cancers are hereditary and the risk is considerably higher with the presence of mutations in 
BRCA1 and/or BRCA2 (Breast Cancer gene 1 and 2) (Cuzick, 2003), or genetic variations in 
other DNA repair genes (Goldgar et al., 2011, Casadei et al., 2011, Antoniou et al., 2014, 
Desrichard et al., 2011). Compared to sporadic breast cancers, hereditary breast cancer also has a 
low age at onset of disease (Margolin and Lindblom, 2006). Additionally, family history 
accounts for  15-20% of all breast cancers (Lynch et al., 2008). A positive family history is an 
important breast cancer risk factor that is shown to increase risk 2 fold with a first or second 
degree relative affected by the disease. Having two first degree relatives affected, triples the risk 
of breast cancer (Cuzick, 2003). Accurate information on comprehensive family history is 
important in individual risk assessment. 
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1.2.3. Germline mutations in breast cancer susceptibility genes 
 
Germline mutations in DNA repair genes can be heritable and account for 15-20% of familial 
breast cancer cases (West et al., 2003, Lynch et al., 2008). Genetic predispositions to these genes 
are associated with enhanced risk of developing breast cancer. These susceptibility genes are 
divided into high-risk and moderate to low-risk susceptibility genes. Compared to the general 
population, the risk associated with high-risk genes is four times more; the risk is doubled from 
the general population with moderate-risk genes and less than twice with low-risk susceptibility 
genes. BRCA1 and BRCA2 are the most described high-risk genes, whereas moderate-risk 
susceptibility genes include ATM, CHEK2 and PALB2 (Hollestelle et al., 2010). Single 
nucleotide polymorphisms have been detected that confer low-risk of breast cancer (Beggs and 
Hodgson, 2009). Table 1 highlights some important high risk and moderate risk genes associated 
with breast cancer. Many of these genes are involved in the same pathway for repair of DNA 
double strand breaks (DSB) through homologous recombination (HR). 
 
In addition, several genome-wide association studies revealed a large number of SNPs, each 
individually associated with a small increased risk to breast cancer, but a combination of these 
SNPs may have an additive effect. Large studies conducted by breast cancer consortiums show 
breast cancer susceptibility SNPs and environmental factors that modify breast cancer risk. 
Smoking, alcohol consumption, age at menarche and first full term pregnancy were all identified 
with significant evidence linking it to increased breast cancer risk (Barrdahl et al., 2017). 
However, breast cancer genetic susceptibility variants are not always associated with increased 
risk. Certain SNPs also play a protective role against breast cancer (Kirchhoff et al., 2012).  
Evaluating the function of SNPs in risk assessment of breast cancers is, therefore, essential. 
Studies are emerging to evaluate if “polygenic risk scores” could have an added value to predict 
risks for breast and/or ovarian cancer (Li et al., 2017, Kuchenbaecker et al., 2017, Jervis et al., 
2014). 
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Table 1: Breast cancer susceptibility genes showing penetrance and lifetime risk. 
Gene Penetrance Lifetime risk * Function Reference 
BRCA1 High 40-70% 
Genomic stability 
and DNA DSB 
repair 
(Takaoka and 
Miki, 2017, 
Winter et al., 
2016) 
BRCA2 High 20-57% 
Genomic stability 
and DNA DSB 
repair 
(Foulkes and 
Sugano, 2016, 
Winter et al., 
2016) 
TP53 High 56-90% Genomic stability 
(Yeo et al., 
2016, Dumay 
et al., 2013) 
PTEN High 50-80% Genomic stability 
(Hopkins et 
al., 2014, 
McCabe et al., 
2016) 
CHEK2 Moderate 25-37% DNA DSB repair 
(Adank et al., 
2011, 
Apostolou and 
Papasotiriou, 
2017) 
PALB2 Moderate 20-40% DNA DSB repair 
(Foo et al., 
2017) 
ATM Moderate 15-20% DNA DSB repair 
(Goldgar et 
al., 2011) 
BARD1 Moderate Differs DNA DSB repair 
(Gass et al., 
2016, Zhao et 
al., 2017) 
* Modified (Apostolou and Fostira, 2013, van Marcke et al., 2016) 
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1.2.4. Role of BRCA1 and BRCA2 
 
Germline BRCA1 and BRCA2 mutations account for 20-25% of all familial breast cancers and 
may account for up to 5% of all breast cancers. BRCA1 and BRCA2 are tumour suppressor genes 
playing a significant role in DNA DSB. BRCA1/2 proteins are important in DNA repair 
pathways and reduced expression or inactivating mutations in these genes can lead to impaired 
DNA repair. The integrity of the DNA is maintained by BRCA’s interaction with recombination 
proteins that belong to the family of Rad proteins. Defects in BRCA1/2 contribute to genetic 
instability and irregularities in the cell cycle checkpoints leading to an increased probability of 
tumourigenesis (Khanna and Jackson, 2001).  
 
BRCA1 gene is located on chromosome 17 and encodes 1863 amino acids (Figure 2) (Welcsh 
and King, 2001). The structure of BRCA1 includes 3 main domains of interest; i) the RING-
finger domain – accountable for E3 ubiquitin ligase activity, ii) exon 11-13 – region known to 
contain binding domains for other proteins and iii) the BRCA1-terminal (BRCT) – domain for 
binding ATM-phosphorylated proteins (Figure 4). In addition to DNA damage response, BRCA1 
plays a central role in cell cycle checkpoint activation and transcriptional regulation (Clark et al., 
2012).  
 
Chromosome 13 shelters the BRCA2 gene which encodes 3418 amino acids. In contrast to 
BRCA1, the N-terminal domain of BRCA2 is a transcriptional activation site proceeded by a 
series of repeat sequences termed BRC. These sequence motifs are highly conserved and act as a 
medium for interaction between BRCA2 and RAD51. The nuclear localisation site (NLS) 
located in the C-terminal contains a DNA-binding site (Shamoo, 2003). The BRCA2 and RAD51 
interaction is pivotal in DNA recombination and regulation of DNA repair of single-strand 
breaks and DSB (Pellegrini and Venkitaraman, 2004).  
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 Figure 2: Illustrative structure of BRCA1 and BRCA2. BRCA1 consists of 3 main function 
domains and encodes 1863 amino acids. BRCA2 consists of 8 BRC repeats important for 
binding DNA repair proteins. Image adapted from (Venkitaraman, 2001, Orr and Savage, 
2015). 
 
1.3. Breast cancer in South Africa 
 
Similar to other developing countries, SA has a higher incidence of early-onset breast cancer. 
Compared to other developing nations, the age at diagnosis in African women is relatively low 
(Walker et al., 2004, McCormack et al., 2013). Although breast cancer is predominantly 
observed in the white population, increasing numbers of young black South African women are 
frequently diagnosed with the disease. Young African women usually present with advance 
disease, poor prognosis and disproportionately high mortality rates (Dickens et al., 2014a, Basro 
and Apffelstaedt, 2010, Matatiele and Van den Heever, 2008). Arguably, an emerging factor 
linked with increase of breast cancer in young women is parity. Although conferring a protective 
role in breast cancer, parity is related to increased risk in young African women (Palmer et al., 
2003). While the growing incidence of breast cancer in young South African women could also 
be due to a younger population structure, it is likely that these women are carriers of unique 
mutations associated with breast cancer. This can further be attributed to genetic predispositions 
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since BRCA1/2 mutations are often observed in premenopausal breast cancer (Young et al., 
2009). Therefore, carrying a deleterious mutation increases the risk of developing early-onset 
breast cancer.  
1.4. Screening and detection 
 
Regular screening is essential in early detection of benign or malignant breast tumours. Patients 
with early diagnosis can be provided with appropriate treatment.  Screenings include self- and 
clinical examinations, mammography and ultrasounds frequently for younger women or women 
with dense breasts, magnetic resonance imaging (MRI) and breast biopsy. Mammography is the 
mainstream method for breast cancer detection. It functions by exposing breast tissue 
composition attenuating x-rays to distinguish fat and epithelial tissue (Boyd et al., 2010). 
Although, mammography has potential benefits in detecting breast cancer, women with dense 
breast are at a loss as cancerous tissue can be missed, this trend is often observed in young 
women (Corsetti et al., 2008). Following the detection of an abnormal breast image using 
mammography, a breast biopsy is conducted for efficient diagnosis prior to any form of 
treatment (Ely and Vioral, 2007).  
 
Even though MRI is not recommended routinely, it is broadly utilised for screening high risk 
women; for instance, carriers of germline mutations in high risk breast cancer gene and those 
with a family history. MRI offers high sensitivity even in women with dense breasts. However, 
there is lack of evidence that benefits of MRI may precede that of a mammogram (Morrow et al., 
2011, Kriege et al., 2004). Due to the higher incidence of breast cancer in young African women, 
mammography screening in SA is routinely recommended for women 40 years and above 
(Synman, 2010).  
 
1.5. Classification of breast cancer 
 
Breast cancer is categorised into several histopathological subtypes and staging systems by the 
American Joint Committee on Cancer staging (AJCC) based on the histopathology type, grade 
and stage of tumour, and expressions of proteins and genes.  
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1.5.1. Histopathology 
 
The histopathology is classified into two main categories depending on whether the malignant 
cells originate in the milk ducts or the lobules (Figure 3). The presence of abnormal cells 
confined to the lining of the milk ducts is classified as ductal carcinoma in situ (DCIS). 
Similarly, lobular carcinoma in situ (LCIS) occurs when abnormal cells are observed in the 
lobules of breast ducts. LCIS is usually not categorised as malignant, however, it increases the 
risk of malignancy. The disease is further categorised into invasive or non-invasive (Herbst, 
2011). The most common and rapid growing breast cancer which accounts for 80% of all 
invasive breast cancer is the infiltrating or invasive ductal carcinoma (IDC); the invasive lobular 
carcinoma accounts for about 10% (Ely and Vioral, 2007).  
 
Figure 3: Anatomy of the breast - indicating the ducts and lobules (Komen, 2016). 
 
A second staging system introduced is known as the Tumour-Nodal-Metastases (TNM) 
considers various aspects such as: i) size of the tumour, ii) presence of cancer cells in the lymph 
nodes and iii) distant metastases of the cancer cells. The combination of the histopathology 
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report, staging and the clinical data often provide an indication of the prognosis and is used as 
guideline in determining the treatment options (Singletary, 2002).  
1.5.2. Hormone receptors for breast cancer 
 
In addition to the pathological features and staging, gene expression profiling has deciphered 
molecular subtypes of breast cancers based on the expression or lack of expression of hormonal 
receptors. Estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth 
factor receptor 2 (HER2) are the biomarkers that have prognostic value and are beneficial for 
treatment evaluation (See section 1.7 on therapy). The presence or absence of the receptors 
classifies the tumour as hormone receptor-positive or receptor-negative respectively. 
 
Estrogen plays a key role in facilitating the development and progression of breast cancer. The 
estrogen hormone attaches to the ER receptor and mediates its function of cellular proliferation 
and differentiation of breast tissue. However, this function is not confined to normal cells only. 
Cancerous breast cells will also proliferate by estrogen (Russo and Russo, 2006). ER expression 
is linked with genomic instability by generating oxidative damage to DNA and inducing double 
strand breaks that can result in breast cancer. Rapidly proliferating cells do not allow sufficient 
time for DNA damage repair leading to accumulation of DNA damaged cells. ER also interacts 
with various DNA repair proteins and alters the DNA damage response (Caldon, 2014). In the 
absence of strictly regulated DNA repair, cell proliferation driven by ER signalling may lead to 
mutations that may lead to breast cancer (Matta et al., 2016). ER positive breast cancers 
contribute to about 75% of all breast cancers and are more predominant in postmenopausal 
women.  
 
The progesterone hormone activates the PR and functions in cell proliferation. Excess PR 
contributes to the development of breast cancer. PR expression is regulated by ER and gains anti-
oncogenic functions in ER-positive tumours. Also, PR is a predictive factor for the response of 
hormonal therapies in ER-positive cancers (Mohammed et al., 2015, Allred, 2010).   
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HER2 gene is a proto-oncogene that functions in and regulates cell proliferation and 
differentiation. Overexpression of HER2 induces malignancy by stimulating the formation of 
tumours. HER2 is overexpressed in roughly about 20% of breast cancers. In SA, 26% of breast 
cancer patients are HER2+ (Vanderpuye et al., 2017a). In comparison to HER2- breast cancers, 
HER2+ phenotypes are thought to be clinically unique and present with poor prognosis 
(Burstein, 2005).  
 
By molecular classifications, IDC and ILC histological subtypes can further be categorised as 4 
phenotypes namely luminal A (ER+/PR+/HER2-), luminal B (ER+/PR+/HER2+), HER2 
overexpressing (ER-/PR-/HER2+) and triple negative breast cancer (ER-/PR-/HER2-) (TNBC) 
(Inic et al., 2014). Luminal cancers are generally associated with good prognosis and the most 
prominently occurring subtype is the luminal A (Stead et al., 2009, Anders and Carey, 2008). 
Luminal B cancers are known to have lower expression of ER than luminal A subtypes and 
generally higher graded tumours (Tamimi et al., 2008). 
 
1.6. Triple negative breast cancer 
 
Tumours lacking the expression of hormone receptors, termed as triple negative (TN), account 
for 10-20% of breast cancers worldwide (Bauer et al., 2007, Carey et al., 2010, Reis-Filho and 
Tutt, 2008, Foulkes et al., 2010, Vona-Davis et al., 2008, Alcantara et al., 2017). The prevalence 
of TNBC in SA ranges between 14-26% (Prodehl, 2016, McCormack et al., 2013, Dickens et al., 
2014a, Dickens et al., 2014b), although other African nations have relatively higher prevalence 
of TNBC compared to SA and the western counterparts (Vanderpuye et al., 2017b). TNBCs are 
associated with aggressive tumour progression, poor prognosis, higher rate of recurrence and 
mortality. The frequent occurrence of TNBC is strongly correlated with young or premenopausal 
African women. TNBC poses a clinical challenge as these tumours are hard to treat with 
hormonal and/or targeted therapy (See section on therapy below) (Foulkes et al., 2010).  
 
Germline mutations in BRCA are associated with the TN phenotype (Dietze et al., 2015), with 
about 75% BRCA1 mutation-related breast cancers present with the TN subtype (Bayraktar et al., 
2011, Rakha and Chan, 2011). The combination of presenting a BRCA mutation and TN 
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phenotype is frequently observed in early-onset of the disease (Young et al., 2009, Robertson et 
al., 2012). 
 
1.7. Therapy for breast cancer 
 
Based on the staging, local and systemic treatment options are offered to patients. Local 
treatments directly affect the tumour only and systemic treatments are generally used to treat the 
spread of cancer anywhere in the body. Different treatment modalities available for breast cancer 
are surgery, chemotherapy, radiotherapy, hormonal and targeted therapy (Ely and Vioral, 2007).  
 
Surgery is conducted for inoperable tumours as well as for primary tumours to assist with the 
staging of the cancer. The two main types of surgery are i) breast conserving surgery such as a 
lumpectomy where only the tumour is removed and is recommended for early stage cancers and 
ii) mastectomy involves the removal of the entire breast. For women who are at high risk and 
have advanced cancers, a double mastectomy is generally recommended (Ely and Vioral, 2007). 
 
Chemotherapy is a mainstream therapy for treating breast cancer. It is administered 
intravenously in a combination of 2 or 3 drugs and circulates in the bloodstream also reaching 
cancerous cells that may have spread from the vicinity of the breast tissue (Ely and Vioral, 
2007). Despite successful outcome, administering chemotherapy is often accompanied with 
serious and/or permanent side effects. Older patients receiving chemotherapy are at risk of 
cardiac toxicity and secondary cancers such as acute myeloid leukaemia. The side effects in the 
younger patient population are more and comprise fluctuations in menstrual cycle, infertility and 
premature menopause. Due to its harsh effects, chemotherapy is often administered in cycles 
allowing the body to recover (Azim et al., 2011). 
 
Residual malignant cells following surgery are frequently treated with radiotherapy. 
Radiotherapy is the therapeutic use of high-energy beams to eradicate cancer cells which is 
achieved by external beam therapy or internal beam using a radioactive source. As with 
chemotherapy, radiotherapy is also associated with important side effects such as edema, fatigue, 
skin reaction mimicking sun burns (Ely and Vioral, 2007) and ischemic heart disease resulting 
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from exposure of radiation to the chest area (Darby et al., 2013). To control progression and 
local-regional recurrence, it is utilized as a principle treatment for TNBC (Dragun et al., 2011) 
and as a mainstream treatment in the management of most malignancies. 
 
Hormone positive breast cancers are fuelled by estrogen in the blood and are treated systemically 
with hormone therapy that block the function of estrogen. Target hormonal treatments such as 
tamoxifen and aromatase inhibitors are available for these cancers and are known to have good 
prognosis. Tamoxifen is the most commonly used hormonal drug that mediates its effect by 
blocking the function of estrogen entirely, although it is effective in 5-10% of ER-negative 
tumours (Manna and Holz, 2016). It is widely used in treating pre- and postmenopausal ER 
positive breast cancers (Hurvitz and Pietras, 2008). In contrast to tamoxifen, aromatase inhibitors 
are a class of drugs used to endogenously lower estrogen levels in postmenopausal women. 
Commonly noted side effects with hormonal therapy are fatigue, hot flashes, bone thinning and 
seldom blood clots (Ely and Vioral, 2007). 
 
Cancer cells, at times, react to certain proteins that allow them to rapidly multiply. One such 
protein correlated to breast cancer is HER2. Targeted therapy permits drugs such as Herceptin, 
which is an anti-HER2 monoclonal antibody, to regulate cell growth. In HER2 overexpressing 
cancers, Herceptin binds to HER2 to inhibit the growth of cancer cells. In comparison to other 
treatments, the side effects of targeted therapy are relatively mild such as fever, nausea, vomiting 
and headaches. Certain targeted drugs are administered in conjunction with chemotherapy (Ely 
and Vioral, 2007).  
 
Benefits of hormonal or targeted therapy are absent in TNBC patients. Treatment modalities 
available at present are certain chemotherapy regimens, radiation therapy and surgery. However, 
the response rate of TNBC to chemotherapy is often associated with poor prognosis (Yagata et 
al., 2011, Wang, 2011).  
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2. Fanconi Anaemia 
2.1. Incidence of Fanconi anaemia 
 
Fanconi anaemia (FA) is an autosomal recessive trait and cancer-prone chromosomal instability 
disorder. The incidence of FA in Europe and United States was documented to be approximately 
3 in a million. Certain populations have founder mutations and the incidence rate varies 
(Tischkowitz and Hodgson, 2003). In SA, with mixed ethnicity in the population, prevalence of 
FA ranges between 1/22 000 for the white Afrikaners to 1/40 000 in the black South Africans 
(Tipping et al., 2001, Feben et al., 2014a, Rosendorff et al., 1987). The occurrence of FA within 
the black population is primarily due to the presence of the homozygous FANCG founder 
mutation c.637_643delTACCGCC in 80% of this population (Feben et al., 2014b, Feben et al., 
2015). 
 
2.2. Clinical defects 
 
FA is a familial form of aplastic anaemia. The clinical manifestations of FA include congenital 
and developmental abnormalities, and haematological defects. FA patients are at high risk to 
develop acute myelogenous leukaemia due to impaired bone marrow function and the incidence 
of solid tumours are also increased (Alter, 2014). South African black FA patients initially 
present with severe aplastic anaemia and cytopenia. Other symptoms of the disease include 
epistaxis and patients are significantly underweight compared to the general population (Feben et 
al., 2015, Feben et al., 2014c). In the absence of molecular diagnosis, FA is treated as aplastic 
anaemia which could lead to bone marrow failure. In this instance, the only known curative 
treatment modality is haematopoietic stem cell (HSC) transplantation. However, graft rejections 
occur at a high rate and are related to poor survival in patients receiving HSC from related or 
unrelated donors. Full body radiation is used as myeloablative conditioning to minimise donor 
rejections. Prior to conditioning with radiation, it is vital to know the molecular diagnosis of 
aplastic anaemia patients to rule out FA as these patients are highly sensitive to radiation and 
would pose a challenge with conditioning regimes (Dalle, 2008, MacMillan et al., 2000, Yabe et 
al., 2006). 
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Molecularly, FA cells are hypersensitive to DNA cross-linking agents such as mitomycin C 
(MMC) and diepoxybutane (DEB) which are utilised to quantify chromosomal aberrations 
diagnostically. Sensitivity to chemotherapy and radiotherapy in FA patients has previously been 
documented. For patients with cancers associated with haematology, it is recommended that FA 
diagnostics be conducted before initiating chemotherapy as FA patients are highly sensitive to 
cytotoxic chemotherapy (Goldsby et al., 1999, Alter, 2002a). 
 
2.3. Molecular pathology 
 
Twenty-two FA patients have been found to carry biallelic pathogenic variants in any of 20 
genes, FANCA (MIM #607139), FANCC (MIM #613899), FANCD1/BRCA2 (MIM #600185), 
FANCD2 (MIM #613984), FANCE (MIM #613976), FANCF (MIM #613897), FANCG/XRCC9 
(MIM #602956), FANCI (MIM #611360), FANCJ/BRIP1 (MIM #605882), FANCL (MIM 
#608111), FANCM (MIM #609644), FANCN (MIM #610832)/PALB2 (MIM #610355), FANCO 
(MIM #613390)/RAD51C (MIM #602774), FANCP (MIM #613951)/SLX4 (MIM #613278), 
FANCQ (MIM #615272)/ERCC4 (MIM #133520)/XPF (MIM #278760), FANCS/BRCA1 (MIM 
#113705), FANCT (MIM #616435)/UBE2T (MIM #610538), FANCU (MIM #617247)/XRCC2 
(MIM #600375), FANCV (MIM #617243)/MAD2L2 (MIM #604094)/REV7, and 
FANCW/RFWD3 (MIM #614151). Variants in FANCB (MIM #300515), an X-linked gene and 
an autosomal dominant variant in FANCR (MIM #617244)/RAD51 (MIM #179617), can also 
cause the disease, resulting in a total of 22 FA genes reported thus far (Table 2) (Mamrak et al., 
2017, Kottemann and Smogorzewska, 2013, Rickman et al., 2015, Wang and Smogorzewska, 
2015, Knies et al., 2017). Each of these are involved in DNA interstrand crosslink damage 
recognition and repair (Dong et al., 2015, Park et al., 2016). Homozygous or compound 
heterozygous mutations in these complementation groups will result in the FA-phenotype. 
Amongst these documented FA genes, the most frequently occurring mutations are observed in 
FANCA, FANCC and FANCG (Brooks et al., 2012). Literature has shown an overlap of the FA 
and breast cancer genes. For instance, BRCA2 (FANCD1) (Alter et al., 2007) and BRCA1 
(FANCS) and PALB2 (FANCN) (Tischkowitz and Xia, 2010, Sawyer et al., 2015) are shown to 
be associated with a highly increased risk for breast cancer in patients with heterozygous 
germline mutations in these genes, while biallelic inactivation leads to FA. 
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Table 2: Overview of the 22 FA genes identified 
Complementation 
Groups 
Gene Name / 
Alternative Name 
Chromosomal 
Location 
Estimated Frequency 
FA-A FANCA 16q24.3 60-70% 
FA-B FANCB Xp22.31 2% 
FA-C FANCC 9p22.3 14% 
FA-D1 FANCD1 / BRCA2 13q12.3 3% 
FA-D2 FANCD2 3p25.3 3% 
FA-E FANCE 6p21.3 3% 
FA-F FANCF 11p15 2% 
FA-G FANCG 9p13 10% 
FA-I FANCI 15p26.1 1% 
FA-J FANCJ / BRIP1 17q22 2% 
FA-L FANCL 2p16.1 0.2% 
FA-M FANCM 14q21.3 0.2% 
FA-N FANCN / PALB2 16p21 0.7% 
FA-O FANCO / RAD51C 17q25.1 0.2% 
FA-P FANCP / SLX4 16p13.3 0.2% 
FA-Q FANCQ / ERCC4 16p13.12 Rare 
FA-R FANCR / RAD51 15q15.1 Rare 
FA-S FANCS / BRCA1 17q21.31 Rare 
FA-T FANCT / UBE2T 1q32.1 Rare 
FA-U FANCU / XRCC2 7q36.1 Rare 
FA-V FANCV / REV7 1p36.22 Rare 
FA-W FANCW / RFWD3 16q23.1 Rare 
Modified from (Rosselli, 2016, Wu, 2013) 
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2.3.1. FA in Ashkenazi Jews 
 
The most prevalent biallelic mutation in FA is observed in FANCA and it was the second FANC 
gene to be cloned in 1996. Expression of FANCA ubiquitously conducted in lower amounts. 
Pathogenic mutations associated with this gene occur as point mutations, base pair changes and 
often as large deletions. Patients harbouring FANCA mutations are commonly compound 
heterozygous. A founder mutation in this gene has been described in the Afrikaner population 
(Tischkowitz and Hodgson, 2003). 
 
2.3.2. FA in the Afrikaner population 
 
In 1992, FANCC was the first FA gene to be cloned by complementation method. Approximately 
14% of FA cases are due to pathogenic mutations in FANCC and are most frequently observed in 
the Ashkenazi Jews as a founder effect. The same founder mutation has been reported in the 
Japanese population with slightly mild phenotype (Tischkowitz and Hodgson, 2003). However, 
FANCC mutations are not exclusive to these populations alone (de Vries et al., 2012). FANCC 
functions in promoting different forms of DNA repair (Niedzwiedz et al., 2004) and signalling of 
apoptosis (Taniguchi and D'Andrea, 2006).  
 
2.3.3. FA in black South Africans 
 
The XRCC9 (X-ray repair cross-complementing protein 9) and FANCG are identical genes 
functioning in chromosomal instability repair. In roughly 82% of the black FA patients in 
Southern Africa, the presence of a founder mutation has been reported (Dong et al., 2015). In 
response to DNA damage, FANCG co-localises to RAD51 and interacts with BRCA1 to initiate 
repair (Hussain et al., 2003).    
 
2.4. Fanconi anaemia pathways 
 
The FA/BRCA repair pathway is pivotal in maintaining genomic instability since the proteins 
encoded from FANC genes are actively involved in DNA repair (Figure 4).  
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 Figure 4: The Fanconi anaemia pathway. Illustration of the Fanconi anaemia pathway 
displaying the i) core complex (green) ii) ID2 complex (purple) and iii) downstream effectors 
(blue). Image modified (Haitjema et al., 2013). 
 
The FANC proteins are subgrouped into 3 main categories known as (i) the core complex (ii) 
ID2 complex and (iii) the downstream effectors. In response to damage caused by DNA cross-
linking agents or ionising radiation (IR), the activated core complex formed by 9 FA proteins 
(FANC-A, B, C, E, F, G, M, L and T) activates the ID2 complex, comprised of 
FANCD2/FANCI protein, by mono-ubiquitination and phosphorylation. The mono-
ubiquitination of ID2 is catalysed by FANCU (also known as UBET2). The ID2 complex plays a 
critical role in the pathway by translocating to the damage sites which triggers the recruitment of 
downstream effectors (FANC-D1, J, N, O, P, Q, R, S, U, V and W) in the S/G2 phase. The 
damage is subsequently repaired by homologous recombination. Following the repair, the ID2 
complex undergoes deubiquitination and the FA/BRCA pathway is regulated. Exogenous or 
endogenous damage causes an increase in the number of FA cells in the G2 phase as a result of S 
phase checkpoint inefficiency (Sala-Trepat et al., 2000). 
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3. Radiation and biological effects of radiation 
3.1. Ionising radiation 
 
The electromagnetic spectrum illustrates the various types of known radiation (Figure 5). 
Radiation is energy beams that travel through a vacuum or matter causing excitation or ionisation 
when energy is absorbed. IR is a type of electromagnetic wave that releases electrons in a 
process known as ionisation as it interacts with matter. The two forms of ionising radiation are i) 
electromagnetic waves that include X-rays and γ-rays, and ii) particles which are neutrons, beta 
and alpha particles (Joiner and van der Kogel, 2009).  
Figure 5: The electromagnetic spectrum. The different ranges of ionising and non-ionising 
radiation (Genius and Lipp, 2012). 
Linear energy transfer (LET) describes the amount of energy transferred by IR per unit distance 
as it travels the path. When ionisation events are widely spaced, it is termed as low-LET and 
high-LET radiation deposit greater energy in a small distance. X-rays and γ-rays are low-LET 
radiation and high-LET radiation includes alpha particles and neutrons. The biological effects of 
IR depend on its LET (Joiner and van der Kogel, 2009).      
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3.2. Biological effects of ionising radiation 
 
Increased toxicity and decreased cell survival are consequences of high- and low-LET radiation. 
Exposure to either forms of LET radiation can cause substantial DNA damage (Baeyens, 2005, 
Niemantsverdriet et al., 2012). DNA damage triggered by IR can occur either by direct or 
indirect mode of action (Figure 6). In direct action, DNA is ionised by the deposition of radiation 
energy introducing chemical alterations. Direct action is predominantly caused by high-LET 
radiation sources. The indirect action ionises water molecules to produces reactive species that 
damage target molecules. Indirect action primarily occurs with water to form highly reactive free 
radicals that damage DNA (Hall, 2012, Baeyens, 2005).  
 
Figure 6: The direct and indirect ionisation mechanism of radiation. In the direct mode, 
radiation energy is deposited directly on the DNA and in indirect mode, radiation energy is 
absorbed by the surrounding medium to form reactive species (Frush and Slovis, 2015).  
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DNA contains genetic material essential for cell survival and damage to DNA is the most 
significant biological effect. The different types of damage inflicted are i) base damage, ii) 
single-strand break, iii) DSB, iv) crosslinks and v) bulky lesions (Figure 7). DSB are considered 
the most lethal form of radiation-induced damage to the DNA. Exposure to IR has chromosomal 
damaging effects which are the most important effects of radiation inducing various types of 
DNA damage (Jackson and Bartek, 2009).  
 
Figure 7: Types of DNA damages. The different types of DNA damage resulting from 
endogenous or exogenous agents (Arjunan et al., 2015).  
DNA damage response (DDR) is a network of pathways that initially sense DNA damage using 
sensor proteins such as MRN-ATM, Ku-DNA-PKcs and ATRIP-ATR. These sensor proteins 
then signal DNA damage and activate three effector pathways to determine the outcome of 
damaged DNA. The 3 effectors pathways are DNA repair, cell cycle checkpoints and apoptosis. 
Cell cycle checkpoints are activated depending on the integrity on the DNA which leads to cell 
cycle delay. There are 3 main checkpoints of every stage of the cell cycle: G1/S (Gap 1 
phase/Synthesis) checkpoint, intra-S checkpoint and the G2/M (Gap 2 phase/Mitosis) 
checkpoint. To prevent the introduction of mutations due to misrepair, damaged DNA is repaired 
during this delay in the cell cycle. However, if the induced damage is intense and cannot be 
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repaired, the cell undergoes apoptosis (Jackson and Bartek, 2009, Joiner and van der Kogel, 
2009).    
3.3. DNA repair mechanisms 
 
The cell employs various DNA damage repair pathways namely nucleotide excision repair 
(NER), base excision repair (BER), mismatched repair (MMR), HR and non-homologous end 
joining (NHEJ). DSB are predominantly repaired by HR and NHEJ pathways in different phases 
of the cell cycle.  
NER: Xeroderma pigmentosum (XP) is the most documented disorder linked with defective 
NER pathway. This pathway repairs damage through global-genome NER (GG-NER) or 
transcription-coupled NER (TC-NER). DNA damage is recognised by specialised proteins that 
have high affinity for distorted DNA. In GG-NER, DNA damage-binding protein and the XP 
complementation group C recognises the defect; damage recognition in the TC-NER is 
facilitated by Cockayne syndrome group A (CSA) and Cockayne syndrome group B (CSB) 
proteins. DNA duplex is then unwound and large portion of about 27 nucleotides is excised by 
XP complementation group G and XP complementation group F-ERCC1 endonucleases. Gapped 
DNA is processed by DNA polymerase using the complementary strand and ligated by DNA 
ligase (Hakem, 2008). 
BER: The BER pathway recognises base damages and repairs through short-patch BER for 
single bases and long-patch BER for up to 13 bases. To initiate the repair process, DNA 
glycosylase enzyme removes the damaged base, DNA polymerase-β incorporates a new 
nucleotide and repair is completed by DNA ligase activity. An impaired BER pathway is 
associated with an autosomal recessive disorder known as MUTYH-associated polyposis. 
Biallelic mutations in MUTYH, an important gene in BER, significantly increases the risk of 
colorectal cancers (Hakem, 2008).  
MMR: The MMR pathway is responsible for rectifying insertions, deletions and substitutional 
errors incurred during DNA synthesis. MSH and MLH family of proteins are important in this 
repair pathway. The MSH binds to the incorrectly incorporated nucleotides and information is 
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communicated to replicate machinery by the MLH protein. This is followed by gap-filling by the 
polymerase and final ligation (Jackson and Bartek, 2009). Hereditary non-polyposis colorectal 
cancer results from a compromised MMR pathway (Hakem, 2008). 
HR: HR, known as the error-free repair, primarily repairs DNA DSB in the S and the G2 phase 
where a homologous DNA strand participates in the repair (Figure 8). The HR pathway is 
processed in 3 main steps: i) end-processing ii) the Holliday junction and iii) strand resolution. 
ATM/ATR mobilises repair factors to the ends of the damaged DNA resulting in the recruitment 
of the MRN complex - MRE11-RAD50-NBS1 - and the BRCA1/2 proteins. RAD51 protein 
interacts with BRCA1/2 during the initiation of strand invasion. The nuclease complex, Rad50, 
facilitates the resection and DNA polymerase extends the damaged strand using the 
complementary homologous template. The resulting interwound strands, known as the Holliday 
junction, are resolved into either crossover or non-crossover DNA molecules. Ligation of the two 
strands occurs by the action of DNA ligase I activity. Other than DSB repair, HR is also 
associated with interstrand crosslinks. It is implicated in breast cancer and FA (Jackson and 
Bartek, 2009).  
SSA: Another homology-directed repair mechanism is single strand annealing (SSA). Proteins 
involved in SSA are RAD52, ERCC1 and Rad1/Rad10. Subsequent to end resection, DSB are 
repaired when sequence repeats are available. The annealing of homology strands form flaps that 
are clipped away and cause loss of sequence. This way SSA introduces error during repair (Kass 
and Jasin, 2010). 
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 Figure 8: DNA double strand repair pathways. Homologous recombination (left) uses 
homologous strand to repair damage and non-homologous end joining (right) repair DNA 
double strand breaks using non-homologous strands (Peng and Lin, 2011).  
 
NHEJ: NHEJ repairs DNA damage using a non-homologous template, therefore it is the 
preferred repair pathway in phases where there is no homologous template available and it is 
error-prone (Figure 8). In NHEJ repair pathway, the end recognition is achieved by the Ku70/80 
heterodimer that activates the DNA-dependent protein kinase (DNA-PK) catalytic subunit. The 
binding of the DNA-PK and the nuclease Artemis to the DNA ends results in phosphorylation 
that cleaves the DNA hairpins. The XRCC4, XLF and the ligase IV are then recruited to the site 
to ligate the damaged ends. The MRN complex is also capable of endonuclease activity and may 
play a role in end processing (Helleday et al., 2007). There is evidence that defective NHEJ is 
associated with immunodeficiency, thymic lymphomas and hereditary autosomal LigIV 
syndrome. Defects in this pathway are linked with chromosomal instability and radiosensitivity 
(Hakem, 2008).  
MMEJ: An alternate form of NHEJ known as microhomology-mediated end joining (MMEJ) 
uses a homologous template of 1-16 base pairs (bp) that aligns the damaged ends. This repair 
process occurs in the early S phase to the G2 phase when a micro homologous template is made 
25 | Page
available. Like NHEJ, MMEJ is error-prone since deletions are introduced by the removal of bp 
to allow the annealing of the homologous template (Sfeir and Symington, 2015).  
B-NHEJ: When the repair pathways are all compromised, the cell activates a backup or alternate 
pathway termed as the B-NHEJ. B-NHEJ is activated when components of the classical NHEJ 
have defects and cannot be utilised. Despite slower repair kinetics and more prone to error, 
majority of breaks are repaired. B-NHEJ is less efficient than classical NHEJ. B-NHEJ is 
advantageous as it functions throughout the cell cycle when needed with increased functionality 
observed in the G2 phase (Dueva and Iliakis, 2013, Mladenov and Iliakis, 2011).    
4. Biomarkers for chromosomal radiosensitivity 
 
Various assays can predict chromosomal radiosensitivity and monitor exposure of IR by 
evaluating DNA damage. The dicentric assay is the golden standard for biological dosimetry. 
The cytokinesis-block micronucleus (CBMN) assay is widely used for chromosomal 
radiosensitivity studies.  
4.1. Dicentric assay 
 
Dicentrics are chromosomes with two centromeres that result from misrepair of DNA damage by 
IR exposure (Figure 9). The number of dicentric chromosomes is directly proportional to the 
dose of IR. The assay is easily reproducible with low levels of background, sensitive for low 
doses and quantifies the exposure making it the golden standard. Previously, the assay was 
known to be laborious and analysing chromosome aberrations is strenuous, however, the assay 
has recently been automated (Agrawala et al., 2010).     
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 Figure 9: Dicentric chromosome. Abnormal chromosomes with two centromeres resulting 
from misrepair or abnormal fusion (Medicine, 2017). 
 
4.2. Cytokinesis-block micronucleus assay 
 
Chromosomal radiosensitivity is evaluated by analysing micronuclei (MNi) in cells (Figure 10). 
MNi are small fragments of DNA that lag behind following a complete nuclear division and 
serve as biomarkers for radiation induced DNA damage and radiosensitivity. MN contain either 
whole chromosomes that did not travel to opposite ends of the poles during division or acentric 
fragments where the centromere is absent (Fenech, 2000). Factors such as HIV, smoking and age 
influence the formation of MN (Ban et al., 1993, Hallberg et al., 1997, Baeyens et al., 2010).  
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 Figure 10: The cytokinesis-block micronucleus assay. Binucleate cells result from 
lymphocytes that complete one nuclear division after exposure and micronuclei are biomarkers 
for radiation-induced damage (Baeyens, 2005).  
The CBMN assay, commonly also known as the MN assay, can be conducted on peripheral 
blood lymphocytes (PBL) to evaluate chromosomal radiosensitivity in the G0 (Gap 0) phase. 
PBLs are easy to obtain by venepuncture and used extensively to detect and analyse radiation-
induced damage. For radiosensitivity testing, cells are exposed to IR, lymphocytes are stimulated 
to cell growth and cytoplasmic division is blocked by the addition of Cytochalasin B (Cyto B). 
This allows distinguishing of the binucleate cells (BN), cells that have been divided once after 
exposure, and MN. The BN cells are scored using the automated microscopic system, Metafer 
(MetaSystems). This is a high throughput scanning system that is capable of rapid scanning of 
cells at high magnification. This has improved the CBMN assay by decreasing the total scoring 
time and increasing reproducibility. With the use of fluorescent in situ hydridisation (FISH) 
utilising pan-centromeric probes, the CBMN assay can be made sensitive to differentiating 
between spontaneous MN and radiation-induced chromosome fragments. This FISH-based MN 
assay can also be used in biological dosimetry to detect low dose DNA damages. 
 
A modified version of the CBMN assay allows the detection of chromosomal radiosensitivity in 
the S/G2 phase of the cell cycle. The distinguishable difference in the S/G2 MN assay are i) the 
lymphocytes cultures are first stimulated to growth, ii) cultures are only irradiated 72 hours after 
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incubation, iii) cytokinesis is blocked immediately after irradiation and iv) cells are harvested 8 
hours post irradiation. This allows the detection of DNA damage prompted by IR in the S/G2 
phase. The G/M checkpoint efficiency can also be evaluated by addition of a radiosensitiser such 
as caffeine. Caffeine abrogates the G2/M checkpoint and permits the progression of damaged 
cells into mitosis (Pantelias and Terzoudi, 2011). Additionally, the assay is valuable in 
identifying BRCA mutation carriers and could be implemented in a routine diagnostic setting.  
5. Biomarkers for DNA damage repair 
5.1. γ-H2AX foci assay 
 
A nucleosome complex consists of histone octamers that wrap the DNA. These histone octamers 
consist of separate histone proteins named H2A, H2B, H3 and H4. H2AX, a variant of H2A 
protein family, is phosphorylated by ATM/ATR in response to DSB. The phosphorylated H2AX 
is known as γ-H2AX. The formation of γ-H2AX foci increases as IR exposure increases but 
disappears as a result of DNA repair. Labelled antibodies to the H2AX foci represent DNA 
damage and can be visualised microscopically to quantify DNA damage (Figure 11). Therefore 
the assay is a sensitive biological dosimetry assay (Kuo and Yang, 2008).  
With the development in research and imaging, an automated platform to analyse γ-H2AX foci is 
available through the MetaSystems. Clusters of foci images are captured by the detection of the 
fluorescent signals from the antibodies. γ-H2AX foci assay can also be performed with a drop of 
blood (Heylmann and Kaina, 2016). 
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 Figure 11: Lymphocytes with γ-H2AX foci. γ-H2AX foci clusters are indicated by green 
spots. The absence of green spots indicates foci formation (bottom right corner) (Metasystems, 
2017). 
 
5.2. RAD51 foci assay 
 
RAD51 is an important protein in HR repair. By interacting with both BRCA1/2, RAD51 is 
recruited to the damage sites to facilitate in DNA repair by exchanging strands between DNA. In 
the absence of RAD51 proteins, radiation treatment to mice embryonic cells has caused cell 
death, highlighting the importance of RAD51 in DNA DSB repair. Exposing cells to IR causes 
damage and activates RAD51 to accumulate at the damage site. This process can be visualised 
microscopically following immunofluorescent staining techniques. This allows the quantification 
of RAD51 foci and examines defects in the HR repair pathway (Figure 12). Defective HR 
pathway will exhibit decreased accumulation of RAD51 foci. During efficient HR repair, the 
accumulation of RAD51 foci is larger (Yuan et al., 1999, Shah et al., 2014).     
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 Figure 12: RAD51 foci assay. Following irradiation of cells, the red spots (left block) indicates 
presence of RAD51 foci. Right block shows no accumulation of RAD51 foci (Vrieling, 2016).  
 
Radiation-induced RAD51 foci formation is suppressed in BRCA2-mutated cells. BRCA1-
mutated cells did not show radiation-induced RAD51 foci repression. These results suggest the 
importance of BRCA2 in RAD51 foci formation (Yuan et al., 1999).  
 
6. Clinical and chromosomal radiosensitivity 
 
Sensitivity of cells to the effects of radiation is known as radiosensitivity. This may result in 
chromosomal aberrations leading to chromosomal instability. Therefore DNA damage response 
is highly crucial and extremely critical in maintaining genomic stability (Khanna and Jackson, 
2001). Radiosensitivity of cells is dependent on the phase of the cell cycle (Pawlik and 
Keyomarsi, 2004) and it is also dependent on cell type. Radiosensitivity of different cell types is 
dependent on factors such as dividing status, cell differentiation and mitotic activity (Washington 
and Leaver, 2015).  
Some patients undergoing radiotherapy display increased clinical radiosensitivity by showing 
adverse normal tissues side-effects. The first indication for a possible inherited basis for such 
clinical radiosensitivity came from patients with rare genetics syndromes such as Ataxia 
Telangiectasia (AT) and Nijmegen breakage syndrome (NBS) (Jeggo and Lavin, 2009). These 
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patients were shown to display not only clinical, but also in vitro chromosomal radiosensitivity 
(Huo et al., 1994). Patients with these syndromes have germline mutations in genes involved in 
DNA damage repair. Patients with AT and NBS also display predisposition to many cancers. 
Their increased chromosomal radiosensitivity led to studies that showed an enhanced in vitro 
chromosomal radiosensitivity in patients with different cancers, such as head and neck, 
colorectal, prostate, breast and lung cancer (Parshad et al., 1983, Riches et al., 2001, Baeyens et 
al., 2002a). 
 
6.1. Chromosomal radiosensitivity in breast cancer 
 
European studies have indicated elevated chromosomal radiosensitivity in familial and sporadic 
breast cancer. Radiation-induced MNi in the G0 cells and chromatid breaks in the G2-phase cells 
were observed in increased frequencies in breast cancer populations (Baeyens et al., 2002b, 
Riches et al., 2001, Terzoudi et al., 2000). European breast cancer patients’ exhibit elevated 
sensitivity to chromosomal damage induced by IR (Baria et al., 2001, Poggioli et al., 2010, 
Ryabchenko et al., 2012, Auer et al., 2014, Varga et al., 2007). Outside of Europe, in vitro 
chromosomal radiosensitivity of breast cancer patients in other populations has also been 
investigated by evaluating damage in the G2 phase. The non-Hispanic white and Mexican 
American patients’ exhibit enhanced chromosomal radiosensitivity. The results in African 
American population have been conflicting (Wang et al., 2012, Natarajan et al., 2006). The 
differences observed in chromosomal radiosensitivity of breast cancer patients with distinct 
ancestral backgrounds could mean that ethnicity is a potential factor associated with the effects 
of radiation. 
 
Increased chromosomal radiosensitivity can be correlated to various factors including age and 
defects in DNA repair proteins such as BRCA1/2 mutations (Auer et al., 2014, Becker et al., 
2012). Defects in BRCA contribute to impaired DNA repair and make the cells susceptible to the 
damaging effects of IR. The association between increased chromosomal radiosensitivity and 
BRCA mutations as a confounding factor was a contradictory subject (Ernestos et al., 2010, 
Baeyens et al., 2004). The BRCA genes are key role players in maintaining genomic stability by 
interacting with various proteins involved in DNA damage repair. Efficient repair, particularly in 
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the G2 phase, following exposure to IR ensures optimal DNA damage repair and, additionally, 
BRCA functions in checkpoint efficiency. The importance of BRCA in chromosomal 
radiosensitivity has been confirmed in BRCA1/2 mutation carries in the absence of breast cancer 
compared to non-BRCA1/2 carriers (Baert et al., 2016, Baert et al., 2017, Barwell et al., 2007). 
Various factors effecting chromosomal radiosensitivity in breast cancer can be studied in vitro by 
mimicking biological responses to IR in breast cancer cell lines (Sprung et al., 2005, Zhu et al., 
2015).      
 
Normal tissue effects in breast cancer patients undergoing radiotherapy have been documented. 
By altering the radiation dose, the normal cellular side effects can be limited. Efficient doses of 
IR are, however, required to kill malignant cells. Chromosomally radiosensitive breast cancer 
patients may react severely to IR and display increased normal tissue side effects. By assessing 
individual chromosomal radiosensitivity of breast cancer patients, the radiotherapy treatments 
can be tailored to suit individual patients (Huber et al., 2011, Barber et al., 2000). 
Chromosomally radiosensitive patients are also at high risk in developing secondary cancers. It 
was reported that 8% of all cancers are radiation-induced secondary malignancies (Habash et al., 
2017). Assessing genetic predisposition, particularly in the DNA repair proteins, in these patients 
is crucial. Acute side effects of radiotherapy are associated with genetic alterations (Andreassen 
and Alsner, 2009). Therefore, chromosomal radiosensitivity studies are extremely important for 
patients that require radiotherapy. Despite the breast cancer burden in South Africa, 
chromosomal radiosensitivity has never been evaluated before.    
 
6.2. Chromosomal radiosensitivity in Fanconi anaemia 
 
FA patients undergoing radiotherapy display increased clinical radiosensitivity by exhibiting 
adverse normal tissues side-effects (Birkeland et al., 2011, Alter, 2002b). Evidence suggests that 
FA patients are chromosomally radiosensitive to IR (Higurashi and Conen, 1973, Heddle et al., 
1978, Higurashi and Conen, 1971). FA patients exhibit significantly higher DNA damage 
indicating chromosomal instability (Camelo et al., 2008). Previous studies have shown that FA 
patients exhibit sensitivity to the damaging effects of IR. Despite available evidence, literature 
data on chromosomal radiosensitivity of FA patients is very limited.  
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The FA/BRCA pathway is involved in DNA DSB repair by HR and in the processing of DNA 
damage induced by MMC. MMC sensitivity in FA patients is widely described (Cohen et al., 
1982, Cervenka and Hirsch, 1983, Mozdarani et al., 2011, Talmoudi et al., 2013). In the presence 
of hematopoietic somatic mosaicism, the diagnosis of FA patients with MMC can be a challenge 
(Pinto et al., 2009). There is an urgent need for an efficient diagnostic test for FA patients who 
have deficiencies in FA genes that important for DNA repair. 
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CHAPTER 2 
Research aims and objectives 
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AIM 
The general aim of this study was to evaluate the chromosomal instability and radiosensitivity of 
South African breast cancer, with focus on the triple negative patients, and FA patients. Patients 
harbouring mutations in DNA repair genes are expected to be chromosomally instable. TNBC 
patients frequently have defects in DNA repair pathways. Radiosensitivity information is 
particularly important in South Africa as radiotherapy is often the only treatment possible for late 
diagnosed inoperable breast cancers. FA is also characterised by DNA repair defects and 
associated with chromosomal instability. Chromosomal instability and radiosensitivity in these 
population groups was investigated using the G0 and S/G2 MN assay. The link between 
radiosensitivity and DNA repair genes in these population groups was also explored by genetic 
screening.   
OBJECTIVES 
The study will be divided as follows:  
Primary objectives: 
1. Investigate chromosomal instability and radiosensitivity of a selected cohort of triple 
negative and luminal breast cancer patients in South Africa compared to healthy controls 
using the G0 and S/G2 MN assay. Collect clinical and social data of patients to 
investigate if there is an influence of clinical parameters on chromosomal radiosensitivity. 
Investigate the influence of age and ethnicity on chromosomal radiosensitivity. 
2. Investigate chromosomal instability and radiosensitivity of FA patients and parents using 
the G0 and S/G2 MN assay. Analyse correlations between FANC mutations in FA 
patients with results of the MN assays. 
3. Analyse the suitability and sensitivity of the G0 and S/G2 MN assay for the identification 
of radiosensitive breast cancer and FA patients in South Africa. 
4. Optimise a novel chromosomal breakage test using MMC for diagnosis of FA patients. 
Compare MMC-induced DNA damage in FA patients, parents and controls using the 
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optimised MMC MN assay. Analyse correlations between FANC mutations and results of 
MMC MN assay.  
Secondary objectives:  
1. Investigate the mechanisms underlying chromosomal radiosensitivity of breast cancer 
patients in South Africa by scrutinising mutations in DNA repair genes (BRCA1, BRCA2, 
PALB2, CHEK2) using next generation sequencing (NGS) complemented with multiplex 
ligation-dependent probe amplification (MLPA). 
 
2. Analyse correlation between the mutation analysis results of breast cancer patients with 
the MN assays results. 
 
3. Optimise a FANC gene panel for mutation analysis for 20 FANC genes using NGS 
complemented with MLPA. 
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CHAPTER 3 
Chromosomal radiosensitivity of 
lymphocytes in South African breast 
cancer patients of different ethnicity: An 
indirect measure of cancer susceptibility 
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According to South Africa (SA)’s most recent cancer 
registry, breast cancer is the leading cancer among 
SA women, with a lifetime risk of 1 in 34.[1] SA is 
a country with citizens of diverse ethnicity: black 
African (80.2%), white Caucasian (8.5%), mixed/
coloured (8.9%) and Indian/Asian (2.4%).[2] The lifetime risk of 
breast cancer differs according to ethnicity: 1/52 in black women, 
1/22 in coloured women, 1/19 in Indian women and 1/18 in white 
women.[1] While the incidence is lowest among black women, it is 
rising as a result of increased life expectancy and urbanisation, which 
leads to lifestyle changes that elevate exposure to known risk factors 
for breast cancer such as dietary changes, decreased exercise, delayed 
and decreased parity, and reduction in breastfeeding.[3] Although 
there is a lower incidence of breast cancer in SA in comparison with 
developed countries, the mortality rate of existing breast cancer 
patients is higher owing to limited access to diagnostic centres, 
particularly in rural areas, lack of awareness, low standards of 
healthcare facilities and limited screening.[4]
Familial breast cancer caused by mutations in high-penetrance genes 
such as BRCA 1 and BRCA 2 accounts for only 5% of all breast cancers. 
The majority of breast cancers are sporadic and are due to mutations in 
a number of low-penetrance genes. Candidate genes for breast cancer 
risk include those involved in DNA damage repair pathways. Mutations 
in genes regulating these pathways are characterised by increased 
chromosomal radiosensitivity.[5] Measurement of chromosomal 
radiosensitivity has been used as an indirect measure of cancer 
susceptibility. The association between chromosomal radiosensitivity 
and cancer risk is supported by the following facts: cancer-prone 
disorders such as ataxia telangiectasia present with high chromosomal 
radiosensitivity; elevated chromosomal radiosensitivity is an indicator 
of defects in DNA repair that could lead to the chromosomal 
instability often observed in cancer; and chromosomal radiosensitivity 
is linked with early events in carcinogenesis.[6]
Several studies (reviewed in Cardinale et al.[7]) on European, Asian 
and American populations have shown breast cancer patients to 
have elevated chromosomal radiosensitivity compared with healthy 
individuals. Studies on the chromosomal radiosensitivity of breast 
cancer patients have never been performed in SA.
Chromosomal radiosensitivity can be measured using the 
cytokinesis-block micronucleus assay. Micronuclei (MN) are 
small nuclei that form in the cytoplasm when chromosomes or 
chromosome fragments are not incorporated into the daughter nuclei 
subsequent to cell division. MN can contain whole chromosomes 
(mis-segregated during mitosis) or acentric fragments, which are 
usually the result of misrepaired or unrepaired DNA double-strand 
breaks. MN are counted in cells that have undergone a single division; 
however, cytokinesis is blocked by adding cytochalasin B, which 
results in binucleated (BN) cells. This assay is well established, robust 
and can be performed on lymphocytes, which are easily obtained 
through venepuncture. The automation of MN scoring with the 
Metafer 4 platform (MetaSystems, Germany) has minimised the 
variability of the assay and rendered it rapid and less subjective.
Background. Breast cancer is the leading cancer among South African (SA) women. SA has citizens from diverse ethnic groups, and the 
lifetime risk of breast cancer differs according to ethnicity. Candidate genes for increased breast cancer risk are those involved in DNA 
damage repair pathways, and mutations in these genes are characterised by increased chromosomal radiosensitivity. Several European 
studies have shown that breast cancer patients are more sensitive to ionising radiation than healthy individuals.
Objectives. To investigate the in vitro chromosomal radiosensitivity of SA women with breast cancer and the possible influence of ethnicity 
and clinical parameters on chromosomal radiosensitivity.
Methods. Chromosomal radiosensitivity was analysed with the micronucleus assay using lymphocytes of breast cancer patients and healthy 
individuals of different ethnic groups. Lymphocytes were irradiated in vitro with 2 Gy or 4 Gy, and micronuclei (MN) were scored 70 hours 
after irradiation. These MN frequencies were correlated with the ethnicity and clinical parameters of the breast cancer patients.
Results. MN values were higher in breast cancer patients than in healthy controls. This was noted for black and white breast cancer patients 
at the different radiation doses. No correlations could be demonstrated between MN values and clinical parameters of the breast cancer, 
except that MN values were significantly higher in oestrogen receptor (ER)-positive breast cancers.
Conclusion. SA breast cancer patients have elevated chromosomal radiosensitivity compared with healthy controls. ER positivity also 
influences chromosomal radiosensitivity.
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Objective
To measure the chromosomal radiosensitivity 
of SA breast cancer patients in a case-control 
study design with the micronucleus assay and 
the Metafer 4 scoring system. Recent studies 
have shown how tumour characteristics of 
breast cancer can differ among different ethnic 
groups.[8,9] The differences between the ethnic 
groups point to differences in the underlying 
biology of the disease and led to the idea 
of comparing chromosomal radiosensitivity 
in different ethnic groups. We also assessed 
whether there was an influence of clinical 
parameters on chromosomal radiosensitivity.
Materials and methods
Subjects
Blood samples were collected from 68 breast 
cancer patients (mean age (standard deviation 
(SD)) 52 (12)) recruited from Charlotte 
Maxeke Johannesburg Academic Hospital 
(CMJAH), a public hospital in Johannesburg, 
Gauteng Province, South Africa, and Donald 
Gordon Medical Centre, a private hospital in 
Johannesburg. We included 30 black breast 
cancer patients (mean age 47 (12) years), 25 
white breast cancer patients (mean age 59 
(11) years), 7 Indian breast cancer patients 
(mean age 45 (8) years) and 6 coloured breast 
cancer patients (mean age 49 (8) years). 
Exclusion criteria included prior chemo- and/
or radiotherapy. Clinical and biographical 
information on the patients was obtained 
through questionnaires and hospital files. 
All patients were categorised by race (black, 
white, Indian, coloured) based on patients’ self-
reported data from the questionnaires. Most 
of the breast cancer patients (80.0%) had inva-
sive ductal carcinomas, of which 31.1% were 
stage 0 - I, 53.3% stage II and 15.6% stage 
III. Overall 74.1% were oestrogen receptor 
(ER)-positive, 63.8% were progesterone 
receptor (PG)-positive and 78.6% were human 
epidermal growth factor receptor 2 (HER2)-
negative. No participant was HIV-positive.
Blood samples from 70 healthy controls 
(mean age (SD) 35 (12) years), including 20 
black women (mean age 36 (15) years), 35 
white women (mean age 36 (10) years), 8 
Indian women (mean age 32 (6) years) and 
7 coloured women (mean age 31 (13) years), 
were also collected. The healthy donors were 
staff members and students from CMJAH, 
where the study was undertaken. All donors 
signed informed consent. Ethical approval for 
the study was obtained through the Human 
Research Ethics Committee, University of the 
Witwatersrand, Johannesburg (M110248).
Irradiations and micronucleus assay
The protocol for the micronucleus assay 
described by Herd et al.[10] was used in this 
study. In brief, 0.5 mL of heparinised blood 
was added to 4.5 mL of RPMI 1640 (Bio-
Whittaker, USA) supplemented with 13% 
fetal bovine serum (Gibco-Invitrogen, USA), 
and antibiotics (50 U/mL penicillin and 
50 mg/mL streptomycin; Gibco-Invitrogen, 
USA). The medium was pre-warmed to 37°C 
and gassed (5% CO2/95% air). Culture flasks 
with blood and medium were irradiated 
with doses of 2 Gy or 4 Gy of X-rays using 
a 6 MV photon beam from a medical linear 
accelerator (Siemens Healthcare, Germany). 
A 0 Gy dose was used as a sham-irradiated 
control. For each dose point, two cultures 
were set up. Immediately after irradiation the 
lymphocytes were stimulated with 100  µL 
phytohaemagglutinin (stock solution 1 mg/
mL; Sigma-Aldrich, USA), and 23 hours 
later 20 µL cytochalasin B (stock solution 
of 1.5 mg/mL; Sigma-Aldrich) was added 
to block cytokinesis. Cells were harvested 
at 70 hours after stimulation using a cold 
(4°C) hypotonic shock with 7 mL 0.075M 
KCl (Merck, Germany). This was followed 
by fixation in methanol:acetic acid:Ringer 
(0.9% NaCl) solution (4:1:5) (Merck). 
Fixed cell suspensions were dropped on 
coded slides and stored at 4°C. Slides were 
mounted with Vectashield containing DAPI 
(4,6-diamidino-2-phenylindole; Vector Lab-
oratories, USA) before being scanned auto-
matically with the Metafer 4 system. The 
classifier and scoring method was based on 
Herd et al.[10] Each dose point was scored 
by at least two scorers. All results were 
normalised to an MN frequency in 1 000 BN 
Table 1. Spontaneous and radiation-induced MN values in breast cancer patients and 
healthy controls, according to ethnicity
Group Patients Controls p-values
Black  
n 30 20
MN/1 000 BN cells, mean (SD)
0 Gy 14 (8)* 10 (4) 0.0087
2 Gy 179 (30)* 159 (31) 0.0273
4 Gy 498 (91)* 449 (66) 0.0324
White  
n 25 35
MN/1 000 BN cells, mean (SD)
0 Gy 16 (7)* 11 (4) 0.0083
2 Gy 172 (24)* 158 (23) 0.0253
4 Gy 507 (79)* 443 (35) 0.0006
Coloured
n 6 7
MN/1 000 BN cells, mean (SD)
0 Gy 12 (9) 12 (7) 0.6043
2 Gy 193 (49) 169 (20) 0.4697
4 Gy 487 (103) 444 (51) 0.5281
Indian
n 7 8
MN/1 000 BN cells, mean (SD)
0 Gy 11 (6) 11 (5) 0.8427
2 Gy 172 (28) 177 (34) 0.8000
4 Gy 467 (91) 470 (74) 0.9305
All groups
n 68 70
MN/1 000 BN cells, mean (SD)
0 Gy 14 (7)* 11 (5) 0.0012
2 Gy 177 (30)* 161 (27) 0.0014
4 Gy 497 (86)* 448 (52) 0.0001
*Significantly different from controls.
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cells. Radiation-induced MN values were 
obtained by subtracting baseline (0 Gy dose) 
values from those obtained in irradiated 
samples.
Statistical analysis was performed with 
Graphpad Prism 6. Differences between 
means of MN yields of patients and controls 
in black and white populations were tested 
for significance with the unpaired Student’s 
t-test. For comparison of differences in MN 
values in the Indian and coloured subgroups, 
and between ER receptor subgroups, the 
Mann-Whitney U-test was applied. This test 
is used for small sample sizes. To analyse the 
correlations between age, clinical parameters 
and MN values, we used Pearson’s 
correlation coefficient. The confidence level 
of the statistical tests was 95%, and statistical 
significance was set at p<0.05.
Results
The results obtained with the micronucleus 
assay on the samples of 68 breast cancer 
patients and 70 healthy individuals are 
presented in Table 1. The mean spontaneous 
MN yields of all the breast cancer patients 
were significantly higher than those of the 
healthy controls (p<0.005). The spontaneous 
MN yields were significantly correlated 
with the age of the healthy individuals, but 
this correlation could not be observed in 
the breast cancer patient group (p<0.005). 
To investigate whether ethnicity had an 
influence on chromosomal radiosensitivity, 
we split the breast cancer patients and 
the healthy controls into four subgroups 
(black, white, coloured and Indian). When 
the patients and controls were grouped 
according to their ethnicity, the significantly 
higher number of spontaneous MN was 
only seen in the black and white patients 
compared with the healthy individuals of the 
same ethnicity.
The radiation-induced MN yield was 
calculated by subtracting the spontaneous 
yield from the yield in the irradiated 
cells. For the whole group of breast 
cancer patients, the mean MN yields were 
significantly higher than in the whole 
group of healthy individuals for both 2 
Gy and 4 Gy irradiations. Grouping the 
samples according to their ethnicity revealed 
significantly higher radiation-induced MN 
values in the black and white breast cancer 
patients for both 2 Gy and 4 Gy. This 
could not be observed in the coloured and 
Indian subgroups (Table 1). Histograms of 
radiation-induced MN after 4 Gy for the four 
ethnic subgroups are presented in Fig. 1. The 
MN distribution after 2 Gy showed similar 
patterns for the four subgroups (data not 
shown). Although no significant differences 
in mean MN values could be seen in the 
coloured group, there was a shift of values 
towards the higher range. This shift was not 
noted in the Indian population.
All the breast cancer patients were also 
split into groups according to clinical 
parameters, and MN values in these groups 
were compared. No significant correlation 
could be found between clinical parameters 
(tumour histological type, size and staging) 
and MN yields of the breast cancer patients. 
There was an effect of ER positivity on the MN 
yields (Fig. 2). Breast cancers positive for ER 
receptors had significantly higher radiation-
induced MN values than ER-negative breast 
cancers for both 2 Gy and 4 Gy (ER-positive 
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Fig. 1. Distribution of MN yields after 4 Gy of breast cancer patients and healthy individuals. (Dark blue 
bars = breast cancer patients; light blue bars = healthy individuals.)
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185 MN/1 000 BN cells (2 Gy), 518 MN/1 000  BN cells (4 Gy); 
ER-negative 159 MN/1 000 BN cells (2 Gy), 468 MN/1 000 BN cells 
(4 Gy)) (p=0.0031 and p=0.044, respectively).
Discussion
This study investigated whether SA breast cancer patients are more 
sensitive than healthy individuals to DNA damage caused by ionising 
radiation. Since differences in breast tumour characteristics are 
noted between ethnic populations, we also evaluated the possible 
differences of chromosomal radiosensitivity in the four SA ethnic 
groups.
Higher spontaneous mean MN frequencies, which were seen in 
breast cancer patients in this study, have been linked with higher 
levels of genetic instability. These significantly higher mean MN 
values occurred mainly in the white and black patients, who had 
significantly higher MN values than controls of the same ethnicity. 
The higher ages of the cancer patients, which is a limitation in our 
study, could have played a role in the elevated spontaneous MN 
values; Thierens et al.[11] have suggested an increase of 0.58 MN/
year. The higher levels of spontaneous MN in the breast cancer 
patients could also suggest higher chromosomal instability, which is 
associated with an increased risk of cancer.
The higher chromosomal radiosensitivity observed in the whole 
group of SA breast cancer patients and in the white patients in 
this study is in agreement with several international studies. It is 
interesting that the significantly higher MN values were also seen 
in black breast cancer patients, who have never been studied for 
chromosomal radiosensitivity with the micronucleus assay. This 
trend is in contrast with a study performed by Wang et al.,[12] who 
looked at chromatid breaks in young breast cancer patients and 
noted significantly higher chromatid breaks in white American breast 
cancer patients than white controls, but not in African-American 
breast cancer patients compared with black controls.
The MN values of the coloured patients and controls were not 
significantly different, although higher MN values were observed in 
the patients. However, the small sample size of this subgroup limits 
conclusions. The other small subgroups were the Indian patients and 
controls, between whom no differences in mean MN values were 
found.
Black African breast cancer patients are known to have more 
aggressive tumour phenotypes than white women, and a higher 
prevalence of triple-negative and premenopausal breast cancers.[8,9] 
These differences were not reflected in differences in chromosomal 
radiosensitivity of white and black breast cancer patients in our 
study. We found no correlation between the MN values and most 
of the clinical parameters investigated, which is in agreement with 
Baeyens et al.[13] There was an effect of ER status on MN values, with 
ER-positive women having significantly higher MN values. A similar 
trend was observed in the study of Riches et al.,[14] where patients with 
increased G2 radiosensitivity had a higher proportion of ER-positive 
tumours. The underlying reason for the higher radiation-induced 
MN in this type of breast cancer is unknown, but it could be based 
on interactions between the double-strand break repair kinase 
DNA-PK and ERs.[15] The link between ERs and MN could suggest 
a prognostic value of the micronucleus assay for ER-positive breast 
cancers. Black and coloured women with breast cancer have a higher 
incidence of ER-negative cancers,[8,9] which could have led to lower 
MN values in these groups. However, we did not observe this in our 
study. Enlarging the sample sizes and subgrouping the cancer patients 
into ethnic groups and into ER-positive and negative patients could 
provide greater insight.
Conclusion
Our results showed that SA breast cancer patients have elevated 
chromosomal radiosensitivity compared with healthy controls. The 
presence of ER positivity also influenced this radiosensitivity. More 
rigorous extended studies on the different ethnic groups are needed 
to validate our findings and to unravel the underlying mechanisms.
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Abstract
The micronucleus assay (MN assay) is a well-established assay in genetic toxicology, biomonitoring 
of mutagen-exposed populations and chromosomal radiosensitivity testing. To evaluate the effect 
of storage time on the chromosomal radiosensitivity assessment in lymphocytes, micronuclei 
(MN) yields in blood samples received and processed on the same day were compared with MN 
yields obtained when blood cultures were set up 24 and 48 h after blood sampling. Furthermore, 
the influence of general anaesthesia on MN and binucleated cells (BN) yields in the MN assay 
was considered. Blood samples of 10 healthy donors were irradiated and blood cultures were set 
up during the same day of blood sampling or with a delay of 24 or 48 h. The MN assay was also 
performed on two blood samples from 60 women undergoing breast surgery. The first blood sample 
was taken before general anaesthesia and the second sample, 2 h after anaesthesia induction. Fifty 
percent of the blood samples were transported to the cytogenetics lab within 2 h while the other 
50% reached the lab after 24 h. The results of this study show a decrease in BN and an increase 
in MN yields with increasing storage time before irradiation and setting up of the MN assay for 
both healthy controls and patients. The administration of general anaesthesia in patients resulted in 
lower BN yields, higher spontaneous MN yields but no differences in radiation-induced MN yields. In 
conclusion, this study indicates that the time between blood sampling and the in vitro irradiation of 
the samples for the MN assay influences the MN yields. Delays of more than 24 h should be avoided. 
To assess chromosomal radiosensitivity in patients, blood samples should be taken before induction 
of general anaesthesia as anaesthesia can have an impact on the reliability of the MN results.
Introduction
The micronucleus assay (MN assay), is a well-established assay 
to assess chromosomal damage in the field of genetic toxicology, 
human biomonitoring of mutagen-exposed populations and chro-
mosomal radiosensitivity testing. Over the years, many case–control 
radiosensitivity studies performed on cancer patients have shown 
that MN can also be used as biomarker for cancer predisposition. 
Cancer patients may have defects in repair of DNA damage and this 
can be reflected in enhanced chromosomal radiosensitivity (1–3). To 
assess chromosomal radiosensitivity with the MN assay, lympho-
cytes of patients are irradiated in vitro and stimulated into division. 
Micronuclei (MN), which represent small nuclei that form in the 
cytoplasm when chromosomes or chromosome fragments are not 
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incorporated into the daughter nuclei subsequent to cell division, 
are scored in binucleated cells (BN), which can be accumulated by 
blocking cytokinesis with cytochalasin-B. MN can contain: whole 
chromosomes (missegregated during mitosis), acentric fragments 
resulting from misrepaired or unrepaired DNA double-strand breaks 
or other complex chromosomal fragments (4). Automation of the 
MN scoring with the Metafer platform (Metasystems) has further 
improved this test by allowing it to become especially rapid and 
reproducible (5,6). The automated Metafer system scans the slide for 
BN and subsequently counts the number of MN in these cells based 
on a number of pre-programmed settings or classifiers (7). The cells 
are then displayed in a gallery, where they can be manually checked 
and corrected for false positives and negatives. A factor influencing 
the reliability and sensitivity of the automated MN scoring is the 
yield of BN per sample.
The blood samples, on which the MN assay will be performed, 
often need to be transported to cytogenetic laboratories. This transit 
time can vary from 1 h to more than 100 h (8) and the conditions 
(temperature changes) during this transit time can influence the out-
come of the MN assay (9,10). We noticed at the start of our radiosen-
sitivity study on breast cancer patients that the time between blood 
sampling and the initiation of the MN assay could vary between 2 
and 24 h, due to time delays and other logistics involved in the dif-
ferent theatre procedures.
Besides blood storage time, another confounding factor in chro-
mosomal radiosensitivity studies is the administration of general 
anaesthesia. Often blood samples of cancer patients are collected 
when the patients undergo curative procedures and are under gen-
eral anaesthesia. Although the mutagenic/genotoxic effects of anaes-
thesia have been widely studied in lymphocytes of patients and 
personnel, the effect of anaesthetic agents on in vitro chromosomal 
radiosensitivity assessment using the MN assay has not been inves-
tigated (11,12).
In the present study, we investigated the effect of blood storage 
time on in vitro chromosomal radiosensitivity, by comparing the 
spontaneous and in vitro radiation-induced MN yields, in blood 
samples of 10 healthy individuals processed for radiosensitivity 
assessment on the same day and 24 or 48 h after blood sampling. 
Additionally, the effect of blood storage time on in vitro chromo-
somal radiosensitivity was also analysed in a group of patients 
undergoing breast surgery. In this patient group, we also investigated 
the influence of general anaesthesia on spontaneous and in vitro 
radiation-induced MN.
Materials and methods
Study population and blood sampling
Ten milliliters of heparinised peripheral blood was collected from 
10 healthy women (mean age: 29  years; staff members and stu-
dents from the University of Witwatersrand). These volunteers had 
no known previous exposure to cytotoxic or genotoxic agents. The 
blood samples were stored at room temperature in the cytogenetic 
lab and the MN assay was started up immediately (within 2 h) after 
venepuncture (Day 0); within 24 h after venepuncture (Day 1) and 
48 h after venepuncture (Day 2).
Concurrently, 60 female patients were recruited from Wits 
University Donald Gordon Medical Centre, a private hospital 
in Johannesburg where they were undergoing breast surgery for 
cancer treatment or elective procedures. None of the patients had 
received chemotherapy or radiotherapy prior to sample collection. 
Both the effect of blood storage time and anaesthesia on MN yields 
was assessed in these patients. To assess the effect of general anaes-
thesia on MN results, heparinised venous blood (10 ml) was drawn 
from patients at two time points: before the induction of general 
anaesthesia and just before completion of surgery, ~120 min after 
the anaesthesia was administered. To assess the effect of blood stor-
age time, we performed the MN assay on blood samples of patients 
taken before and after anaesthesia, and that were transported to the 
cytogenetics laboratory within 2 h of surgery (group A—Day 0) or 
that were stored at room temperature in the theatre and transported 
to the cytogenetics lab after 24 h (group B—Day 1). There were 30 
patients (mean age: 46 years; age range: 27–65 years) in group A and 
30 patients (mean age: 45 years; age range: 21–87 years) in group 
B. All blood donors signed an informed consent and the study was 
approved by the Human Research Ethics Committee, University of 
Witwatersrand, Johannesburg, South Africa (M10372).
Anaesthesia procedure of patients going for breast 
operation
The anaesthetic procedure included the following steps: all patients 
were fully monitored during surgery with standard American Society 
of Anaesthesiology (ASA) monitoring consisting of three lead elec-
trocardiogram, peripheral oxygen saturation (SpO2), non-invasive 
arterial pressure (systolic and diastolic), end-tidal C02 (PETCO2) 
and end-tidal Desflurane (DSF). Patients were given the choice of 
midazolam oral premedication (15 mg) or none. All patients were 
given Cefazolin (1 g) prior to induction. All patients were induced 
with Propofol (2 mg/kg, iv), in addition to Fentanyl (2 ug/kg, iv) and 
maintained with DSF at a minimum alveolar concentration of at least 
1.0 and no greater than 1.3. All patients received neuromuscular 
blockade with rocuronium bromide (0.9 mg/kg, iv). The lungs were 
mechanically ventilated using volume control mode with tidal vol-
umes of 8 ml/kg and inspired oxygen concentration (FiO2) of between 
40 and 50% in air at 0.5–1 l/min. Respiratory rate was titrated to 
maintain PETCO2 concentration at 34–40  mmHg. Balanced anal-
gesia with Morphine (titrated up to 10 mg, IV), Paracetamol (1g, 
IV) and Parecoxib (40 mg, IV) was given to all patients. All patients 
received Granisetron (1 mg, IV) and Decadron (8 mg, IV) as antiemet-
ics. All patients had reversal of their neuromuscular blockade with 
neostigmine (2.5 mg, IV) and Glycopyrulate (0.4 mg, IV).
Automated-MN assay
Cultures for the MN assay were initiated according to a standard 
protocol in our laboratory. Briefly, 0.5 ml of blood was diluted in 
4.5 ml of complete culture medium [RPMI (Roswell Park Memorial 
Institute) 1640 (BioWhittaker, Walkersville, MD, USA) supplemented 
with 13% foetal bovine serum (Gibco-Invitrogen, New York, NY, 
USA) and 50 U/ml penicillin and 50 mg/ml streptomycin (Gibco-
Invitrogen). The blood cultures were irradiated with 2 and 4 Gy 6 
MV X-rays at a dose rate of ~1.33 Gy/min. A 0 Gy dose was used 
as a sham-irradiated control. All cultures were set up in duplicate. 
After irradiation, 100 µl phytohaemagglutinin (PHA) (stock solution 
1 mg/ml) (Sigma-Aldrich, St Louis, MO, USA) was added as mito-
gen and 23 h later 20 µl cytochalasin B (stock solution of 1.5 mg/ml, 
Sigma-Aldrich) was added to block cytokinesis. Cells were harvested 
70 h after stimulation using a cold (4°C) hypotonic shock with 7 ml 
0.075 M KCl (Merck, Darmstadt, Germany), followed by fixation in 
methanol:acetic acid:Ringer (0.9% NaCl) solution (4:1:5) (Merck) 
at 4°C (6). A day later, cells were then fixed another three times with 
methanol:acetic acid (4:1) (Merck) and stored overnight at 4°C. To 
standardise the slide preparation, all cells were concentrated in 250 µl 
fixative and 40 µl of cell suspensions were dropped on clean slides 
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the following day. Mounting was done with vectashield containing 
DAPI (4,6-diamidino-2-ohenylindole; Vector Laboratories, Brussels, 
Belgium). Slides were coded and scanned with the MSearch software 
module of the Metafer 4 scanning system (MetaSystems), using a 
Zeiss Imager.Z2 microsope (Zeiss). A maximum of 1000 BN per slide 
was scanned. The classifier and scoring method was based on Herd 
et al. (13). Briefly, Msearch software module of Metasystems identi-
fies BNs and displays them in an image gallery with a MN count 
per cell. All automated scorings (BN and MN) were visually checked 
and validated by two scorers to correct for false positive and false 
negative MN and to reject unsuitable cells. The BN yields represented 
in this article are the total number of true BN cells scanned on two 
slides. The MN results were normalised to a MN yield in 1000 BN.
Statistical analysis
Statistical analysis was performed with the software Graphpad Prism 
6. The comparison of mean MN yields and BN yields between the 
two patient groups was done with the unpaired student t-test, while 
the comparison of the blood samples before and after anaesthesia 
were compared with the paired student t-test. The mean MN yields 
and BN yields of the healthy controls at the three time points were 
compared with the Wilcoxon test. The level of statistical significance 
was set at P < 0.05.
Results
Effect of blood storage time on MN and BN yields in 
healthy individuals
To study the effect of blood storage time on the MN results, the MN 
assay was performed in blood samples of healthy individuals with 
different storage times before initiating the MN assay. The delayed 
initiation of the MN assay had no effect on the spontaneous MN 
values. However, the radiation-induced MN yields increased sig-
nificantly as the time between blood sampling and irradiations and 
initiation of the MN assay increased (P = 0.0137 and P = 0.0020 
for 2 and 4 Gy, respectively at Day 1; P = 0.0039 and P = 0.0020 
for 2 and 4 Gy, respectively at Day 2) (Figure 1; Table 1). The BN 
yields decreased significantly after 24 h (Day 1)  for the 4 Gy dose 
(P = 0.0195) and after 48 h (Day 2) for both doses (P = 0.0098 and 
P = 0.002 for 2 and 4 Gy, respectively).
Effect of blood storage time on MN and BN yields in 
patients undergoing breast operations
The effect of blood storage time on the MN results was also analysed 
in a group of patients undergoing breast operations. For patients in 
group A, the blood samples were processed for MN analysis within 2 h 
after venepuncture while for patients belonging to group B the blood 
samples were processed 1 day after blood sampling. The MN yields 
of both groups are presented in Figure 2. The spontaneous MN yields 
between both groups were not significantly different. On the other 
hand, the radiation-induced MN yields for both the 2 and 4 Gy doses 
were significantly higher in group B (P = 0.0027 and P = 0.0030 for 2 
and 4 Gy, respectively). The differences noted in MN yields between 
the two patient groups, were not reflected in the BN yields, although 
the BN yields decreased as the dose increased (Table 2).
Effect of anaesthetics on the MN yields in patients 
undergoing breast operations
Table  3 shows mean MN yields and BN yields obtained with the 
MN assay performed on blood samples of breast surgery patients 
before they received anaesthetic agents and on blood samples of the 
same patients after 2 h of general anaesthesia. The spontaneous MN 
yields were significantly increased after administration of anaesthesia 
(P = 0.0017). No significant differences were observed between the 
mean radiation-induced MN yields before or after anaesthesia, but 
the coefficients of variation were higher in the ‘after anaesthesia’ sam-
ples. The mean yields of BN were significantly lower in the samples 
from the ‘after anaesthesia’ group for all radiation doses (P < 0.01).
Discussion
The effect of delays between blood sampling time and set up of the 
MN assay (in vitro irradiation and culture initiation) was investi-
gated in the frame of chromosomal radiosensitivity assessment 
with the MN assay. The effect on both spontaneous and in vitro 
radiation-induced MN was investigated. Several studies have shown 
influences on the MN yields of storage temperature, storage time and 
delayed mitogenic stimulation after the blood has been exposed to 
radiation in vivo (14). A reduction of MN yields is often observed 
in samples cultured more than 24 h post-irradiation (14), although 
others have seen no influence of storage time on the MN yields of 
exposed lymphocytes (9).
Regarding spontaneous MN yields, the influence of blood stor-
age temperatures has been studied before, with storage temperatures 
ranging from −196°C (liquid nitrogen) up to 37°C. The effect of 
Figure  1. Mean MN yields per 1000 BN cells (A) and BN yields (B) of 10 
healthy individuals with MN assay initiated immediately after venepuncture 
(Day 0); within 24 h after venepuncture (Day 1) and 48 h after venepuncture 
(Day 2). Error bars = SEM; *=Significantly different from Day 0. 
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storage time has also been previously studied with storage times 
ranging from 4 days to more than 2 years. All these studies reported 
contradictory results (9,15–18). In our present study, we did not 
find significantly higher spontaneous MN yields after 24 and 48 h of 
blood storage at room temperature. Comparably, Belloni et al. (18) 
observed no enhanced apoptosis and no enhanced chromosomal 
radiosensitivity in whole blood cultures stored for 24 or 48 h. The 
spontaneous MN yields were correlated with the age of the donors, 
which is widely described in literature (7,19).
The reason for the higher radiation-induced MN yields observed 
in blood samples stored at room temperature for longer than 24 h 
before initiation of the MN assay are still unclear. A possible expla-
nation could be that physiological cellular processes are impaired 
when the blood is stored at room temperature (20) and that DNA 
repair processes are not optimally functioning at the moment the 
cells are exposed to ionising radiation. Another hypothesis for the 
higher MN yields after longer blood storage times could be due to 
the fact that blood cells, during storage at room temperature, will 
release stress factors such as cytokines (21) and oxidative radicals 
that may affect the DNA before the cells are exposed to in vitro irra-
diation. A third explanation could be that during blood storage, cells 
become hypoxic and acute hypoxia can increase the level of oxida-
tive DNA damage and affect the chromosomal instability (22). The 
result of this oxidative stress may be undetectable in non-irradiated 
samples but may result in an additive effect when combined with 
exposure to ionising radiation.
The decrease in BN yields observed after higher doses of radiation is 
in agreement with other literature data and is due to the fact that higher 
doses will result in more highly damaged cells, which will not divide 
anymore and will go into apoptosis upon exposure (23). This will result 
in lower BN counts using the automated Metafer platform. If the highly 
Table 1. Mean BN yields and MN yields per 1000 BN cells for 10 healthy individuals with MN assay initiated immediately after venepunc-
ture (Day 0); within 24 h after venepuncture (Day 1) and 48 h after venepuncture (Day 2)
Day 0 Day 1 Day 2
BN MN BN MN BN MN
0 Gy Mean 1636.0 10.7 1563.0 7.8 1689.0 10.0
SEM 82.7 1.2 155.5 1.4 52.2 1.6
CV (%) 16.0 35.3 31.5 58.5 9.8 51.0
Range (min–max) 1017–1847 6–17 593–1839 3–18 1355–1861 4–18
P value versus day 0 0.5566 0.07 0.5566 0.9121
2 Gy Mean 1615.0 163.4 1562.0 201.9 1129.0 230.1
SEM 27.9 4.8 58.2 9.9 134.8 12.5
CV (%) 5.5 9.3 11.8 15.5 37.7 17.1
Range (min–max) 1490–1728 144–197 1158–1747 166–269 642–1790 163–292
P value versus Day 0 0.6953 0.0137* 0.0195* 0.002*
4 Gy Mean 1101.0 477.4 795.5 565.1 386.1 657.5
SEM 58.5 14.8 90.3 27.0 55.7 38.3
CV (%) 16.8 9.8 35.9 15.1 45.7 18.4
Range (min–max) 794–1401 384–544 450–1293 441–749 223–785 460–860
P value versus Day 0 0.0098* 0.0039* 0.002* 0.002*
*Significantly different from Day 0.
Figure 2. Mean MN yields per 1000 BN for 60 patients under going breast 
surgery. Group A (n = 30): blood samples received and MN cultures set up 
within 24 h after venepuncture (Day 0). Group B (n  =  30): blood samples 
received and MN cultures set up 1 day after blood sampling (Day 1). Error 
bars = SEM. *Significantly different from group A.
Table 2. Mean MN yields per 1000 BN for 60 patients under going 
breast surgery
Group A—Day 0 Group B—Day 1
MN MN
0 Gy Mean 12.7 12.1
SEM 1.1 1.2
CV (%) 48.7 56.0
Range (min–max) 3–29 3–39
P value versus group A 0.7072
2 Gy Mean 173.1 194.9
SEM 4.2 5.6
CV (%) 13.1 15.7
Range (min–max) 128–211 141–250
P value versus group A 0.0027*
4 Gy Mean 477.4 532.0
SEM 11.3 13.6
CV (%) 13.0 13.6
Range (min–max) 370–652 413–694
P value versus group A 0.003*
Group A (n = 30): blood samples received and MN cultures set up within 
24 h after venepuncture (Day 0); group B (n = 30): blood samples received 
and MN cultures set up 1 day after blood sampling (Day 1).
*Significantly different from group A.
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damaged cells in the samples that were stored more than 24 h before 
starting the MN assay undergo apoptosis, we can assume that, depend-
ing on blood storage time, we are looking with the MN assay at another 
pool of surviving lymphocytes that are still able to divide but with a 
lower DNA integrity or lower DNA repair capacity. Although Belloni 
et al. (18) did not detect higher levels of apoptosis in blood samples 
stored at 20°C for 48 h, Carloni et al. (24) has shown that adding PHA 
to lymphocyte cultures prevents the cells from undergoing apoptosis. 
Whether the DNA integrity or repair capacity has decreased during the 
delays in sample processing remains to be investigated.
In the second part of the study, the influence of general anaesthe-
sia on the MN assay was investigated. For this part, we compared the 
MN yields of blood samples from patients before and after induc-
tion of general anaesthesia to study the effect of anaesthetic agents 
on the spontaneous and radiation-induced MN. Several studies 
have shown that anaesthetic agents have genotoxic, mutagenic and 
hematologic effects and can also have an influence on DNA damage/
repair processes and apoptosis. In some studies, it was shown that 
the MN yields are increased in operating theatre personnel occupa-
tionally exposed to different anaesthetic gases (12,25,26). However, 
Wiesner et  al. (11) only observed increased MN yields in anaes-
thetists exposed to high levels of anaesthetics. Anaesthetic agents 
have been demonstrated to induce oxidative stress by increasing the 
concentrations of reactive oxygen species, which could cause DNA 
damage (27–29). Later studies showed contradictory results (30,31). 
The conflicting results on the genotoxicity of general anaesthetics 
in operating personnel or patients going for surgery could be due 
to different combinations and concentrations of anaesthetic agents 
used in the different studies. In our study, we detected a significant 
increase in the spontaneous MN yields in blood samples of patients 
that received general anaesthesia before blood sampling. According 
to Karabiyik et  al. (32) anaesthetic agent-induced DNA damage 
would be completely repaired by the cells by the fifth postoperative 
day. The observed increase in the spontaneous MN yields in blood 
samples of patients that received general anaesthesia could also be a 
result of oxidative stress caused by surgical trauma (33,34).
Unexpectedly, we could not observe differences in mean radi-
ation-induced MN yields between the samples before and after 
anaesthesia, although higher variations in MN yields were seen in 
the samples after anaesthesia. The DNA damage induced by irradi-
ating cells with 2 and 4 Gy X-rays possibly dominates the effect of 
the oxidative stress induced by the anaesthetic agents, which is only 
reflected in the higher spontaneous MN in non-irradiated samples. 
As general anaesthesia can also have aneugenic besides clastogenic 
characteristics (26), the use of a pancentromere probe in combina-
tion with the MN assay on these samples may clarify the origin of the 
observed MN. The effect of anaesthesia on BN yields (significantly 
lower BN yields after anaesthesia) can be a limiting factor influenc-
ing the reliability of the assay. It has been reported in the literature 
that apoptosis is enhanced during the early post-operative period in 
lymphocytes isolated from patients undergoing surgery under general 
anaesthesia (33). Although we do not see an effect of general anaes-
thesia on radiation-induced MN, exposure to general anaesthesia in 
combination with ionising radiation should be further investigated, 
as this can be important for the recently developed intraoperative 
radiotherapy treatments for several cancers. Our results suggest that 
blood samples after administration of general anaesthesia could be 
used to assess chromosomal radiosensitivity of individuals but the 
influence on lowering BN could be a limiting factor.
In conclusion, the results of this study indicate that blood storage 
time has an influence on the radiation-induced MN yields and by 
this can be a confounding factor when assessing the in vitro chromo-
somal radiosensitivity in patients by mean of the MN assay. Fresh 
blood samples from cancer patients should also preferably be taken 
before administration of general anaesthesia, as the anaesthetics can 
have an impact on the reliability of the MN results.
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Table 3. Mean MN yields per 1000 BN and BN yields for 60 patients that underwent breast surgery
Before Anaesthesia After Anaesthesia
BN MN BN MN
0 Gy Mean 1781.0 12.4 1667.0 14.9
SD 118.7 6.5 312.0 7.9
CV (%) 6.7 52.0 18.7 53.2
Range (min–max) 1058–1951 3–39 553–1916 3–42
P values 0.0098* 0.0017*
2 Gy Mean 1623.0 184.0 1340.0 178.8
SD 229.5 28.9 465.3 32.8
CV (%) 14.1 15.7 34.7 18.3
Range (min–max) 871–1891 128–250 314–1888 127–262
P values <0.0001* 0.2228
4 Gy Mean 1133.0 503.7 829.9 494.5
SD 402.5 72.0 464.3 94.2
CV (%) 35.5 14.3 56.0 19.0
Range (min–max) 290–1805 370–694 156–1782 351–733
P values <0.0001* 0.6219
*Significantly different from ‘before anaesthesia’ group with paired t-test. 
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INTRODUCTION 
 
Breast cancer is the most common cancer in South Africa (SA) and the second overall cause of 
mortality. As estimated by the national cancer registry, the lifetime risk in SA is 1 in 26 (NCR, 
2013). Environmental factors, lifestyle changes, reproductive and hormonal changes all 
contribute to breast cancer risk (Porter, 2009, Li et al., 2016). The risk is considerably greater 
with family history; women with a first degree relative with breast cancer have a 3.3-fold higher 
risk. Familial breast cancer is primarily linked with early-onset of the disease (Skol et al., 2016). 
With a young population structure, SA has a high incidence of breast cancer in young women 
exhibiting adverse tumour pathology. Additionally, genetic predisposition can contribute to the 
rise of early-onset breast cancer incidence (McCormack et al., 2013, Basro and Apffelstaedt, 
2010). Germline mutations in DNA repair genes such as BRCA1 and BRCA2 also confer to high 
breast cancer risk accounting for 15-20% of familial breast cancer and about 5% of all breast 
cancers (Nathanson et al., 2001).  
 
Breast cancer is subtyped based on the presence of receptors on the tumour. The presence of 
estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor 
receptor 2 (HER2) have prognostic values and are essential in patient management. Breast 
cancers expressing receptors are known as luminal subtypes. Luminal A is ER+/PR+/HER2- 
whereas luminal B is ER+/PR+/HER2+. When HER2 is highly expressed, the tumour is 
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 classified as HER2+ (Inic et al., 2014). Triple negative breast cancer (TNBC) is defined by the 
absence of ER, PR and HER2 and accounts for 10-20% of all breast cancers worldwide (Foulkes 
et al., 2010, Reis-Filho and Tutt, 2008, Alcantara et al., 2017) and ranges between 14-26% in SA 
(Dickens et al., 2014, McCormack et al., 2013). Aggressive tumour progression, higher grade 
tumours and metastases are features of TNBC that contribute to higher mortality rates. 
Population studies show the frequent occurrence of TNBC in young African women compared to 
Caucasian women (Sturtz et al., 2014). Women with TNBC are more likely to have mutated 
BRCA genes (Yeh et al., 2017, Dietze et al., 2015, Bowen et al., 2008). About 75% of BRCA1 
mutation-related breast cancers present with the triple negative (TN) subtype (Bayraktar et al., 
2011, Rakha and Chan, 2011) and BRCA1 mutations largely being identified in TN patients with 
family history; the possibility of germline mutations is elevated in young TN patients (Robertson 
et al., 2012). The available treatment modalities for TN are chemotherapy regimens, 
radiotherapy and surgery. Targeted hormonal therapy was considered insignificant in treating TN 
tumours until recently. TN patients with androgen receptors, frequently expressed in breast 
cancer tumours, showed improved outcome following tamoxifen treatment (Hilborn et al., 2016) 
and increased chemosensitivity (Wang et al., 2017). To control progression and local-regional 
recurrence, radiotherapy is also utilised as the principle treatment for TNBC (Dragun et al., 
2011). 
 
The most detrimental biological effect of radiation is the production of double strand breaks 
(DSB) of DNA. The two main DNA repair pathways that function in DSB repair are 
homologous recombination (HR) and non-homologous end-joining (NHEJ). A third repair 
mechanism, the alternate-end-joining (Alt-EJ), has also been described in the repair of DSB 
(Ceccaldi et al., 2016, Iliakis et al., 2015). DNA repair genes, such as BRCA, are allied with 
chromosomal stability and have critical functions in repair pathways. TN tumours with BRCA 
mutations can be, therefore, deficient in the HR DNA repair pathway (Sharma, 2016). The 
availability of a homologous template of DNA for repair determines the pathway to be utilised. 
Hence, HR exclusively repairs damage in the late S and G2 phase of the cell cycle. NHEJ utilises 
a non-homologous template for repair and therefore is available for repair throughout the cell 
cycle. Similar to the NHEJ, alt-EJ pathway operates throughout all phases of the cell cycle and 
acts as a backup pathway when NHEJ and HR are absent or defective. Due to the error-prone 
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 mechanism of alt-EJ, the pathway generally gives rise to translocations, mutations and 
alterations leading to chromosomal instability (Iliakis et al., 2015). As part of the response to 
DNA damage repair, at every stage of the cell cycle, checkpoints are activated to prevent 
replication of damaged DNA by allowing adequate time for repair. A number of proteins, 
including BRCA, are involved in the activation of these checkpoints (Fernet et al., 2010). 
BRCA1/2 genes are essential in regulation of the G2/M checkpoint and HR repair (Prakash et al., 
2015). The G2/M checkpoints can be abrogated in the presence of caffeine and allows the 
progression of cells to mitosis (Jiang et al., 2000). By exploiting this trait of caffeine, the 
efficiency of the checkpoints and repair pathways can be evaluated. Upon exposure to ionising 
radiation (IR), the checkpoints are also activated as response to damaged DNA. Therefore, 
defects in checkpoints or its activating proteins are associated with radiosensitivity (Slonina et 
al., 2016).  
 
Deficiencies in DNA repair genes are linked with predisposition to cancer and elevate 
chromosomal radiosensitivity in breast cancer patients (Khanna and Jackson, 2001, Terzoudi et 
al., 2000). TNBC patients, particularly, have reduced expression of DNA repair genes and 
associated with deleterious BRCA mutations. Breast cancer patients have been shown to exhibit 
chromosomal radiosensitivity in the G0 and S/G2 phase where DSB are primarily repaired by 
NHEJ and HR respectively (Poggioli et al., 2010, Baeyens et al., 2005, Scott et al., 1999, 
Baeyens et al., 2002). Chromosomal radiosensitivity can be evaluated using the micronucleus 
(MN) assay (Fenech, 2000). The assay is extensively used in human biomonitoring subsequent to 
mutagen exposure and to analyse radiation-induced damage (Vral et al., 2011). Defects in DNA 
repair genes and age are factors that commonly influence the frequency of micronuclei (MNi) 
(Fenech and Bonassi, 2011).  
 
In the present study, we assessed the in vitro chromosomal radiosensitivity of TNBC compared 
to luminal breast cancer patients and healthy individuals by performing the MN assay in the G0 
and S/G2 phases of the cell cycle. The influence of age in this group of patients and the influence 
of positive mutations in breast cancer susceptibility genes such as BRCA on chromosomal 
radiosensitivity was also assessed.  
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 METHODS AND MATERIALS 
 
Sample collection: Patients were recruited from Charlotte Maxeke Johannesburg Academic 
Hospital (CMJAH) and WITS Donald Gordon Medical Centre. Blood samples were collected 
from 83 breast cancer patients. Previous neo-adjuvant chemotherapy and radiotherapy was the 
exclusion criteria of the study. Patients were categorised as young/old TN and young/old luminal 
breast cancer patients (Figure 1). All patients less than 50 years of age were categorised as young 
patients. All patients 50 years or above were categorised as older patients. Ninety healthy 
individuals with no personal history of breast cancer, who were students and staff members from 
CMJAH, were also enrolled in the study as the control population. A signed consent was 
obtained from all patients and controls. The study was approved by the Human Research Ethics 
Committee, University of the Witwatersrand, Johannesburg (M110248). 
 
The mean age of the older patients was 62 years; the mean age of all the young patients was 41 
years. TN patients had a mean age of 50 years and mean age of luminal patients were 53 years. 
The patients with positive mutations in breast cancer susceptibility genes had a mean age of 49 
years.  
 
Figure 1: Overview of patient subgroups included in the study for the G0 and S/G2 MN assays. The red 
inner box indicates patients with positive mutations in breast cancer susceptibility genes. 
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 Mutation analysis: All TNBC and patients ≤50 years were screened for BRCA1, BRCA2, PALB2 
and CHEK2 c.1100delC allele mutations. Mutation analysis was conducted using the MiSeq 
platform and large genomic arrangements were identified using MLPA (Francies et al., 2015b).   
 
G0 MN assay: As previously described, the G0 MN assay was initiated with 0.5ml heparin blood 
samples supplemented with 4.5 ml of pre-warmed culture medium (Baeyens et al., 2016). The 
culture medium comprised of RPMI-1640 with added L-glutamine (Bio-Whittaker, USA), 
antibiotics (10 000 U/ml penicillin and 10 000 μg/ml streptomycin; Gibco-Invitrogen, USA) and 
additional 13% foetal bovine serum (FBS; Gibco-Invitrogen, USA). Following the initial 
incubation at 37°C in 5% CO2, the cells were irradiated using a linear accelerator (Siemens 
Healthcare, Germany) to doses of 2 and 4 Gy X-rays. A 0 Gy dose was used as a control to 
detect spontaneously occurring MNi. Immediately after irradiation, the lymphocytes were 
stimulated to divide with phytohaemagglutinin (PHA; 100 µl, stock solution 1 mg/ml; Sigma-
Aldrich, USA) and further incubated for 23hrs. Cytokinesis block was then induced by addition 
of 20 µl cytochalasin B (Cyto B; stock solution 1.5 mg/ml; Sigma-Aldrich, USA). Cell were then 
harvested 70 hrs post stimulation using an ice cold hypotonic shock of 7 ml of KCL (0.075 M; 
Merck, Germany) and washed in a methanol: acetic acid: ringer solution in a ratio of 4:1:5 
(Merck, Germany). After an overnight storage at 4°C, the cells were washed an additional 3 
times with a methanol: acetic acid solution (4:1; Merck, Germany). The slides were prepared by 
dropping a cell suspension of 40 µl onto methanol-cleaned slides and counter stained with DAPI 
(4,6-diamidino-2-phenylindole; Vector Laboratories). All slides were scanned on the automated 
platform, Metafer MNScore Software (MetaSystems), and scoring of MNi was performed on 
duplicate slides for each condition.  
 
S/G2 MN assay: A modified version of the G0-MN assay was used to detect chromosomal 
radiosensitivity in the S/G2 phase of the cell cycle (Baert et al., 2017). Heparinised blood 
samples were supplemented and cultured in the same manner as the G0 MN assay described 
above. Prior to irradiation, the assay was initiated with the addition of 100 µl PHA (100 µl, stock 
solution 1 mg/ml; Sigma-Aldrich, USA) to stimulate the lymphocytes into division and then 
incubated at 37°C in 5% CO2 for 62 hrs. The cultures were then exposed to X-rays of 2 and 4 Gy 
using a linear accelerator (Siemens Healthcare, Germany). Here, a 0 Gy control was also set up 
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 to detect spontaneous MNi in the S/G2 phase. Instantaneously after irradiation, cytokinesis block 
is induced by addition of 20 µL Cyto B (stock solution 1.5 mg/mL; Sigma-Aldrich, USA). To 
half of the irradiated cultures, 200 µl caffeine (stock solution 100mM; Sigma-Aldrich, USA) was 
added. Caffeine abrogates the G2/M checkpoint and permits the progression of damaged cells 
into mitosis. The efficiency of the G2/M checkpoint can be evaluated with addition of caffeine. 
The harvesting of cells, staining and scoring was accomplished as described above in the G0 MN 
assay. 
 
Radiosensitivity indicator (RIND) score: To evaluate individual radiosensitivity, a 
radiosensitivity score is computed. As a threshold value to determine radiosensitivity, the mean 
MN yield and standard deviation (SD) of the healthy population was utilised. For mild 
radiosensitivity, a score of 1 was assigned when individual MN yield is higher than the mean 
MN yield of healthy controls +1SD. Individual MN yields higher than the mean MN yield +2SD 
of healthy controls were assigned a score of 2 indicating severe radiosensitivity. Any individual 
MN value lower than the mean MN yield +1SD of healthy controls was scored as 0 (Baert et al., 
2017). 
 
To compute a G2/M checkpoint efficiency ratio, the MN values with addition of caffeine was 
divided with the MN values without caffeine (MNCaf+/MNCaf-). Radiosensitivity would be 
indicated by a low checkpoint ratio. The G2/M checkpoint efficiency ratio was converted in a 
similar manner as the radiosensitivity score. For a score of 1, the individual values were lower 
than the mean checkpoint ratio –1SD of healthy controls. Whereas for a score of 2, the values 
were lower than the mean –2SD of healthy controls. If the individual values were greater than 
the mean –1SD of healthy controls, the score was 0 (Baert et al., 2016).   
 
The RIND score was utilised as a comprehensive scoring method to assess radiosensitivity in 
individuals. For the G0 MN assay, a final RIND score was the sum of the RIND score for the 2 
Gy and for the 4 Gy doses. This final G0 RIND score could vary from 0 to 4. For the G2 MN 
assay, we also included the checkpoint efficiency ratio in the calculation of the final RIND score. 
The final RIND score here could vary between 0 and 8. The final RIND score was used to 
categorise our patients into levels of radiosensitivity (Baert et al., 2016).  
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Statistical Analysis: The statistical significance of the study was analysed using GraphPad Prism 
7 software. For the MN score comparison between each group and the control group, the non-
parametric Mann-Whitney test was utilized. The significance level was set at <0.05. Statistical 
measure for the difference in RIND score for the G0 and S/G2 test between the groups were 
analysed using the Fisher’s exact test.  
 
RESULTS 
 
G0 Micronucleus assay: 
Chromosomal instability is stipulated by MNi frequency occurring spontaneously (0 Gy) which 
was evaluated in all breast cancer samples. The spontaneous MN values in the G0 MN assay of 
all breast cancer patients are significantly higher when compared to healthy individuals 
(p=0.0008) (Figure 2).  
 
The effect of age on chromosomal instability and radiosensitivity was investigated between the 
all young and all older patients. Chromosomal instability indicated by enhanced MN values were 
significantly different for all the young patients (p=0.01) and older patients compared to the 
controls (Figure 2). However, the significant difference were higher in the older patients 
(p=0.0044). Compared to the controls, chromosomal radiosensitivity was elevated in all breast 
cancer patients (2 Gy: p=0.0018; 4 Gy: p=0.0084), young and old patients (2 Gy: p=0.0014; 4 
Gy: p=0.0481) with enhanced MN values following radiation (Figure 3). Although, when 
comparing MN values for the 2 Gy dose, no significant differences were observed (p=0.0778) in 
the young patients. The correlation between MN values in the young and old patients were 
assessed and no significant differences were observed for spontaneous and irradiated MN values. 
No correlation between age and chromosomal radiosensitivity was demonstrated in our cohort. 
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Figure 2: Spontaneous MNi frequency of all breast cancer, triple negative, young and older breast cancer 
patients compared to controls G0 MN assay. *Statistically significant from controls (p<0.05). 
 
 
Figure 3: 2 and 4Gy irradiated MN frequencies for triple negative, young and older patients in the G0 
MN assay. *Statistically significant from controls (p<0.05) 
 
Since there was no correlation between age and chromosomal radiosensitivity, the patients were 
all group as TN or luminal breast cancer patients to investigate the effect of TN phenotype on 
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 chromosomal radiosensitivity. The TNBC (p=0.0031) and luminal patients (p=0.0066) exhibit 
chromosomal instability with significantly higher spontaneous MN values. 
 
Similar to the spontaneous MN values, when comparing all breast cancer patients, the MNi 
frequency was significantly different from the controls for both the 2 and 4 Gy irradiation. 
Although, after irradiation, the MN values of TNBC patients were not significantly different 
when compared to controls (2 Gy: p=0.6049; 4 Gy: p=0.9984). The opposite was observed for 
luminal patients (2 Gy: p=0.005; 4Gy: p=0.0016) for both IR doses (Figure 4). Chromosomal 
instability and radiosensitivity was also assessed in the 10 breast cancer patients who were 
positive for mutations in breast cancer susceptibility genes. No significant differences were 
observed in these patients in the spontaneous and irradiated MN values when compared to the 
other breast cancer patients. 
 
Figure 4: 2 and 4Gy irradiated MN frequencies for triple negative and luminal patients compared to 
controls in the G0 MN assay. *Statistically significant from controls (p<0.05) 
 
The RIND score was computed to assess individual radiosensitivity. A RIND score above 2 was 
considered as radiosensitive, with a score of 0 and 1 being radioresistant. Using this threshold for 
the G0 assay, 88% of individuals in the control group were not radiosensitive. Only 11% of TN 
patients exhibited a radiosensitive phenotype compared to 32% of luminal patients with 
enhanced chromosomal radiosensitivity. The remaining 89% of TN patients were not 
radiosensitive compared to 68% of luminal breast cancer patients. When comparing 
chromosomal radiosensitivity in patients who are either TN or luminal, there is a shift in 
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 distribution with higher levels of chromosomal radiosensitivity in the luminal patients (Figure 5). 
The correlation between MN values in the TN and luminal patients were assessed and no 
significant differences were observed for irradiated MN values. 
 
 
Figure 5: G0 RIND scores to assess individual radiosensitivity in triple negative and luminal patients 
compared to controls. 
 
S/G2 Micronucleus assay: 
In vitro chromosomal radiosensitivity focusing in the S/G2 phase of the cell cycle was evaluated 
in 17 TN and 17 luminal breast cancer patients and compared to 17 controls (Figure 1). When 
comparing spontaneous MNi frequencies of patients with controls, 24% all breast cancer patients 
(8/34), 12% of all TN patients (2/17) display chromosomal instability as compared to 35% (6/17) 
luminal patients. By assigning RIND scores, we evaluated the chromosomal radiosensitivity. In 
the TN patients, 76% did not exhibit a radiosensitive phenotype; whereas 47% of luminal 
patients were radiosensitive. Similar to the G0 results, the distribution of luminal breast cancer 
patients show a shift towards chromosomal radiosensitivity (Figure 6).  
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Figure 6: S/G2 RIND scores to assess individual radiosensitivity in triple negative and luminal patients 
compared to controls. 
 
DISCUSSION 
 
The in vitro chromosomal radiosensitivity of TN breast cancer patients in South Africa was 
evaluated in this study and compared to luminal breast cancer patients and healthy individuals. 
As TNBC are often young patients, we investigated if age has an influence on the chromosomal 
radiosensitivity in this population. Since BRCA mutations are also often observed in TNBC 
populations, the effect of mutations in BRCA and other breast cancer susceptibility genes on 
radiosensitivity was also analysed. DNA damage was induced by IR during two different phases 
of the cell cycle: G0 and S/G2 phase. DNA repair pathways in these phases differ and defects in 
these pathways can be reflected as chromosomal radiosensitivity. 
 
The mean spontaneous MNi frequencies in the G0 MN assay are significantly increased in the 
breast cancer patients indicating chromosomal instability. This result is in agreement with our 
previous study where we showed increased chromosomal instability in an unselected South 
African breast cancer population of all ages (Francies et al., 2015a). Various factors influence 
spontaneously occurring MNi such as age, environmental and genetic factors (Orta and 
Gunebakan, 2012, Jones et al., 2011). When comparing the different subgroups of breast cancer 
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 patients in our study, we were able to demonstrate significantly increased mean spontaneous MN 
values in both the TN (mean age = 50) and luminal breast cancer patients (mean age = 53) 
compared to controls. This could be influenced by the different genetic background of the 
patients. In older patients, age-associated decline in DNA repair leads to accumulation of DNA 
damage, possibly contributing to the elevated spontaneous MN values (Thierens et al., 2000). 
Other factors that could influence chromosomal instability in older patients are age-related 
oxidative damage and aneuploidy (Luzhna et al., 2013). 
 
For IR induced damage, MN values were significantly higher, for both the 2 and 4Gy, in the 
whole breast cancer group as expected from our previous findings (Francies et al., 2015a). 
Interestingly, when sub grouping patients in age groups, there were no significant differences in 
MNi between young and older patients. TNBC patients showed lower yield in MN values as 
compared to the luminal patients. Recent studies have brought to light the “radioresistant” 
phenotype in TNBC cell lines compared to non-TNBC cell lines. The TN tumours characteristics 
could contribute to the “radioresistant” phenotype observed in TN patients or TN cell lines. One 
such factor is the microRNAs (miRNAs) that function in post-transcriptional regulation of gene 
expression. miRNAs are implemented in the progression of tumours, metastases and response to 
therapy in breast cancer (Kurozumi et al., 2017). A subset of microRNA’s has been implicated in 
regulating the cellular response of TN cells to IR. A study by Ren et al., (2015) verified the 
overexpression of miRNA 27a in TNBC cell lines and its regulation in radiosensitivity and cell 
proliferation (Ren et al., 2015). Another study showed that miRNA-129-5p is expressed in lower 
levels in TN cell lines compared to luminal cell lines. Upon exposure to irradiation, survival 
fractions were elevated when miRNA-129-5p was knocked down in luminal cell lines and in TN 
cells lines, survival fractions were decreased when miRNA-129-5p was overexpression (Luo et 
al., 2015).   
 
In the second part of the study, individual chromosomal instability and radiosensitivity was 
analysed in the S/G2 phase. Chromosomal instability was more predominant in luminal breast 
cancer patients (35%) than in TNBC patients (12%) when compared to controls. A study of 
Djuzenova et al. using the S/G2 MN assay on peripheral blood mononuclear cells showed that an 
unselected breast cancer population did not exhibit increased spontaneous MN values compared 
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 to the controls. Enhanced spontaneous MN values were only observed in breast cancer patients 
that previously had radiotherapy (Djuzenova et al., 2006). Contrary to their results, we were able 
to demonstrate G2 chromosomal radiosensitivity in luminal patients.  
 
For the evaluation of the 2 Gy - and 4 Gy - induced DNA damage in S/G2 cell phase, the RIND 
scoring system was introduced to evaluated individual radiosensitivity. It was previously 
suggested that patients with high RIND scores could reflect defects in repair and G2/M arrest 
capacity (Baert et al., 2016). The checkpoint efficiency is indicated by a ratio of MNi with 
caffeine divided by MNi without caffeine (MNCaf+/MNCaf-). By combining radiation induced 
MN values and checkpoint efficiency ratio, RIND score distribution of luminal breast cancer 
patients showed a shift towards a radiosensitive phenotype, while the TNBC showed 
radiosensitivity levels were comparable with the healthy individuals. Patients exhibiting 
radiosensitivity could have defects in HR repair and G2/M checkpoint control and expressing 
low levels of DNA repair genes. This defect may be reflected as chromosomal radiosensitivity in 
the S/G2 phase.  
 
A radioresistant phenotype was exhibited in 76% of TN patients. A recent study showed 
upregulation of RAD51 in TNBC tumours when compared to other breast cancer. RAD51 is a 
primary component of the HR pathway. TN cells with enhanced HR repair exhibit 
radioresistance to IR (Gasparini et al., 2014). The overexpression of RAD51 leads to enhanced 
HR capacity which could lead to a “radioresistant” phenotype of TN lymphocytes.  
 
In our previous study, we showed that ER positive breast cancer patients exhibited increased 
chromosomal radiosensitivity (Francies et al., 2015a). It can be hypothesised that in the absence 
of ER receptors in TN cells, the DNA damaging effects of estrogen cannot be mediated and 
could contribute to a “radioresistant” phenotype. Chen et al. (2017) showed elevated radiation-
induced DSB breaks in TN cell lines transfected with ERα and delay in repair compared to wild 
type TN cell line. In the ER-transfected TN cells, the radiation-induced G2/M arrest was 
enhanced and a time-dependent decrease in S phase was observed compared to wild type cells. 
The HR pathway is enhanced in the S phase for efficient DSB repair. A shorter S phase implies 
less time for DNA repair (Chen et al., 2017). These results suggest that the absence of ER in TN 
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 cells permits improved DNA repair and decreased G2/M arrest. Furthermore, cell cycle and 
DNA repair genes are overexpressed in TNBC cells. Therefore, it can be hypothesised that the 
observed chromosomal radioresistance could be attributed to increased expression of DNA 
damage response genes (Engebraaten et al., 2013). 
 
A second hypothesis of the observed radioresistance in TN cells could be the overexpression of 
β-catenin upon exposure to IR. Irregularities of the Wnt/β-catenin pathway are essential for stem 
cell maintenance (Yin et al., 2016). Following IR, cancer stem cells (CSC) in breast cancers are 
reinforced and have enhanced Wnt/β-catenin pathway. CSC are associated with radioresistance. 
CSC in TNBC cells could be maintained by this pathway (Krause et al., 2017, Pohl et al., 2017).  
  
As a third hypothesis, TN radioresistance could also be attributed to HuR, a mRNA binding 
protein that is endogenously overexpressed in TN cells. Resistance to therapy and poor prognosis 
of TNBC was linked to HuR. A study by Mehta et al. (2016) showed significant increase in 
radiation-induced γ-H2AX foci in HuR knockdown TN cells. The scrambled control, however, 
had a higher cell survival rate. When HuR is knocked down, DNA repair genes involved in HR 
were suppressed (Mehta et al., 2016). The overexpression of HuR, therefore, may also maintain 
DNA repair genes in HR for improved repair. 
 
As previously reported in the literature, 17% (3/18) of all our TN patients were positive for 
germline BRCA1/2 mutations (Peshkin et al., 2010, Gonzalez-Angulo et al., 2011) and a slightly 
higher proportion (2/9; 22%) of young patients that have TNBC (Young et al., 2009). This could 
be due to the unique genetic makeup of the under-studied African population.  
 
Studies have shown that defects in BRCA1/2 can be reflected as enhanced chromosomal 
radiosensitivity (Ernestos et al., 2010, Baert et al., 2016, Baert et al., 2017, Barwell et al., 2007). 
BRCA1/2, and other important proteins, plays a central role in the G2/M checkpoint control and 
HR repair. Breast cancer patients with BRCA mutations were shown to have significantly higher 
chromatid breaks indicating chromosomal radiosensitivity (Ernestos et al., 2010). Also, Baert et 
al., (2016 & 2017) confirmed enhanced G2 chromosomal radiosensitivity of BRCA1 and BRCA2 
mutation carriers without breast cancer (Baert et al., 2016, Baert et al., 2017). These results 
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 highlight the significant role of BRCA1/2 in efficient DNA repair and cell cycle checkpoint 
control to eliminate chromosomal aberrations. We were not able to demonstrate significant 
differences in BRCA mutation carriers.  
 
The observations of our study describe chromosomal radiosensitivity in TNBC and luminal 
breast cancer patients. Radiosensitivity data in TN patients is primarily important as they lack 
effective treatment options. We were able to demonstrate a radioresistant phenotype of 
lymphocytes in TN patients. Our results suggest that the healthy lymphocytes in TN patients are 
equipped to handle higher doses of IR, therefore, treatment plans could be altered with adequate 
doses for TNBC patients. However, TNBC patient’s positive for BRCA1/2 mutations should be 
treated with caution and further validations of chromosomal radiosensitivity in the S/G2 phase in 
larger cohorts is necessary.   
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Abstract
Background: Current knowledge of the aetiology of hereditary breast cancer in the four main South African
population groups (black, coloured, Indian and white) is limited. Risk assessments in the black, coloured and Indian
population groups are challenging because of restricted information regarding the underlying genetic contributions
to inherited breast cancer in these populations. We focused this study on premenopausal patients (diagnosed with
breast cancer before the age of 50; n = 78) and triple negative breast cancer (TNBC) patients (n = 30) from the four
South African ethnic groups. The aim of this study was to determine the frequency and spectrum of germline
mutations in BRCA1, BRCA2 and PALB2 and to evaluate the presence of the CHEK2 c.1100delC allele in these
patients.
Methods: In total, 108 South African breast cancer patients underwent mutation screening using a Next-Generation
Sequencing (NGS) approach in combination with Multiplex Ligation-dependent Probe Amplification (MLPA) to
detect large rearrangements in BRCA1 and BRCA2.
Results: In 13 (12 %) patients a deleterious mutation in BRCA1/2 was detected, three of which were novel
mutations in black patients. None of the study participants was found to have an unequivocal pathogenic mutation
in PALB2. Two (white) patients tested positive for the CHEK2 c.1100delC mutation, however, one of these also
carried a deleterious BRCA2 mutation. Additionally, six variants of unknown clinical significance were identified
(4 in BRCA2, 2 in PALB2), all in black patients. Within the group of TNBC patients, a higher mutation frequency was
obtained (23.3 %; 7/30) than in the group of patients diagnosed before the age of 50 (7.7 %; 6/78).
Conclusion: This study highlights the importance of evaluating germline mutations in major breast cancer genes in
all of the South African population groups. This NGS study shows that mutation analysis is warranted in South
African patients with triple negative and/or in premenopausal breast cancer.
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Background
Breast cancer is the most common cancer amongst
South African women with a lifetime risk of 1 in 32 [1].
South Africa is a country consisting of citizens from
diverse ethnic groups. These include: black/African
(79.8 %), white/Caucasian (8.7 %), mixed ancestry/
coloured (9.0 %) and Indian/Asian (2.5 %) (Statistics
South Africa, 2013) [2]. According to the most recent
report from the National Cancer Registry of South Af-
rica, the lifetime risk of developing breast cancer differs
according to ethnicity. The lifetime risk is 1/53 in black
women, 1/15 in white women, 1/21 in coloured women
and 1/20 in Indian women (National Cancer registry,
NHLS, 2006) [1].
Breast cancer has a strong heritable component, with
approximately 15–20 % of cases exhibiting a family his-
tory of the disease [3, 4]. Mutations in genes such as
BRCA1 and BRCA2 lead to autosomal dominant inher-
ited cancer susceptibility and confer a high lifetime risk
of breast cancer, as well as ovarian and other cancers.
Recently it was suggested that the risk to develop breast
cancer for PALB2 mutation carriers is as high as the risk
borne by BRCA2 mutation carriers [5]. Identification of
mutations in these genes through clinical genetic testing
enables patients to undergo screening and prevention
strategies, some of which provide reduced morbidity. In
addition, the c.1100delC mutation in CHEK2 has been
identified as a susceptibility allele with incomplete pene-
trance and is associated with moderate lifetime risks of
breast cancer. Data on the prevalence and spectrum of
mutations in these genes are widely available for individ-
uals of European descent. However, data for cohorts
with African ancestry are scarce [6].
A few South African studies on mutations in BRCA1,
BRCA2 and PALB2 are available [7–10].Three South
African population groups exist in which the presence
of BRCA1/2 founder mutations occur; these are the
Ashkenazi Jewish population [11], the Afrikaans
population [7] and the black Xhosa population [10].
Other family-specific mutations have also been identi-
fied, as is typical of populations elsewhere. Table 1
shows data from studies done in South Africa to date.
These studies have been performed mostly in white
breast cancer patient cohorts. Furthermore, African
populations are known to exhibit greater genomic di-
versity when compared to white populations, and gen-
etic findings in one population cannot necessarily be
extrapolated to another [12]. Consequently, there is a
need to establish the aetiology of inherited breast
cancer in this population. The epidemiology of breast
cancer in South African black populations exhibits a
number of unique trends when compared to other
population groups worldwide. The difference in
underlying genetic architecture, family structure,
limited financial and human resources, limited com-
munity knowledge of breast cancer, limited informa-
tion on family history and historical difficulty
accessing health care, makes it more complex to per-
form risk assessments in these populations [13]. Over-
all, the cancer incidence in sub-Saharan Africa is
lower as compared to developed countries but there
is evidence to suggest changes in the disease burden
as the impact of communicable diseases is mitigated
[14]. South African women tend to be diagnosed with
breast cancer at younger ages [15–17]. However, the
diagnosis only occurs at advanced stage due to the lack of
awareness, access to diagnostic centres available and lim-
ited screening. Hence, the inclusion criterion for a “young”
breast cancer or premenopausal (PM) breast cancer pa-
tient was set at 50 years (See Additional file 1: Table S1).
While this could be due to a younger population struc-
ture, it is possible that these younger women carry unique
mutations in certain genes. Breast cancer in young women
is correlated with aggressive tumour progression, lack of
expression of receptors and poor prognosis [18]. Further-
more, it is often attributed to a genetic predisposition with
germline mutations in the BRCA1/2 genes [19–22]. Youn-
ger women of African descent are known to be in the
high-risk group with decreased survival rates [23].
Another factor that is generally considered as an in-
dicator of genetic susceptibility to breast cancer is the
so-called “triple negative” histological phenotype. Ap-
proximately 15 % of breast cancers lack the expression
of estrogen receptors, progesterone receptors and
HER2/NEU receptors and are known as triple negative
breast cancer (TNBC) [24]. This type of breast cancer
is associated with an aggressive disease progression,
higher histological grade, poor prognosis, high rate of
recurrence and decreased survival rates. The frequent
occurrence of TNBC is strongly correlated with younger
patients of African descent and increased incidence has
been noted among black South African breast cancer
patients [16, 17, 25]. The strong association between
TNBC and mutations in the BRCA1 gene, seen in
European and American populations [26, 27], has not
been investigated in a South African cohort.
This study aimed to evaluate the contribution of germline
BRCA1, BRCA2 and PALB2 mutations and the CHEK2
c.1100delC allele to breast cancer in a high-risk South
African cohort. Individuals included in the study were of
different ethnicities (with a majority from the understudied
black population) and had been diagnosed with premeno-
pausal breast cancer (less than 50 years) or exhibited the
“triple negative” histological phenotype. We chose to ana-
lyse BRCA1, BRCA2 and PALB2 as associated risks are well
established and clinically relevant. In addition, the preva-
lence of CHEK2 c.1100delC was evaluated in this cohort
and compared with the prevalence in individuals of
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European ancestry. We applied a cost efficient next gener-
ation sequencing (NGS) approach for analysis of the
complete coding regions of BRCA1, BRCA2 and PALB2
[28]. Furthermore, large rearrangements have been reported
in both BRCA1 and BRCA2 in several populations which
may be missed by sequencing. We therefore complemented
the sequencing approach with multiplex ligation-dependent
probe amplification (MLPA), for these two genes.
Table 1 Literature overview on BRCA1 and BRCA2 mutations detected in a South African population
Study (Reference) Ethnic group Gene Mutation detected Patients/families tested Frequency (%) Detection method
Yawitch & Van
Rensburg 2000 [51]
Black BRCA1 N/A 0/206 0 PTT and SSCP/HA; limited
to regions with Afrikaner
founder mutations
Reeves et al., 2004 [7] White/Ashkenazi
Jewish
BRCA1 c.68_69delAG 4/18 4.4 PTT and SSCP/HA
White BRCA1 c.329dupA 1/18 1.1
White BRCA1 c.1008dupA 1/18 1.1
White BRCA1 c.1352C > A; p.S451* 1/18 1.1
White/Afrikaner BRCA1 c.1374delC 2/18 2.2
White/Afrikaner BRCA1 c.2641G > T; p.E881* 5/18 5.6
Indian BRCA1 c.4957insC 1/18 1.1
White/Ashkenazi
Jewish
BRCA1 c.5266dupC 3/18 3.3
Schlebusch et al.,
2010 [52]
White/Afrikaner,
Ashkenazi
Jewish, Black,
Indian
BRCA1 N/A 26/129 20.2 PTT and SSCP/HA and
MLPA
BRCA2 N/A 43/129 33.3
Sluiter et al., 2011 [9] White/Afrikaner BRCA1 + BRCA2 N/A 0/36 MLPA
White/Ashkenazi
Jewish
BRCA1 Ex23-24del 1/30 3.3
BRCA2 N/A 0/30
Van der Merwe et al.,
2012 [10]
Coloured BRCA1 c. 1504_1508delTTAAA 1/105 1.0 PTT and SSCP/HA
BRCA1 c. 2641G > T;p. E881* 1/105 1.0
BRCA2 c. 2826_2829delAATT 1/105 1.0
BRCA2 c. 5771_5774delTTCA 4/105 3.8
BRCA2 c. 6448dupTA 1/105 1.0
BRCA2 c. 7934delG 1/105 1.0
Black BRCA2 c. 5771_5774delTTCA 4/16 25.0
Schoeman et al.,
2013 [13]
White, Mixed
Ancestry, Black
BRCA1 c. 2641G > T; p. E881* 7/302 2.3 SSCP/HA
BRCA1 c. 68_69delAG 2/302 0.7
BRCA1 c. 1374delC 2/302 0.7
BRCA1 c. 5266dupC 1/302 0.3
BRCA2 c. 7934delG 17/302 5.6
BRCA2 c. 5771_5774delTTCA 7/302 2.3
BRCA1 N/A 4/302 1.3 PTT
BRCA2 N/A 5/302 1.7
BRCA1 N/A 2/302 0.7 Sequencing
BRCA2 N/A 2/302 0.7 Sequencing
BRCA1 N/A 18/302 6.0
PTT protein truncation test, SSCP/HA PCR-single strand conformation polymorphism/heteroduplex analysis, N/A mutations were not described; * indicates the presence
of a premature stop codon (cfr. nomenclature HGVS (Human Genome Variation Society))
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Methods
Patients
EDTA blood samples of 108 breast cancer patients were
collected from breast clinics in two state hospitals and a
private hospital in Johannesburg - Charlotte Maxeke
Johannesburg Academic Hospital, Chris Hani Baragwanath
Academic Hospital and Wits Donald Gordon Medical
Centre respectively. Patients were selected if their tumour
was triple-negative (TN), and/or their breast cancer diagno-
sis was premenopausal. All patients were categorized as
black, white, Indian or coloured based on patients’
self-reported data from questionnaires. The cohort
consisted of 85 black patients (78.7 %), 16 white pa-
tients (14.8 %), 5 Indians (4.6 %) and 2 coloureds
(1.9 %). Table 2 presents the overview of the distribu-
tion of ethnicity in the cohort. All patients signed in-
formed consent. Pathology data were obtained from
the hospital files. Genetic counselling was offered to
the patients, prior to obtaining their consent.
The study was approved by the Human Research Ethics
Committee (Medical), University of the Witwatersrand
(No. M091023; M110922; M130450).
DNA extraction
Genomic DNA was extracted from 4 - 6 ml of peripheral
blood using a modified version of the standard salting
out method [29].
Target enrichment, library preparation and sequencing
BRCA1, BRCA2 and PALB2 analysis was successfully
conducted on 108 samples using Illumina’s Miseq desk-
top sequencer. Target enrichment was achieved by high
throughput PCR. Primers were designed for the
complete coding region including splice site regions of
BRCA1 (31 amplicons), BRCA2 (42 amplicons) and
PALB2 (19 amplicons) using Primer XL (www.pxlence.-
com). PCR conditions according to the protocol de-
scribed by De Leeneer et al. were utilised [28].
Library preparation was performed using a modified
version of the Nextera XT (Illumina) protocol. Sequen-
cing was conducted on the MiSeq v2 instrument (Illu-
mina Inc.) according to manufacturer’s instructions. The
approach is described in detail by De Leeneer et al. [28].
Sanger sequencing
All genetic variants and pathogenic mutations identified
via NGS were confirmed with Sanger sequencing. For
confirmation by Sanger sequencing, an independent
PCR amplification step was performed. In addition, the
presence of all deleterious mutations was confirmed on
an independently extracted DNA sample. All fragments
with a coverage of <28× were also analysed by Sanger se-
quencing. For an overview of the number of amplicons
that required Sanger sequencing, refer to Additional file 2:
Table S2.
Nucleotide positions and protein translation correspond
to reference sequence and Genbank account number
NM_007294.3; NP_009225.1 for BRCA1, NM_000059.3;
NP_000050.2 for BRCA2, NM_024675.3; NP_078951.2 for
PALB2 and NM_007194.3 for CHEK2 c.1100delC. Nu-
cleotide numbering uses the A of the ATG translation ini-
tiation start site as nucleotide 1.
MLPA
Large genomic rearrangements and/or gene dosage al-
terations in both the BRCA1 and BRCA2 genes were
screened for in 108 patient samples using MLPA.
BRCA1 MLPA analysis was performed using the SALSA
MLPA P002 probemix (version C2-1113) (MRC-Hol-
land) and BRCA2/CHEK2 MLPA using the SALSA
MLPA P045 probemix (version B3-1113) (MRC-Hol-
land). MLPA setup was performed according to the
manufacturer’s protocol. Fragment detection and sizing
was conducted using capillary gel electrophoresis on the
ABI 3730XL genetic analyser (Applied Biosciences). All
fragments positive for the CHEK2 mutation (c.1100delC)
in the MLPA analysis were confirmed with Sanger
sequencing.
The screening was performed in a research setting.
We used the infrastructure and the protocols supplied
by a molecular diagnostic laboratory with an ISO15189
accreditation.
Data analysis
Mapping of sequencing data was performed with CLC
bio Genomics Workbench v6 software (CLC bio Inc.).
Various in-house scripts were used for sequence analysis
[28]. The Sanger sequencing data were analysed using
SeqPilot v4.1.2 build 512 and SeqSpace v2.5.0. MLPA
data were analysed using Coffalyser (MRC-Holland).
Variants of unknown significance (VUS) were evalu-
ated using in silico mutation interpretation software –
Alamut. We used the computational algorithms of SIFT,
AlignGVGD, Polyphen and Mutation Taster for mis-
sense varaints and the splice site prediction programs
SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer
and Human Splicing Finder for intronic, silent and mis-
sense variants. Based on these predictions and in
Table 2 Overview of distribution of ethnicity in our South African
cohort
Black
(%)
White
(%)
Indian
(%)
Coloured
(%)
Dx < 50 n = 92 TNBC 7 (7.6) 4 (4.3) 2 (2.2) 1 (1.1)
Not TNBC 70 (76.1) 5 (5.4) 2 (2.2) 1 (1.1)
Dx > 50 n = 16 TNBC 8 (50.0) 7 (43.8) 1 (6.3) 0
Total n = 108 85 (78.7) 16 (14.8) 5 (4.6) 2 (1.9)
Dx: Age at diagnosis
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combination with a study of the literature and published
minor allele frequencies, variants were classified in five
classes. Unfortunately, due to limited availability of data,
Bayesian likelihood analyses could not be performed to
calculate the degree of likelihood of pathogenicity.
Therefore, we applied the following rules:
– Variants with a MAF (minor allele frequency) of
> 0.01 were classified as class 1 (data not shown)
– Variants were classified as class 2 if all prediction
programs provided neutral scores (data not shown)
– Variants with two or more programs with
deleterious predictions were allocated to class 3
(Table 5)
– All truncating and unequivocal splice site variants
were considered as deleterious, in addition to
missense variants in the RING domain of BRCA1
(class 4–5) (Table 3)
Statistical analysis
Mutation frequency was calculated with 95 % confidence
intervals. The Fisher’s exact test was used to compare
mutation frequencies in the different groups of patients.
Statistical analysis was performed with Graphpad Prism
software.
Results
In the total study population (n = 108), 15 heterozygous
pathogenic mutations in 14 patients were identified
(12.9 %; 95 % CI = 7.3–20.8 %): six in BRCA1, seven in
BRCA2; two patients were found to carry CHEK2
c.1100delC of which one patient also harboured a dele-
terious BRCA2 mutation. All mutations were identified
by sequencing on Miseq, except a large deletion in
BRCA1 and the CHEK2 c.1100delC mutation which
were detected by MLPA. No unequivocal deleterious
mutations were identified in the PALB2 gene (Table 3).
The distribution of BRCA1/2 mutations among the
different subgroups (TNBC and/or PM) and based on
ethnicity is presented in Table 4. A significantly higher
mutation detection ratio was obtained within the group
of TNBC patients (7/30; 23.3 %; 95 % CI = 9.9–42.3 %)
compared to the premenopausal breast cancer group
without TNBC (6/78; 7.7 %; 95 % CI = 2.9–16.0 %) (p =
0.0432). Not surprisingly, the highest mutation detection
ratio was obtained within the subgroup of TNBC pa-
tients diagnosed before the age of 50 (5/14; 35.7 %; 95 %
CI = 12.7–64.9 %).
The BRCA2 c.7934delG Afrikaner founder mutation
was identified in 2 (white) patients, one with TNBC and
one diagnosed with premenopausal breast cancer. In the
black patient population, two previously unreported mu-
tations were identified in BRCA1 (c.1155G > A and
c.1953_1954insA) and one in BRCA2 (c.582G > A) (see
Table 3). Six (6/85; 7.1 %; 95 % CI = 2.6–14.7 %) patho-
genic BRCA1/2 mutations were observed in the black
population group and five (5/16; 31.3 %; 95 % CI = 11.0–
58.7 %) in the white population group. Two mutations
were identified in the Indian group (2/5; 40 %; 95 % CI
= 5.3–85.3 %) and no mutations were identified either in
Table 3 BRCA1, BRCA2 and CHEK2 germline pathogenic mutations identified in triple negative and premenopausal breast cancer
patients using NGS and MLPA
Patient no. Ethnicity Category Gene Exon Nucleotide change Amino acid change Mutation effect Reference
1 White TNBC/PM BRCA1 4 c.181 T > G p.Cys61Gly Missense [53]
2 Black TNBC/PM BRCA1 4 c.212G > A p.Arg71Lys Missense [54]
3 Indian TNBC/PM BRCA1 10 c.3593 T > A p.Leu1198* Nonsense [55]
4 Black PM BRCA1 10 c.1155G > A p.Trp385* Nonsense Novel
5 Black PM BRCA1 10 c.1953_1954insA p.Lys652fs Frameshift Novel
6 White TNBC BRCA1a 1–2 - - Deletion [30]
7 Black PM BRCA2 7 c.582G > A p.Trp194* Nonsense Novel
8 Black TNBC BRCA2 11 c.5771_5774delTTCA p.Ile1924fs Frameshift [10]
9 White PM BRCA2 11 c.5213_5216delCTTA p.Thr1738fs Frameshift [56]
CHEK2a 11 c.1100delC p.Thr367fs Frameshift [39]
10 White TNBC BRCA2 17 c.7934delG p.Arg2645fs Frameshift [10]
11 White PM BRCA2 17 c.7934delG p.Arg2645fs Frameshift [10]
12 Indian TNBC/PM BRCA2 21 c.8754 + 1G > A Non-coding Splice site [57]
13 Black PM BRCA2 23 c.9097_9098insA p.Thr3033fs Frameshift [53]
14 White PM CHEK2a 11 c.1100delC p.Thr367fs Frameshift [39]
PM Premenopausal
aMLPA results
*indicates the presence of a premature stop codon (cfr. nomenclature HGVS (Human Genome Variation Society))
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BRCA1 or BRCA2 in the two coloured individuals
studied.
To detect large genomic rearrangements in BRCA1
and BRCA2, 108 samples were analysed using MLPA. A
white TNBC patient was found to be heterozygous for a
BRCA1 exon 1a-2 deletion. Several deletions including
these exons but with different breakpoints have previ-
ously been described (for an overview of deletions affect-
ing these exons: [30]). As the number of large
rearrangements reported in PALB2 is extremely small
[31], MLPA for PALB2 was not conducted in this
cohort.
The CHEK2 mutation (c.1100delC) was observed in 2/
108 (1.9 %) patients. Both of these patients were white,
premenopausal patients. One of these patients was also
positive for a deleterious BRCA2 mutation.
In addition to pathogenic mutations, several VUS
were identified: 1 in BRCA1, 3 in BRCA2 and 2 in
PALB2. In Table 5 we provide an overview of the
variants which were classified as class 3 based on in
silico prediction programs. Three of the four in silico
prediction programs used classified the BRCA2 vari-
ant c.9875C > T and c.7712A > G as “probably dam-
aging”. The BRCA2 variant c.9875C > T was
Table 4 BRCA1 and BRCA2 germline pathogenic mutations identified using NGS and MLPA in a South African cohort divided
according to premenopausal diagnosis, triple negative status and ethnicity
Total n = 108 Dx < 50 n = 92 (85.2 %) Dx > 50 n = 16 (14.8 %) Total no.
of mutations per
ethnic group
TNBC n = 14 (13.0 %) Not TNBC n = 78 (72.2 %) TNBC
Black n = 85 (78.7 %) n = 7 n = 70 n = 8 6 (7.1 %)
Mutations BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2
c.212G > A - c.1155G > A c.582G > A - c.5771_5774delTTCA
- - c.1953_1954insA c.9097_9098insA - -
White n = 16 (14.8 %) n = 4 n = 5 n = 7 5 (31.3 %)
Mutations BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2
c.181 T > G c.7934delG - c.7934delG Exon 1a-2 del -
- - - c.5213_5216delCTTA - -
Indian n = 5 (4.6 %) n = 2 n = 2 n = 1 2 (40.0 %)
Mutations BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2
c.3593 T > A c.8754 + 1G > A - - - -
Coloured n = 2
(1.9 %)
n = 1 n = 1 0 0
Mutations - - -
Total mutations per
subgroup
5 (35.7 %) 6 (7.7 %) 2 (12.5 %)
Table 5 In silico predictions obtained for variants of unknown significance in the South African cohort
In silico prediction programs
Ethnicity Variant Gene Amino acid
change
Occurrence Classification Align
GVGDa
SIFT Mutation
Taster
PolyPhen Refs
Black c.1843_1845delTCT BRCA1 p.Ser615del 1 3 - - - - [58–60]
Black c.4798_4800delAAT BRCA2 p.Asn1600del 1 3 - - - - [61]
Black c.7712A > G BRCA2 p.Glu2571Gly 1 3 C0 Deleterious Disease
causing
Probably
damaging
[62]
Black c.9875C > T BRCA2 p.Pro3292Leu 2 3 C0 Affect protein
function
Disease
causing
Probably
damaging
[63]
Black c.118A > G PALB2 p.Arg40Gly 1 3 C0 Affect protein
function
Polymorphism Probably
damaging
Novel
Black c.2845 T > C PALB2 p.Cys949Arg 1 3 C0 Affect protein
function
Disease
causing
Probably
damaging
Novel
aSpectrum of prediction classes (C0, C15, C25, C35, C45, C55, C65) with C0 less likely to be deleterious and C65 most likely
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identified in two black patients. Two of the four pre-
diction programs consulted classified the PALB2 var-
iants c.118A > G and c.2845 T > C as “probably
damaging”.
Discussion
The current study is the first study performing mutation
analyses in BRCA1, BRCA2 and PALB2 and determining
the frequency of CHEK2 c.1100delC in triple negative
and/or premenopausal breast cancer patients in South
Africa through both next generation sequencing and
large rearrangement testing. In total we detected 13
BRCA1/2 mutations in our study cohort of 108 patients
(12 %; 95 % CI = 6.6–19.7 %), thus reinforcing the im-
portant contribution of germline BRCA1 and BRCA2
mutations to inherited breast cancer in this mixed South
Africa cohort. Two patients harboured a CHEK2
c.1100delC mutation, one of them in combination with a
deleterious BRCA2 mutation. Previous studies done on
South African breast cancer populations reported
BRCA1/2 mutation frequenciess of 1 to 25 % [7–10] (for
an overview: see Table 1). The prevalence of mutations
in BRCA1/2 genes in these South African studies varies
by inclusion criteria, ethnicity and mutation screening
techniques used. None of these studies looked specific-
ally at TNBC or premenopausal patients.
The mutation frequency was higher in the subgroup of
TNBC than in the premenopausal breast cancer patients:
23.3 % (7/30) of TNBC patients harbour a pathogenic mu-
tation in either BRCA1 or BRCA2, compared to 12.0 %
(11/92) of all premenopausal breast cancer patients.
Various studies have shown the frequency of BRCA1
mutations to be higher than BRCA2 in patients exhibit-
ing the triple negative phenotype [27, 32, 33]. In our
study 13.3 % (4/30) of TNBC patients had a pathogenic
mutation in BRCA1 compared to 10 % (3/30) in BRCA2.
In our premenopausal cohort, the prevalence of
BRCA1 mutations were similar (5/92; 5.4 %) to BRCA2
mutations (6/92; 6.5 %). BRCA2 mutations are in general
less frequent than BRCA1 in younger white women with
breast cancer [19]. A relatively high number of BRCA2
mutations compared to BRCA1 has been reported in
other studies of young black populations [34–36] and is
contradictory to the scenario in Western populations.
This could be due to the unique genetic background of
African patients.
In the black population, the overall frequency of muta-
tions identified was 7.1 % as compared to 31.3 % in the
white population. Due to the presence of the BRCA2
c.7934delG Afrikaner founder mutation, BRCA2 is the
most important contributor in the white population in
our study cohort, while BRCA1 and BRCA2 mutations
were observed in equal numbers in the black patients
studied. We identified neither the Ashkenazi Jewish nor
the Xhosa mutations in our study groups. Our patient
cohort was recruited in the region of Johannesburg and
is characterized by diverse population structure/ethnic
backgrounds. Therefore we did not anticipate finding a
large number of founder mutations.
The CHEK2 c.1100delC allele contributes to a moder-
ate increased breast cancer risk. The frequency is esti-
mated to be only 1 % in familial breast cancer and 0.5 %
in early onset breast cancer [37, 38]. In the Dutch popu-
lation the prevalence in the general population is 1.1 %,
2.5 % in unselected breast cancer cases, and up to 4.9 %
in familial breast cancer cases [39]. Within our South
African cohort we identified this allele in two white pa-
tients (2/16 = 12.5 %), but in none of the patients from
other ethnicities (0/92). White Afrikaner South Africans
mainly descend from Dutch immigrants which could
explain the higher percentage of CHEK2 c.1100delC in
this cohort.
Previous studies that aimed to clarify the prevalence of
BRCA1/2 mutations in black populations from other
parts of Africa and African Americans have indicated
similar rates [6, 22, 27, 36, 40]; although it is difficult to
compare them since eligibility criteria for study partici-
pation varies extensively. Churpek et al. [40] reported a
pick-up rate of 26 % (47/180) for pathogenic mutations
in a group of black patients with early onset disease (age
of diagnosis <45) and 25 % pick-up rate (26/103) for
pathogenic mutations in triple negative black patients.
Here we report BRCA1/2 mutation frequency of 14 %
(1/7) in the premenopausal triple negative black sub-
group. Our overall mutation detection rate of BRCA1/2
mutations in the black premenopausal breast cancer pa-
tients was 6.5 % (5/77). This is similar to the mutation
rate reported in a study by Pal et al. [22] in young black
African American breast cancer patients (9 %; 13/144).
Although the prevalences are similar among the studies
on West African, African American breast cancers and
our study, we identified 3 novel mutations in the South
African black patients. Furthermore, historical evidence
has shown that African Americans descend from West
African ancestry and so it is not surprising that there
are some differences between these two and the South
African black population, who have some distinct gen-
etic differences at the population level [12, 41].
Large genomic rearrangements in BRCA, detected
with MLPA, were only observed in 0.9 % (1/108) of our
cohort. No large rearrangements were identified in the
black South African breast cancer patients. Generally,
low frequencies for large rearrangements have been re-
ported in black patients, e.g. Pal et al., [22], detected 2
rearrangements in 144 young African-American women
with breast cancer (1.4 %), both of which were in
BRCA1. Zhang et al., [42] reported one BRCA1 exon de-
letion (0.3 %) in a cohort of 352 Nigerian breast cancer
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patients. In another South African study on 52 unrelated
families of European ancestry, only 1 large deletion was
detected in BRCA1 [9]. The lack of detection in BRCA2
led the authors to suggest that large rearrangements in
BRCA2 might not play a role in inherited breast cancer
in South African patients [9]. However, to draw final con-
clusions on the presence of large rearrangements in both
white and black South African breast cancer patients, a
larger patient population should be extensively studied.
Gene sequencing techniques also resulted in the
identification of several VUS. Based on in silico pre-
dictions, we assigned a class (class 1– 3) to each VUS
for clinical interpretation [43]. VUS with a probability
of increased pathogenicity are assigned a higher class.
A number of studies have presented models and per-
formed functional assays for the classification of VUS
in BRCA1/2 [43–46]. We detected six VUS in the 85
black patients of our cohort and none in the 16 white pa-
tients. Also other studies suggested that the frequency of
VUS is higher in patients of African descent, for instance
Nanda et al. [47].
A previous study conducted in a South African cohort
revealed a pathogenic PALB2 mutation in 2 % of early
onset white breast cancer patients [8]. Our cohort con-
sisted of a small number of white patients and no un-
equivocal deleterious mutations in PALB2 were
identified. However two missense variants with suggest-
ive in silico predictions were identified (Table 5) that
warrant further functional analyses. Until recently, the
pathogenic effect of PALB2 missense variants has not
been firmly proven. For some missense variants in the
WD40 domain (from amino acids 853–1186) [48] al-
tered patterns of direct binding to the RAD51C, RAD51
and BRCA2 h proteins in biochemical assays have been
shown [49]. We identified a missense variant in the
WD40 domain (c.2845 T > C; p.Cys949Arg). In order to
elucidate the pathogenicity of missense variants in
PALB2, additional (functional, segregation) analyses are
required.
We focused on identifying mutations in BRCA1,
BRCA2 and PALB2 and the CHEK2 c.1100delC muta-
tion, as the risks for the development of breast and
associated cancers with these genes have been deter-
mined by analysing large study populations. The
search for the remaining genetic contribution towards
breast and ovarian cancer has been carried out exten-
sively, with numerous other genes being identified.
However, at this time, the contribution and associated
risks of mutations in most of these genes is not yet
well established. As the prevalence of mutations in
each of these genes is much lower than germline
BRCA1/2 mutations in the large cohorts (white
American) of patients investigated up until now [50],
international collaborations in populations of different
ethnicities will be required to gain insight into the
exact risks associated with mutations in these genes.
Conclusion
This study is the first to evaluate the use of NGS tech-
nology as a diagnostic testing platform for inherited
breast cancer in a South African cohort. The results pre-
sented herein are particularly relevant for inherited can-
cer testing in the black population of South Africa, a
previously under-researched group. The NGS approach
applied [28] is a cost and time effective approach; it
shows great promise for BRCA1/2 screening in develop-
ing countries like South Africa. The advent of NGS
allows the costs of mutation analysis to fall dramatically,
which should allow testing to become more widely avail-
able, especially in countries with limited healthcare re-
sources, like South Africa. This will create opportunities
to improve patient treatment and challenges for breast
cancer multidisciplinary teams. The finding of a germline
deleterious mutation could alter treatment decisions; for
instance, women with germline mutations might opt for
more radical surgery or may consider prophylactic surgery
to the contralateral breast or ovaries.
Our results have highlighted the contribution of
BRCA1/2 germline mutations in South African breast
cancer patients with triple negative breast tumours and/
or premenopausal breast cancer of different ethnicities.
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A B S T R A C T
Fanconi Anaemia (FA) is an autosomal recessive disorder characterised by defects in DNA repair, associated with
chromosomal instability and cellular hypersensitivity to DNA cross-linking agents such as mitomycin C (MMC).
The FA repair pathway involves complex DNA repair mechanisms crucial for genomic stability. Deﬁciencies in
DNA repair genes give rise to chromosomal radiosensitivity. FA patients have shown increased clinical radio-
sensitivity by exhibiting adverse normal tissue side-eﬀects. The study aimed to investigate chromosomal
radiosensitivity of homozygous and heterozygous carriers of FA mutations using three micronucleus (MN) as-
says. The G0 and S/G2 MN assays are cytogenetic assays to evaluate DNA damage induced by ionising radiation
in diﬀerent phases of the cell cycle. The MMC MN assay detects DNA damage induced by a crosslinking agent in
the G0 phase. Patients with a clinical diagnosis of FA and their parents were screened for the complete coding
region of 20 FA genes. Blood samples of all FA patients and parents were exposed to ionising radiation of 2 and
4 Gy. Chromosomal radiosensitivity was evaluated in the G0 and S/G2 phase. Most of our patients were
homozygous for the founder mutation FANCG c.637_643delTACCGCC; p.(Tyr213Lysfs*6) while one patient was
compound heterozygous for FANCG c.637_643delTACCGCC and FANCG c.1379G>A, p.(Gly460Asp), a novel
missense mutation. Another patient was compound heterozygous for two deleterious FANCA mutations. In FA
patients, the G0- and S/G2-MN assays show signiﬁcantly increased chromosomal radiosensitivity and genomic
instability. Moreover, chromosomal damage was signiﬁcantly elevated in MMC treated FA cells. We also ob-
served an increase in chromosomal radiosensitivity and genomic instability in the parents using 3 assays. The
eﬀect was signiﬁcant using the MMC MN assay. The MMC MN assay is advantageous as it is less labour intense,
time eﬀective and has potential as a reliable alternative method for detecting FA patients from parents and
controls.
1. Introduction
Fanconi Anaemia (FA) is primarily an autosomal recessive disorder
that is clinically characterized by congenital malformations, pro-
gressive development of hypoplastic anaemia and cancer predisposition
that often results in haematological malignancies such as acute
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myelogenous leukaemia (AML) or myelodysplasia (MDS) as well as
various solid tumours, especially head and neck squamous carcinoma.
Recent determination of the carrier frequency gave an estimate of more
than 1/200 [1], with an expected prevalence at birth of at least 1/160
000. In certain populations, the carrier frequency is much higher, due to
founder mutations. In South Africa, with mixed ethnicity in the popu-
lation, the prevalence of FA ranges between 1/22 000 for the white
Afrikaners to 1/40 000 in the black South Africans [2,3].
Twenty-one diﬀerent FANC genes have been reported in literature
FANCA, FANCB, FANCC, FANCD1 (also known as BRCA2), FANCD2,
FANCE, FANCF, FANCG, FANCI, FANCJ (also known as BRIP1 or
BACH1), FANCL, FANCM, FANCN (also known as PALB2), FANCO (also
known as RAD51C), FANCP (also known as SLX4), FANCQ (also known
as XPF or ERCC4), FANCR (also known as RAD51), FANCS (also known
as BRCA1), FANCT (also known as UBE2T), FANCU (also known as
XRCC2) [4,5], and very recently REV7 (also known as MAD2L2 or
FANCV) was identiﬁed as a novel FA gene [6]. FA is most often in-
herited in an autosomal recessive manner, however, also autosomal
dominant (FANCR/RAD51) and X-linked forms (FANCB) have been
reported [7]. Next generation sequencing (NGS) allows eﬃcient iden-
tiﬁcation of causal mutations in this genetically heterogeneous disease.
Deleterious mutations in FANCA, FANCC and FANCG are identiﬁed in
80–90% of the FA cases [8].
All currently known FA genes encode for a cluster of proteins re-
sponsible for repair of stalled DNA replication forks by unhooking DNA
interstrand cross-links (ICL) and promoting homologous recombination
(HR). The FA/BRCA repair pathway is pivotal in maintaining genomic
stability. The FANC genes are sub grouped into 3 main categories
known as (i) the core complex (ii) ID2 complex and (iii) the down-
stream eﬀectors. In response to damage caused by DNA crosslinking
agents or ionising radiation (IR), the activated core complex formed by
8 FA genes (A, B, C, E, F, G, M, and L) activates the ID2 complex,
comprised of FANCD2/FANCI gene, by mono-ubiquitination and phos-
phorylation. The mono-ubiquitination of ID2 is catalysed by the E2
ubiquitin-conjugating enzyme FANCT/UBE2T [9]. The ID2 complex
plays a critical role in the pathway by translocating to the damage sites
which triggers the recruitment of downstream eﬀectors (D1, J, N, O, P,
Q, R, S and U) in the S/G2 phase. The damage is subsequently repaired
by HR. Following the repair, the ID2 complex undergoes deubiquiti-
nation and the core complex genes are unassembled [10,4,11]. The
latest identiﬁed FA gene, REV7/FANCV, a subunit of DNA polymerase ζ
involved in translesion DNA synthesis (TLS) seems to act as a necessary
downstream eﬀector of the FA-BRCA pathway, most likely functioning
in the TLS step of ICL repair [12].
In FA patients’ cancer treatment by chemotherapy or radiotherapy is
complicated because of the possibility of side eﬀects due to the un-
derlying defect in DNA damage response. Sensitivity to chemotherapy
and radiotherapy in FA patients has previously been documented
[13,14]. Radiosensitivity is the susceptibility of cells to the DNA da-
maging eﬀects of IR. Exposure to IR causes a variety of DNA damage of
which the double strand breaks are the most important [15]. Double
strand breaks (dsb) are repaired predominantly by two main DNA re-
pair pathways: i) HR which requires a homologous DNA strand for re-
pair and ii) non-homologous end-joining (NHEJ). The cell is selective
on which DNA repair pathway to use depending on the phase of the cell
cycle. In the S/G2 phase where a homologous strand is present, the HR
repair pathway is preferred over NHEJ. The NHEJ repairs double strand
breaks is predominant in the remaining phases of the cell cycle [16].
Some older studies suggested that FA patients, similar to patients
with ataxia telangiectasia or Nijmegen breakage syndrome, are char-
acterised by an increased in vitro chromosomal radiosensitivity [17,18],
while others report the contrary [19]. However, literature on chromo-
somal radiosensitivity of FA patients is very limited.
It is well established that FA cells are hypersensitive to DNA
crosslinking agents such as mitomycin C (MMC) and diepoxybutane
(DEB) [20]. Chromosome fragility is pathognomonic in the diagnosis:
FA is classically diagnosed by treating lymphocytes of patients with
MMC or DEB and subsequent quantiﬁcation of all types of chromosomal
breakages and radial forms [21]. The major challenge with this assay is
the low quality slides and the need of highly experienced personnel to
analyse chromosomal breakages; furthermore, it is labour intense and
time consuming. We propose here a more robust assay to identify FA
patients by detecting micronuclei (MNi) and evaluate if this can be used
to distinguish heterozygous carriers from non-carriers. The cytokinesis-
block micronucleus assay (CBMN) in human lymphocytes is a well-es-
tablished assay for measuring chromosomal aberrations after in vivo or
in vitro exposure to genotoxic agents. Here, we propose a novel protocol
where MMC is applied to induce MN. Furthermore, we evaluated two
MN protocols using ionising radiation as genotoxic agent: the G0 MN
assay, a well-known cytogenetic assay where cells are irradiated in the
G0 phase of the cell cycle [22,23], and a S/G2 MN assay, in which the
damage is induced in the S/G2 phase [24,25]. In the S/G2 MN assay,
cells were also subjected to caﬀeine treatment. The addition of caﬀeine
to cells abrogates the G2/M cell cycle checkpoint. The abrogation of the
checkpoint permits the progression of damaged cells into mitosis [26].
In this way the eﬃciency of the repair pathway activated when cells are
irradiated in the S/G2 phase can be evaluated.
2. Methods and material
2.1. Study population
Thirteen patients with clinical manifestation of FA and their parents
were recruited from the Paediatric Oncology department at Charlotte
Maxeke Johannesburg Academic hospital and Chris Hani Baragwanath
hospital in South Africa. In addition, one patient and parent was re-
cruited from Cliniques Universitaires Saint-Luc, Belgium. In total,
fourteen FA patients and 14 parents were enrolled in the study and
heparin blood samples were collected. Blood samples from 14 healthy
donors were also collected from student and staﬀ members from the
university and hospital. The mean age of the patients is 11 years. The
youngest patient enrolled in the study was 5 years and the oldest being
17 years. The mean age of the parents enrolled in the study was 40
years and healthy individuals had a mean age of 30 years. Informed
consents were obtained from all donors. Ethics for the study was ap-
proved by the Wits Human Research Ethics Committee (Medical)
(clearance number M141031).
2.2. Mutation analysis
2.2.1. DNA extraction
Genomic DNA was extracted from peripheral blood using the au-
tomated Tecan Freedom EVO®-HSM Workstation (Promega). DNA ex-
traction for 14 patients with clinical manifestations of FA and 14 parent
samples was carried out as per manufacturer’s instructions.
2.2.2. Target enrichment, library preparation and sequencing
Singleplex PCR reactions were performed for the coding region of
all 20 known FA genes. Primers for the coding regions and splice site
regions of all the genes were designed using PrimerXL (www.pxlence.
com). The PCR conditions and the modiﬁed version of the Nextera XT
(Illumina) library preparation protocol utilised in this study were con-
ducted as previously described [27]. Subsequently sequencing was
performed on the Miseq instrument (Illumina).
2.2.3. Sanger sequencing
All pathogenic mutations and variants classiﬁed as likely pathogenic
were conﬁrmed by Sanger sequencing on the ABI3730XL
(ThermoFisher) instrument in the patients. Carriership of a hetero-
zygous mutation was also conﬁrmed in DNA of the parents available.
F.Z. Francies et al. DNA Repair 61 (2018) 17–24
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2.2.4. MLPA
In order to detect large exon spanning deletions/duplications, MLPA
was conducted using the commercially available MLPA kits (MRC-
Holland) for some FA genes (MLPA P031-FANCA mix 1 and P032-
FANCA mix 2 (version: B2-0116), P057-FANCD2-PALB2 (version: B2-
0415) and P260-PALB2-RAD50-RAD51C-RAD51D (version: B1-1114)).
Fragment separation is achieved by capillary electrophoresis using the
ABI model 3730XL sequencer (ThermoFisher).
2.2.5. Data analysis
Sequencing data obtained from the Miseq run was mapped using
CLC Bio Genomics Workbench v7 software (CLC bio Inc.). The se-
quencing analysis was also conducted using other in-house scripts as
previously described [27]. Sanger sequencing data were analysed using
the SeqPilot software v4.1.2 build 512. Coﬀalyer.NET (MRC-Holland)
software was used for MLPA data analysis.
2.3. The cytokinesis-block micronucleus (CBMN) assay to assess radiation
induced DNA damage
2.3.1. G0 CBMN assay
To quantify the chromosomal radiosensitivity of FA patients and
heterozygous carriers, the MN assay was performed as previously de-
scribed. Heparinised blood (0.5 ml) was added to 4.5 ml of pre-warmed
RPMI-1640 supplemented with L-glutamine (Bio-Whittaker, USA), 13%
of foetal bovine serum (FBS; Gibco-Invitrogen, USA) and antibiotics
(50 U/ml penicillin and 50 mg/ml streptomycin; Gibco-Invitrogen,
USA). The cells were irradiated in the G0 phase of the cell cycle with
doses of 2 and 4 Gy 6 MV X-rays at a dose rate of 1.33 Gy/min using a
linear accelerator (Siemens Healthcare, Germany). A sham irradiated
control (0 Gy) culture was also set up to detect spontaneously occurring
MNi. After irradiation, cell division was stimulated in lymphocytes by
the addition 100 μl of phytohaemagglutanin (PHA − stock solution
1 mg/ml; Sigma-Aldrich, USA), and cytokinesis was blocked after 23hr
by adding 20 μl cytochalasin B (Cyto B − stock solution 1.5 mg/ml;
Sigma-Aldrich, USA). Seventy hours post PHA-stimulation, cells were
harvested using a cold hypotonic shock of 7 ml of KCL (0.075 M; Merck,
Germany) and ﬁxed in a methanol: acetic acid: ringer solution (4:1:5)
(Merck, Germany). After overnight storage at 4 °C, the cells were fur-
ther ﬁxed 3 times by using a methanol: acetic acid solution (4:1). A
suspension of cells (40 μl) was dropped onto slides and stained with
acridine orange stain (10 μg/ml) (Sigma-Aldrich, USA). Duplicate slides
were made of each sample, coded and 500 BN cells per slide were
scored using the Zeiss Axioskop ﬂuorescent microscope (Carl Zeiss,
Gottingen, Germany). To obtain radiation-induced MN values, the
spontaneous MN were deducted from the MN values of irradiated
samples.
2.3.2. S/G2 CBMN assay
Compared to the G0 MN assay, this assay is modiﬁed to analyse
chromosomal radiosensitivity when cells are irradiated in the S/G2
phase of the cell cycle as previously described [25]. In short, hepar-
inised blood (0.5 ml) in culture medium was set up and lymphocyte
stimulation was immediately achieved by addition of 100 μl PHA (stock
solution 1 mg/ml; Sigma-Aldrich, USA). Following stimulation, the
cultures were incubated at 37 °C and 5% CO2. The lymphocytes were
irradiated after 72 h to doses of 2 and 4 Gy. To detect spontaneous MNi
in the S/G2 phase of the cell cycle, a control (not irradiated) culture was
also started. Cytokinesis was immediately inhibited after irradiation by
the addition of 20 μl Cyto B (stock solution 1.5 mg/ml; Sigma-Aldrich,
USA) and 200 μl caﬀeine (stock solution 100 mM; Sigma-Aldrich, USA)
was added to a part of the cultures. The cells were harvested 8 h post
irradiation and ﬁxed as described above. Duplicate slides were stained,
coded and 500 BN per slide were scored. Also here, radiation-induced
MN values were obtained by deduction of spontaneous MN from the
MN values of irradiated samples.
2.4. Cytokinesis-block micronucleus assay to assess MMC induced DNA
damage
Mitomycin C Micronucleus assay: This assay was optimized to analyse
the extent of chromosomal breakage induced by MMC in FA patients
and parents (heterozygous carriers). Cultures were initiated by the
addition of 0.5 ml heparinized blood in 4.5 ml culture medium. To
optimize this technique, we used 2 diﬀerent concentrations of MMC
that can induce detectable damage. Concentrations of 0.02 μg/ml or
0.1 μg/ml MMC (stock solution 0.5 mg/ml; Sigma-Aldrich, USA) were
added and lymphocytes were immediately stimulated with PHA
(Sigma-Aldrich, USA). The cultures were incubated at 37 °C and sup-
plemented with 5% CO2. Similar to the G0 MN assay, 23 h later the
cytokinesis was blocked by the addition of Cyto B (Sigma-Aldrich,
USA). Cells were harvested 70 h post stimulation. The staining and
scoring was conducted as described above. MMC-induced MN values
were obtained by deducting spontaneous MN from the MN values in the
samples treated with MMC.
2.5. Nuclear division index
The nuclear division index (NDI) is a measure of cell proliferation
where poor nuclear division is indicated by a low NDI value and a
higher NDI value suggests good proliferative capacity of the cells. The
NDI was calculated for each of the assays by evaluating the number of
mononucleate (N1), binucleate (N2), trinucleate (N3) and polynucleate
(N4) cells. A total (Ntotal) of 500 cells per slide was scored. The formula
used to calculate NDI is: NDI = (N1 + 2N2 + 3N3 + 4N4)/Ntotal.
2.6. Statistical analysis
GraphPad Prism 7 was used to analyse the statistical signiﬁcance of
the study. The comparison of the MN scores between the groups was
conducted using the non-parametric Mann-Whitney. The signiﬁcance
level was set at< 0.05.
3. Results
3.1. Germline mutations
As expected in the 13 black South African patients the large ma-
jority (12/13) was found to be homozygous for the FANCG founder
mutation c.637_643delTACCGCC; p. (Tyr213Lysfs*6). One patient was
heterozygous for the FANCG c.637_643delTACCGCC mutation, and a
novel heterozygous FANCG c.1379G>A, p. (Gly460Asp) missense
variant, which has not been previously described. This variant is not
reported in large databases like ExAC or gnomAD. By this substitution a
highly conserved amino acid (Gly460) is changed into an amino acid
(Asp) with diﬀerent physicochemical properties (Grantham distance: 94
[0–215]). Prediction programs like SIFT, Polyphen and MutationTaster
all support a deleterious eﬀect for this variant. The clinical symptoms
manifested in this patient included microcephaly, hypopigmentation,
short stature, ﬂattened thenar eminence and the bone marrow aspirate
showed aplasia strongly supporting a FA diagnosis. No deleterious
mutation was identiﬁed in the other FA genes screened.
The patient recruited in Belgium, of Cameroonian origin, was found
to be compound heterozygote for two FANCA mutations:
c.987_990delTCAC, p. (His330Alafs*4) and a large deletion spanning
exons 22–28 (c.1901-?_2778 + ?del).
In all 14 parents, from whom DNA was available, we conﬁrmed
heterozygous carriership of the relevant FANCG or FANCA mutation.
3.2. G0 Micronucleus assay
Table 1 shows the data for the 3 endpoints scored in the G0 MN
assay. The spontaneously occurring mean MNi values (non-irradiated
F.Z. Francies et al. DNA Repair 61 (2018) 17–24
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cells) of the FA patients are signiﬁcantly higher compared to the control
group (p = 0.01; see Supplementary tables for p values) indicating
genomic instability in the FA patients. The mean MNi values observed
in BN cells irradiated with 2 Gy and 4 Gy are signiﬁcantly higher in the
patient group when compared to the control group (2 Gy: p = 0.0003;
4 Gy: p = 0.0025); however, MN frequencies between patients and
controls overlap at an individual level. Signiﬁcant diﬀerences in ra-
diation-induced MNi are also observed between FA homozygotes and
FA heterozygous carriers (2 Gy: p = 0.02119; 4 Gy: p = 0.0444). Al-
though the MN yields were higher in the heterozygous carriers com-
pared to controls, no signiﬁcant diﬀerences in either the spontaneous or
irradiated MNi values were demonstrated. In the 2 and 4 Gy irradiated
samples respectively, a 1.5 and 1.3 fold increase of MNi was observed in
the FA patients compared to controls. The parents showed a 1.1 fold
increase both by 2 and 4 Gy radiations. The mean NDI values of the G0
cultures were lower in patients when compared to parents and controls.
This diﬀerence was signiﬁcant in irradiated cultures (p< 0.05).
3.3. S/G2 Micronucleus assay
Table 2 represents the response to DNA damage induction in the S/
G2 phase of the cell cycle, the MNi values of cells irradiated in the S/G2
phase, in the presence of caﬀeine were compared between the 3 groups.
In this phase of the cell cycle, spontaneously occurring MNi values in
the FA patients and interestingly also in the heterozygous carriers were
signiﬁcantly higher compared to the control group. The diﬀerences
were more pronounced than in the G0 phase. FA patients showed sig-
niﬁcant higher radiation-induced MN values than the heterozygous
carriers and controls. Also, when adding caﬀeine we noticed signiﬁcant
diﬀerences in MNi between the FA patients and the control group after
2 Gy and 4 Gy. Similar to the G0 MN assay results, signiﬁcant diﬀer-
ences were observed at a group level. When comparing the FA het-
erozygotes with the control group signiﬁcant diﬀerences were seen
after irradiation with 4 Gy and addition of caﬀeine. In response to IR
and caﬀeine, proliferative capacity of FA cells in the G2 phase was
lower when compared to the controls (p< 0.05). For radiation-in-
duced samples without caﬀeine, FA patients had a 1.9 and 2.1 fold
increase in MNi values for the 2 and 4 Gy respectively, as compared to
the controls. The fold increase in FA heterozygote carriers was 1.2 for
both the 2 and 4 Gy radiation-induced samples. MNi values of radia-
tion-induced samples in the presence of caﬀeine for both FA patients
and parents were similar to the fold increase as those without caﬀeine.
3.4. Mitomycin C micronucleus assay
In order to quantify the sensitivity to DNA crosslinking agents, cells
were subjected to MMC. This assay detects MMC-induced damage
during the G0 phase of the cell cycle. The results of this assay are shown
in Table 3. Spontaneous MNi values of patients obtained in the sham
treated cultures set up together with the radiation and MMC treated
cultures are similar as expected (Table 1 and Table 3). Both con-
centrations of MMC induced signiﬁcantly higher MNi in the FA patients
compared to the FA heterozygotes and control group. The higher con-
centration of MMC even resulted in signiﬁcant diﬀerences in MNi be-
tween the FA heterozygotes and the controls (p< 0.0001). On average,
a 9.7 fold increase of MNi was observed in the FA homozygotes com-
pared to the control group and a 2.5 fold increase of MNi in the parents
versus the control group was seen after treatment with the higher
concentration of MMC (0.1 μg/ml).
Fig. 1 demonstrates the individual fold increase in FA patients and
parents versus the mean of the control population for 0.02 μg/ml and
0.1 μg/ml MMC concentrations; also illustrating similar results in
FANCG and FANCA patients. The horizontal lines represent one stan-
dard deviation (1SD) and two standard deviations (2SD) of the mean.
As presented in Fig. 1, the fold increase can be utilised to identify FA
patients successfully with MMC treatment of 0.02 μg/ml as all patients
have a fold increase above the 2SD. A better discrimination between
parents and controls at the individual level was demonstrated when
0.1 μg/ml MMC concentration was used and parents show a fold in-
crease above 1SD. However, with the higher dose of 0.1 μg/ml MMC,
more experimental failures were observed in the patient group. FA
patients also showed signiﬁcantly lower NDI values following MMC
treatment (p< 0.05); the NDI values were further decreased when FA
cells were treated with larger concentrations of MMC (p< 0.05).
4. Discussion
In this study we applied diﬀerent MN assays in patients diagnosed
with Fanconi Anaemia and their parents. We compared the results of
these two groups with a healthy control group. The genotypes in all
patients were determined and showed biallelic inactivation of FANCG
in the South African patients or FANCA in a patient of Cameroonian
descent. Carriership testing conﬁrmed heterozygosity for a deleterious
FANCG/FANCA mutation in the parents. Our study corroborates the
Table 1
G0 MN assay: Comparison of mean ± SD spontaneous (0 Gy) and radiation-induced (at 2
and 4 Gy) MNi values in 1000 binucleated cells of FA patients, parents and healthy
controls.
0 Gy 2 Gy 4 Gy
aPatients 27.93 ± 9.94* 356.6 ± 70.67** 915.0 ± 160.5**
aParents 23.21 ± 9.80 286.5 ± 78.26 776.2 ± 185.3
aControls 18.29 ± 8.73 255.4 ± 58.48 706.6 ± 179.6
a Mean and SD of 14 patients, 14 parents and 14 controls.
* Signiﬁcantly diﬀerent from controls (p< 0.05).
** Signiﬁcantly diﬀerent from parents and controls (p< 0.05).
Table 2
G2 MN assay: Comparison of mean ± SD of spontaneous (0 Gy) and radiation-induced (at 2 and 4 Gy) MNi values in 1000 binucleated cells of FA patients, parents and healthy controls.
0 Gy 2 Gy 4 Gy 2 Gy C+ 4 Gy C+
aPatients 27.14 ± 9.16** 91.00 ± 40.67** 198.80 ± 73.18** 262.80 ± 121.10** 494.60 ± 257.30*
aParents 18.36 ± 8.57* 57.21 ± 19.54 117.80 ± 31.58 147.40 ± 66.12 346.80 ± 144.70*
aControls 11.50 ± 6.01 48.36 ± 14.51 95.43 ± 32.42 112.20 ± 40.67 248.20 ± 89.61
a Mean and SD of 14 patients, 14 parents and 14 controls.
* Signiﬁcantly diﬀerent from controls (p < 0.05).
** Signiﬁcantly diﬀerent from parents and controls (p < 0.05).
Table 3
MMC MN assay: Comparison of mean ± SD spontaneous (0 μg/ml) and MMC-induced
(at 0.02 and 0.1 μg/ml) MNi values in 1000 binucleated cells of FA patients, parents and
healthy controls.
0 μg/ml 0.02 μg/ml 0.1 μg/ml
aPatients. 30.77 ± 10.87** 466.30 ± 218.40** b979.00 ± 348.10**
aParents 21.42 ± 8.88 42.45 ± 21.54 b256.80 ± 90.09*
aControls 17.69 ± 8.21 31.54 ± 17.76 101.10 ± 34.45
a Mean and SD of 13 FA patients, 12 parents and 13 controls.
b Mean and SD of 6 FA patients and 9 parents.
* Signiﬁcantly diﬀerent from controls (p < 0.05).
** Signiﬁcantly diﬀerent from parents and controls (p < 0.05).
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high prevalence of the FANCG c.637_643delTACCGCC founder muta-
tion in black FA patients [2,28,29]. However, a portion of black FA
individuals present with a heterozygous mutation [30]; this requires
additional screening of the FANCG gene in ﬁrst instance and other FA
genes, if no second deleterious mutation in FANCG can be identiﬁed.
We report here a novel FANCG missense variant c.1379G>A, p.
(Gly460Asp) which is likely pathogenic, in a black South African pa-
tient heterozygous for FANCG c.637_643delTACCGCC. The patient had
a clear clinical diagnosis of FA and the applied assays showed similar
aberrant values like in individuals homozygous for FANCG
c.637_643delTACCGCC, indicative for a deleterious eﬀect of this var-
iant. Carriership testing in the mother conﬁrmed heterozygosity for the
FANCG c.637_643delTACCGCC mutation and absence of c.1379G>A,
p. (Gly460Asp); DNA of the father was not available. This observation
supports the hypothesis that both variants are most likely in trans in the
child. Our study conﬁrms that besides the founder mutation FANCG
c.637_643delTACCGCC a second common FANCG mutation is unlikely
in the black South African population [31].
We evaluated three MN assays to identify FA patients, as these may
be more robust than the classically applied chromosome-breakage
analysis on Giemsa-stained metaphases of lymphocytes/ﬁbroblasts after
addition of MMC or DEB. We induced MNi by addition of MMC in G0
cells or by irradiation of cells in G0 or S/G2 phase of the cell cycle.
NHEJ is the preferentially used DNA repair pathway for dsb in the G0
phase while in S/G2 phase HR plays an important role. The FA/BRCA
pathway is involved in DNA dsb repair by HR and in the processing of
DNA damage induced by MMC.
In ﬁrst instance, we evaluated spontaneously occurring MNi in two
diﬀerent phases of the cell cycle. The FA patients’ exhibit, on average,
signiﬁcantly higher spontaneous MNi frequencies in the G0 phase
compared to controls and heterozygous parents. This conﬁrms the re-
port of Camelo et al. and suggests genomic instability in FA patients
[32]. With the S/G2 MN assay we also observed on average sig-
niﬁcantly more spontaneous MNi in both patients and heterozygous
parents compared to controls. This could be attributed to homozygous
or heterozygous defects in a FA gene, involved in the HR pathway
which is preferentially used during the S/G2 phase of the cell cycle.
However, due to the heterogeneity in spontaneous MNi it was not
possible to consistently demonstrate higher spontaneous MNi values in
each individual FA patient/parent compared to controls.
Subsequently, we scored MNi in irradiated lymphocytes of FA pa-
tients, FA parents and controls. Our results show signiﬁcantly higher
mean MNi frequencies in irradiated lymphocytes of patients in both
phases of the cell cycle when compared to heterozygotes and controls.
Loss-of-function in the FA genes causes disruptions in cell cycle
checkpoints which could explain the enhanced sensitivity in irradiated
FA cells. Increased radiosensitivity in FA cells was also observed in
older and much smaller studies performed on an average of 4 FA
Fig. 1. Fold increase of MNi following MMC treatment. The
individual fold increase of FA patients and parents versus
mean of controls for concentrations of 0.02 μg/ml and 0.1 μg/
ml MMC is presented as bars. The horizontal lines represent
one standard deviation (1SD) and two standard deviations
(2SD) of the mean of controls. Bar with diagonal lines (donor
6): FANCG compound heterozygote patient; bar with checked
blocks (donor 10): FANCA compound heterozygote patient.
All other patients are homozygous for FANCG.
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patients [18,33,17]. (missing a reference here; reference is mentioned
in query notes).
Overall, the mean diﬀerences are larger in S/G2 MNi frequencies
than the mean diﬀerences in G0 MNi frequencies between FA patients,
FA heterozygous carriers and controls. A previous study has also shown
a similar trend in chromosomal radiosensitivity in the G2 phase [34].
This could be due to the impaired repair pathways and checkpoints and
accumulation of unrepaired DNA damage in the G2 phase in FA cells.
Upon exposure to exogenous or endogenous damage, the number of FA
cells in the G2 phase increases and is attributed to the S-phase check-
point ineﬃciency [35]. This is reﬂected in our observation by the lower
NDI values in FA patients when compared to controls that is also in
agreement with previous studies describing poorer proliferative capa-
city and a prolonged G2 phase in FA lymphocytes [19]. In a normal cell
cycle, the cells with unrepaired damage are blocked by G2/M check-
point in order to repair the damage prior to division. In G2, the da-
maged cells are repaired by HR [36]. This characteristic is absent in the
FA cells as they are thought to override the G2/M checkpoint and a
signiﬁcant quantity of unrepaired DNA is carried through to mitosis.
Therefore FA cells have accumulated a greater number of damaged
DNA and are highly prone to cancer [37].
The understanding of the FA pathway is still evolving and new
components continue to be identiﬁed. The FA core complex is normally
formed during S/G2 phases and cells preferentially use HR during this
phase of the cell cycle. However, recent studies described cells derived
from patients with FA mutations in the FA core complex that were not
severely defective in HR repair of dsb and FA core complex-deﬁcient
cells that had impaired HR pathway and thereby favoured NHEJ
[38,39]. These controversial ﬁndings evoke further investigation of the
connections between the FA pathway and the DNA repair pathways.
The ability of caﬀeine to induce DNA damage and G2/M cell cycle
checkpoint abrogation was used in combination with the S/G2 MN
assay in our study. The higher number of MNi in all three groups after
treatment of the cells with IR and caﬀeine conﬁrmed this eﬀect of
caﬀeine on the induction of MNi. The results obtained with the S/
G2 MN assay in combination with caﬀeine also showed higher MN
values in the FA homozygotes compared to heterozygotes and controls,
supporting the study of [40] where it was stated that cells deﬁcient in
FANCD2 developed higher levels of γ-H2AX foci when exposed to caf-
feine and where was suggested that patients with germline or somatic
FANCD2mutations may be hypersensitive to cytotoxicity of coﬀee [40].
Although our FA patients are carriers of FANCG/FANCA mutations, we
also noticed elevated radiation-induced MNi values. Inactivation of
FANCG attributes to a functional collapse of the FA core complex and
reduces DNA damage repair capacity. The MN values in heterozygous
carriers are higher but not signiﬁcantly diﬀerent from the values ob-
tained in the control group after 2 Gy irradiation in combination with
caﬀeine. However, after a 4 Gy dose of IR and caﬀeine we found sig-
niﬁcantly higher levels of residual DNA damage suggesting that less
damage is repaired after exposure to caﬀeine and IR even when a
functional allele of the FA gene is available.
As a group, FA patients showed signiﬁcantly elevated radio-
sensitivity with the G0 and S/G2 MN assays compared to parents and
controls. However, the assays are not suitable as a biomarker for de-
tecting individual FA patients. Since the risk of cancer is elevated in FA
patients, radiosensitivity information in this patient group is relevant
and may be taken into consideration prior to start treatment using IR.
The MMC MN assay is very promising as an individual biomarker
(Table 3 and Fig. 1). Even though cells were treated with low MMC
concentrations, a clear distinction in MNi frequencies between FA
homozygotes, FA heterozygotes and controls was observed. However,
only a low number of binucleated cells were detectable in cells of some
FA patients treated with the highest 0.1 μg/ml concentration of MMC.
This is attributed to the toxic nature of MMC that induces unrepairable
interstrand- crosslinks which lowers cell proliferation of FA cells as
reﬂected in the NDI values. Despite the poor cell proliferation, we were
able to produce conclusive results to identify FA patients. The test is
more robust when applying only 0.02 μg/ml and is optimal for distin-
guishing individual FA patients from individual controls and parents.
Evaluating metaphases in chromosomal-breakage analysis of MMC or
DEB requires a trained eye and can be labour intense. In comparison,
scoring MNi using the MMC MN assay is amenable to automation, it is
relatively straightforward and time eﬃcient. Therefore, we think that
our MMC MN assay has the potential for a reliable alternative for the
classic chromosome breakage assay.
The majority of our FA patients are homozygous for the FANCG
founder mutation. Our cohort also includes two patients that are
compound heterozygotes; one patient with two mutations in FANCG
and the other with two mutations in FANCA. The phenotype observed
in the FANCG homozygous patients are also demonstrated in the
FANCG and FANCA compound heterozygous patients. The observation
suggests that the phenotype is valid for both the FANC genes that form
part of the FA core complex. Although, further validations in larger
patient and parent groups with diﬀerent FANC genotypes are required
prior to implementation as a standard test in clinical setting.
Interestingly, the application of higher MMC concentrations in our
MMC MN assay revealed signiﬁcant diﬀerences between the group of
FA parents and the control group. This distinction could not be made
with a MMC-based chromosome breakage assay [41]. Similarly, iden-
tifying FA parents from controls using the DEB test has shown to be
unsuccessful with chromosomal breaks of parents overlapping with
controls [42,43].
Identiﬁcation of heterozygous mutation carriers may be clinically
relevant in the context of breast cancer prevention as heterozygous
mutations in several FA genes were shown to be associated with an
increased risk for breast cancer [44–49]. The best known breast cancer
gene, BRCA1 (=FANCS) has been shown to interact directly with
FANCD2 and FANCA in response to DNA damage [50]. Similar to our
study, the damaging eﬀects of IR and MMC were evaluated in lym-
phocytes from heterozygous BRCA1/FANCS and BRCA2/FANCD1 mu-
tation carriers (breast cancer patients and healthy carriers). In response
to IR, the heterozygous carriers of both genes did not show elevated
MNi values, but upon exposure to MMC enhanced chromosomal sen-
sitivity was detected in lymphocytes of individuals with heterozygous
BRCA2 mutations [51]. It is clear that larger studies are warranted to
validate our ﬁndings but the MMC MN assay may be promising as an
individual biomarker for functional deﬁciencies in at least some of the
FA genes.
5. Conclusions
In conclusion, this study compared 3 diﬀerent MN assays to char-
acterize FA patients with biallelic inactivated FANCA/FANCG alleles
and to compare the results with heterozygous carriers of FANCA and
FANCGmutations and controls. Chromosomal radiosensitivity of the FA
patients was demonstrated with the G0 and S/G2 MN assay. The MN
assay utilising IR showed on average an increased number of MNi in FA
patients and heterozygous carriers compared to controls, but cannot be
used to identify individual patients. Using the MMC MN assay, we were
able to distinguish FA patients from heterozygous carriers and controls.
Interestingly, with this assay, higher MNi scores were obtained in the
heterozygous parents compared to controls. Further studies are war-
ranted to evaluate the sensitivity and speciﬁcity of this test in FA pa-
tients and parents with other genotypes/mutated FANC genes. The big
advantage of the MMC MN assay is that is less labour intense, more time
eﬀective and less subjective compared to the classic chromosomal
breakage assay. Future research can indicate if this assay can diﬀer-
entiate FANC heterozygote genotypes from healthy controls and can be
used as a functional assay identifying individuals with a heterozygous
defect in genes related to the FA/BRCA pathway.
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CHAPTER 8 
General discussion 
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1. Breast cancer 
 
Breast cancer is often treated with radiotherapy. As radiotherapy is a very useful tool to kill 
cancer cells, it needs to be cautiously used to spare surrounding normal tissue. Although an 
effective treatment, about 5% of patients treated with radiotherapy suffer from normal tissue 
side effects (Sprung et al., 2005). Several parameters will influence the normal tissue 
tolerance of breast cancer patients (Barnett et al., 2009, Mukesh et al., 2012). Normal tissue 
toxicity is presented as clinical manifestations with early and late reactions. Chromosomal 
radiosensitivity has been proposed as a predictor for normal tissue tolerance (Habash et al., 
2017, Vandevoorde et al., 2016). 
 
Chromosomal radiosensitivity has previously also been shown to be a marker for breast 
cancer predisposition. Literature data for chromosomal radiosensitivity in breast cancer 
patients has been explored in various populations (Scott et al., 1999, Baria et al., 2001, 
Ernestos et al., 2010, Terzoudi et al., 2000, Poggioli et al., 2010, Burrill et al., 2000, Baeyens 
et al., 2002, Baeyens et al., 2005). Despite the breast cancer burden, chromosomal 
radiosensitivity has previously not been studied in South Africa. The clinicopathological 
presentations of South African breast cancer patients differ from their European counterparts. 
South African breast cancer patients present with aggressive premenopausal tumours, 
whereas postmenopausal breast cancer is prevalent in the European population; the 
underlying genetic mechanisms in the two populations may also differ (Vanderpuye et al., 
2017, Abdulrahman and Rahman, 2012, Huo et al., 2017). A large systematic review of 
breast cancer in sub-Saharan Africa highlighted the tumour characteristics of women in this 
region. Black African women were shown to be 10-15 years younger in age at diagnosis 
compared to women in developing countries (Jedy-Agba et al., 2016). In this thesis, we 
investigated the chromosomal instability and radiosensitivity in South African breast cancer 
patients. Young African women are affected by aggressive subtypes of breast cancer (Gabriel 
and Domchek, 2010, Bowen et al., 2008). A number of studies have described the association 
of TNBC in young African women (Anders et al., 2009, Carvalho et al., 2010, Assi et al., 
2013). Genetic screening threshold for breast cancer patients recommended are 50 years. 
Robertson et al. recommended BRCA1 screening for TNBC patients below the age of 50 
(Robertson et al., 2012). Additionally, patients below 51 are considered premenopausal and 
treated accordingly. Consequently, assessing the chromosomal instability and radiosensitivity 
of TN patients are essential. The effect of age on chromosomal radiosensitivity was 
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investigated between all young and older patients. Patients who were ≤50 years were 
classified as young and patients >50 years were consider as older patients.  
 
1.1. Chromosomal instability in breast cancer patients 
 
Owing to population diversity in South Africa, we first assessed the influence of ethnicity on 
chromosomal instability and radiosensitivity using the G0 MN assay (Chapter 3). Using this 
assay we analysed the spontaneously occurring spontaneously occurring MNi that are 
indicative of chromosomal instability. Several papers have described environmental and 
genetics factors contributing to the increase in spontaneous MNi frequencies (Jones et al., 
2011, Ramsey et al., 1995, Bolognesi et al., 1997, Orta and Gunebakan, 2012). In chapter 3, 
all breast cancer patients were subgrouped by ethnicity: i) black, ii) white, iii) Indian and iv) 
coloured (mixed race) patients. In our unselected breast cancer cohort, patients manifest 
chromosomal instability compared to healthy individuals. When subgrouping the patients 
based on ethnicity, higher spontaneous MN values were observed in the white (mean age = 
59 years) and black (mean age = 47 years) patients suggesting that ethnicity has an effect on 
chromosomal instability. When chromosomal instability was assessed in lymphocytes in 
Caucasian and African American breast cancer patients, the MN values were significantly 
higher in Caucasian women and significantly lower in African American women (Aboalela et 
al., 2015). Our results demonstrate that black South African patients also exhibit enhanced 
chromosomal instability as measured by the G0 MN assay; these results promote the notion 
that chromosomal instability may vary based on ethnicity. The age of the patients could have 
contributed to enhanced spontaneous MN values.  
 
Similar to the general breast cancer population (Chapter 3), chromosomal instability with 
increased spontaneous MN values was depicted between young and old patients (Chapter 5); 
the enhanced chromosomal instability with the differences being higher in the older patients. 
This could be attributed to the increase of 0.58MN/year as suggested by Thierens et al. 
(2000) (Thierens et al., 2000). Young breast cancer patients have more aggressive tumour 
features and could possibly have a unique genetic composition that results in increased 
spontaneous MNi frequency (Basro and Apffelstaedt, 2010). The age-associated decline in 
DNA repair leads to accumulation of DNA damage, possibly contributing to the elevated 
spontaneous MN values in the older patient group. Other factors that could influence 
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chromosomal instability in these patients are age-related oxidative damage and aneuploidy 
(Luzhna et al., 2013). 
 
Similar to the general breast cancer population (Chapter 3), G0 chromosomal instability with 
increased spontaneous MN values was depicted in TN lymphocytes. In chapter 5, we 
compared the chromosomal instability of all TN (n = 17) and luminal patients (n = 10) in the 
S/G2 phase of the cell cycle. Comparing spontaneous MN values in the S/G2 phase of the 2 
subgroups revealed 35% of the luminal patients as chromosomally instable. Only 14% of TN 
patients had high spontaneous MNi compared to the controls. Given that majority of BRCA1 
carriers develop TNBC, chromosomal instability was also evaluated in all mutation carriers 
in breast cancer susceptibility genes. No statistical significance was observed in the 10 
mutation carriers compared to the controls. In a recent study, BRCA positive populations 
show elevated chromosomal instability (Baert et al., 2016, Baert et al., 2017). Further studies 
are warranted to confirm S/G2 chromosomal instability in TNBC patients who are also 
mutation carriers in breast cancer susceptibility genes, particularly in BRCA. 
 
1.2. Effect of age on chromosomal radiosensitivity 
 
African breast cancer populations are often distinct from other breast cancer populations by 
the different age distributions (Sighoko et al., 2013, Newman, 2005). The incidence of breast 
cancer is more prominent in young black populations (Basro and Apffelstaedt, 2010, Shavers 
et al., 2003); therefore the focus of the next part in this study was the effect of age on 
chromosomal radiosensitivity by investigating young and older breast cancer patients. 
Elevated MNi frequency occurring spontaneously is an indicator of chromosomal instability 
whereas chromosomal radiosensitivity is indicated by a higher frequency of MN values 
induced by radiation. In chapter 3, G0 lymphocytes from a group of unselected patients (n = 
68; mean age = 52) irradiated with 2 and 4 Gy showed increased MN values compared to a 
group of healthy individuals suggesting chromosomal radiosensitivity in the breast cancer 
group. These results are in agreement with previous European studies (Baeyens et al., 2002, 
Baeyens, 2005, Scott et al., 1998). Similar to our study, Baeyens et al. (2002) investigated the 
G0 chromosomal radiosensitivity in an unselected (Belgian) breast cancer cohort but using γ-
rays at high and low dose rate. With a similar sample size as used in our study, they reported 
significantly increased mean radiation-induced MN values in the patient’s population when 
compared to healthy individuals. The mean age of the breast cancer cohort used in our study 
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was slightly higher (52±12) than in Baeyens et al. (2002) (45±10) (Baeyens et al., 2002). 
These results confirm enhanced chromosomal radiosensitivity in the general breast cancer 
population regardless of age.   
 
Auer et al. (2014) investigated the effect of age on chromosomal radiosensitivity in breast 
cancer patients with a 2 Gy dose. The technique for the effect of age was a 3 colour FISH to 
detect metaphase spreads, different from the MN assay used in our study. Their study 
reported increased chromosomal radiosensitivity in an unselected cohort of breast cancer 
patients. Interestingly, they described that enhanced chromosomal radiosensitivity was 
primarily observed in patients aged between 40 and 50 years (Auer et al., 2014). We were 
able to demonstrate increased chromosomal radiosensitivity in a young and older breast 
cancer cohort (Chapter 5). Young patients only displayed significantly enhanced levels of 
MN values for the 4 Gy dose of IR, whereas the increase was significant for the older patients 
for both 2 and 4 Gy doses compared to the controls. However, no significant correlation 
between age and chromosomal radiosensitivity in breast cancer patients in our study was 
demonstrated.  
 
1.3. Effect of ethnicity on chromosomal radiosensitivity 
 
Differences in breast cancer exist between ethnic groups in South Africa (Dickens et al., 
2014, Vorobiof et al., 2001). For instance, black women are known to have more TN 
subtypes than their white counterparts (Awadelkarim et al., 2008) and the incidence of breast 
cancer in the black population is prominent in younger women (Stark et al., 2010). We, 
therefore, wanted to investigate the link between chromosomal radiosensitivity and ethnic 
groups (Chapter 3). As seen in previous international studies, our results are in agreement by 
demonstrating chromosomal radiosensitivity in the white population (Poggioli et al., 2010, 
Burrill et al., 2000, Baeyens et al., 2005). Black patients (n = 30) also showed increased 
chromosomal radiosensitivity for both the 2 and 4 Gy irradiations in the G0 phase. Whereas 
the coloured patients (n = 6) had higher MN values compared to healthy controls although no 
significant differences were noted. The increase in MN values was not observed in the Indian 
cohort. The small group of the Indian and coloured population (n = 6 and n=7) included in 
our study restricts conclusions. Further validations are necessary in order to draw conclusions 
in both the coloured and Indian breast cancer patients. The enhanced chromosomal 
radiosensitivity observed in the black and white patients’ group but not in the coloured and 
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Indian patients’ group suggests diverse DNA damage response and repair mechanisms in 
different ethnic populations. A study has highlighted the role of DNA damage response in 
African American and Caucasian breast cancer populations (Rodriguez-Gil et al., 2010). 
Their results show lymphocytes of young African American breast cancer patient’s show 
significantly increased levels γ-H2AX foci after irradiation compared to Caucasian women. 
γ-H2AX foci denotes the presence of DNA DSB. These results suggest that African 
American patients are prone to elevated DNA damage (Rodriguez-Gil et al., 2010). Similarly, 
our study shows increased chromosomal radiosensitivity in the black patients’ further 
highlighting the difference in African patients and other ethnic groups. There is a need for 
improved understanding of DNA repair in different South African patients, per ethnic group, 
which could be clinically relevant in managing risk assessment and disease prevention.  
 
1.4. Effect of tumour characteristics and triple negative phenotype on chromosomal 
radiosensitivity 
 
Due to the tumour heterogeneity, we investigated the potential effects of clinical parameters 
on chromosomal radiosensitivity (Chapter 3). By subgrouping all patients on tumour receptor 
expression, histological type, size and staging, radiation-induced MN values were elevated in 
the ER positive patients. ER is a steroid hormone and a transcription factor that mediates its 
biological effects through two receptors – ER alpha (ERα) and ER beta (ERβ). ER positive 
breast cancers are more predominant in postmenopausal women (Hurvitz and Pietras, 2008). 
Oxidative damage to the DNA induced by estrogen in the ER positive cells is enhanced by 
exposure to IR. Increase in MNi in ER positive cancers could be a result of pre-existing DNA 
damage plus the radiation-induced DNA damage (Mobley and Brueggemeier, 2004). There is 
evidence of chromosomal radiosensitivity of lymphocytes of ER positive patients was also 
demonstrated in the G2 phase by evaluating chromatid breaks (Riches et al., 2001). As an 
extension of this study, the effect of ERα and ERβ on breast cancer radiosensitivity will be 
investigated in our research group.     
 
Breast cancer patients are clinically categorised into different subtypes. One of the 
classification systems is based on expression of hormonal receptors (ER, PR and HER2).  In 
our first study of chromosomal radiosensitivity on unselected breast cancer group we noted 
that the ER-positive breast cancer patients had a more radiosensitive phenotype compared to 
the ER-negative breast cancer patients. The lack of receptors on TN cells may reduce 
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sensitivity to IR. TNBC occurrence is prominently noted in young African women; therefore 
chromosomal radiosensitivity data is of utmost importance in the South African context. In 
chapter 5, we investigated the G0 chromosomal radiosensitivity of breast cancer patients 
grouped as TN and luminal patients based on the receptor status and age. Chromosomal 
radiosensitivity data in TNBC patients has recently encouraged great interest and results are 
indicative for the radioresistance of TN cells (Ren et al., 2015, Chen et al., 2017a, Mehta et 
al., 2016, Li et al., 2017). Contrary to the observed radioresistant phenotype, there is evidence 
that TNBC have defects in DNA repair genes (Ribeiro et al., 2013). DNA repair genes are 
crucial in damage repair and are involved in different repair pathways; the role of different 
repair pathways was assessed in the study using the G0 and S/G2 MN assay. TNBC patients 
exhibited radioresistance for exposure to IR. In the TN patients, the potential factors 
contributing to radioresistance could be the unique biology of the tumours. High mitotic 
activity is a hallmark of TNBC that can promote radioresistance. Onozato et al. (2017) 
recently demonstrated the radioresistance in highly proliferating cells after IR treatment 
(Onozato et al., 2017). Furthermore, cell cycle and DNA repair genes are overexpressed in 
TNBC. Therefore, it can be hypothesised that the observed chromosomal radioresistance 
could be attributed to increased expression of DNA repair genes (Engebraaten et al., 2013).  
 
DSB are repaired predominantly by two main DNA repair pathways: HR and NHEJ. The cell 
is selective on which DNA repair pathway to use depending on the phase of the cell cycle. In 
the S/G2 phase where a homologous strand is present, the HR repair pathway is preferred 
over NHEJ. NHEJ repair of DSB is predominant in the remaining phases of the cell cycle. 
The role of HR in chromosomal radiosensitivity was investigated in the group of breast 
cancer patients by using an adapted protocol of the G0-MN assay. In this S/G2-MN assay the 
radiation damage was induced in the S/G2 phase (Claes et al., 2013, Baert et al., 2016). Next, 
the S/G2 chromosomal radiosensitivity of TN and luminal patients was investigated (Chapter 
5). Radiation-induced MN values for 2 and 4 Gy demonstrated elevated chromosomal 
radiosensitivity in luminal patients only. Interestingly, lower radiation-induced MN yields 
were observed in TN patients for both doses of IR indicating a “radioresistant” phenotype. 
The first hypothesis for radioresistance observed in TNBC patients could be the result of the 
overexpression of β-catenin upon exposure to IR (Yin et al., 2016). Irregularities of the 
Wnt/β-catenin pathway is essential for stem cell maintenance (Pohl et al., 2017). Cancer stem 
cells (CSC) in breast cancers with enhanced Wnt/β-catenin pathway are reinforced by 
exposure to IR. This may contribute to the constant maintenance of cancer stem cells in 
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TNBC cells. CSC are implicated with chemoresistance, radioresistance and metastases 
(Bartucci et al., 2015, Krause et al., 2017). Furthermore, they also have increased DNA repair 
capacity contributing to therapy resistance (Pranatharthi et al., 2016). Radioresistance noticed 
in TN cells could be a result of enhanced Wnt/β-catenin signalling. Recent studies have 
identified microRNAs as a factor that can regulate radiosensitivity in TNBC (Ren et al., 
2015, Li et al., 2017, Gasparini et al., 2014). Ren et al. (2015) demonstrated the over 
expression of microRNA-27a in TNBC cell lines compared to normal breast cancer cell lines. 
MicroRNA-27a was shown to directly target CDC27, a protein related with chromosomal 
integrity, and downregulate CDC27 rendering the TN cells radioresistant (Ren et al., 2015). 
Similarly, microRNA-454 was also shown to be highly expressed in TN cells. Recently, Li et 
al. (2017) studied the role of microRNA-454 in TN cancers and its response to IR. 
MicroRNA-454 was shown to inhibit apoptosis following the exposure to ionising radiation 
and improving survival of TNBC cells (Li et al., 2017). The IR-induced cell survival leads to 
radioresistance. Although, these studies are conducted on cell lines, microRNAs regulate 
lymphocyte function and development (Lawrie et al., 2008, Belver et al., 2011). Therefore, 
the decrease in IR-induced MNi frequency in lymphocytes of TNBC patients could be a 
result of overexpression of microRNAs that regulate radiosensitivity. 
 
Similar to our results, Nosrati et al. (2017) have shown higher MN values in luminal breast 
cancer patients compared to the control population and a decline in the MNi frequency in 
TNBC patients (Nosrati et al., 2017). The second hypothesis of radioresistance in TNBC 
patients could be due to the enhanced DNA repair in the absence of ER as shown by Chen et 
al. (2017) (Chen et al., 2017b). Using DNA recombinant technology, viral vectors with ERα 
genes were transfected in TNBC cell lines resulting in expression of ER in TN cells. Thus, 
the effect of ERα on TNBC radiosensitivity could be assessed. The authors show increased 
radiation-induced DSB breaks in TN cells transfected with ERα and delay in repair compared 
to wild type TN cells. Compared to the wild type cells, radiation-induced G2/M arrest was 
increased and, in a time-dependent manner, the S phase was decreased in the ER-transfected 
cell. The HR pathway is enhanced in the S phase for efficient DSB repair. A shorter S phase 
implies less time for DNA repair to occur in S phase. This finding suggests that ER impairs 
DNA repair by altering the cell cycle (Chen et al., 2017b). Further investigations on the 
impact of ER on chromosomal radiosensitivity will be investigated in our research group. 
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In chapter 5, we evaluated checkpoint efficiency using caffeine in all TN (n=17) and luminal 
(n=17) breast cancer patients. In the presence of DNA damage, checkpoints are activated in 
order to regulate accurate and effective replication. Caffeine, however, abrogates the 
checkpoints and permits damaged cells to progress through the cell cycle (Vandevoorde et 
al., 2016). The RIND score was computed to assess individual radiosensitivity. A RIND 
score above 2 was considered as radiosensitive. For the radiation-induced MN values for TN 
and luminal patients, 24% of TN versus 47% luminal patients showed elevated chromosomal 
radiosensitivity compared to healthy controls. Chromosomal instability and radiosensitivity in 
the S/G2 phase was previously observed in breast cancer patients (Baria et al., 2001). The 
mean age of breast cancer patients was 56 years. The chromosomal radiosensitivity in this 
cohort was quantified by scoring metaphase spreads in lymphocytes. Chromosomal 
instability in the breast cancer patients group in this study showed no significant increase 
compared to the controls. Significant differences were, however, observed in radiation-
induced chromosomal aberrations (Baria et al., 2001). In the TN patients, 76% of the 
radioresistant phenotype observed could be due to the dominant effect of the underlying 
mechanisms seen in TN cells. The direct or indirect impairment of the HR repair pathway, 
significant in the G2 phase, could have detrimental effects on DNA damage repair leading to 
increased chromosomal radiosensitivity. A recent study showed upregulation of RAD51 in 
TNBC tumours when compared to other breast cancer. RAD51 is a primary component of the 
HR pathway. TN cells with enhanced HR repair exhibit radioresistance to IR (Gasparini et 
al., 2014). The third hypothesis of radioresistance seen in TNBC patients could be a factor as 
recently shown by Mehta et al. (2016). They showed the association between an mRNA-
binding protein, HuR, and radiosensitivity in 3 different TNBC cell lines. HuR was linked to 
cancer therapy resistance and therefore resulting in poor prognosis as seen in TN cancers. 
HuR is endogenous expressed and enhanced expression is described in TN cells. The study 
showed that knockdown of HuR leads to radiosensitisation by inducing oxidative stress and 
increased DNA damage. They saw a significant increase in γ-H2AX foci in HuR knockdown 
TN cells compared to control cells after IR exposure. The scrambled control had a higher cell 
survival rate. Various DNA repair genes involved in HR were suppressed by the silencing of 
HuR; thereby indicating silencing HuR leads to radiosensitisation. (Mehta et al., 2016). Since 
HuR is endogenous expressed and enhanced in TNBC cells, this could be a contributing 
factor to the observed radioresistant phenotype of TNBC lymphocytes in our study.   
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Additional to the G0 MN assay, the radioresistant phenotype seen in the TN patients in the 
S/G2 phase as well may suggest possible differences in cell cycle controls in TN compared to 
luminal breast cancer patients. The S/G2 MN assay with addition of caffeine was previously 
conducted on AT families; the AT patients were classified as highly radiosensitive and 
carriers as radiosensitive (Claes et al., 2013). Another study demonstrated radiosensitivity of 
lymphocytes of AT carriers only to IR in the G2 phase (Terzoudi et al., 2005). AT patients 
have mutated ATM; ATM plays a vital role in the G2/M checkpoint and in DSB repair. 
When ATM is mutated, the DNA damage will override the checkpoint. These results suggest 
that defects in the G2/M checkpoint will be reflected as chromosomal radiosensitivity as seen 
in our luminal breast cancer patients cohort. 
 
1.5. Effect of mutations in breast cancer susceptibility genes and chromosomal 
radiosensitivity 
 
The association of TNBC and BRCA1 mutations has been widely described (Bayraktar et al., 
2011, Gonzalez-Angulo et al., 2011, Lee et al., 2011, Peshkin et al., 2010, Robertson et al., 
2012, Young et al., 2009). Defects in breast cancer susceptibility genes or DNA repair genes 
often make cells vulnerable to effects of IR. TN and/or young South African patients could 
carry unique defects in DNA repair genes. In chapter 6, we aimed to investigate the 
underlying mechanism of this chromosomal radiosensitivity by screening breast cancer 
patients selected for TN status or patients ≤50 years for BRCA1, BRCA2, PALB2 and the 
CHEK2 allele c.1100delC. In our cohort, we detected a total of 12 BRCA1/2 mutations 
(12.8%) and 1 CHEK2 c.1100delC allele (1.1%). Three novel mutations were identified in 
black patients; two in BRCA1 (c.1155G>A; p.Trp385* and c.1953_1954insA; p.Lys652fs) 
and 1 in BRCA2 (c.582G>A; p.Trp194*). Previous South African studies reported deleterious 
BRCA1 mutations in about 20% of the familial breast/ovarian cancers. At that time, the 
standard mutation analysis strategy in South Africa was the protein truncation test (PTT) and 
PCR-single strand conformation polymorphism/heteroduplex analysis (SSCP/HA) (Reeves et 
al., 2004). As these techniques do not allow the detection of exon-spanning 
deletions/duplications, it is advised to complement the strategy with MLPA analysis. Reeves 
et al. applied stringent inclusive criteria for genetic screening compared to our study and 
screened Afrikaner breast cancer families with different founder mutations than the black 
South African breast cancer patients. Furthermore, the applied genetic screening techniques 
are less sensitive than NGS used in our study. Sluiter et al. (2010) screened 52 hereditary 
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breast/ovarian South African families with MLPA who turned out to be negative after 
analysis with PCR-based techniques. With this technique, they identified 1 family with a 
large genomic arrangement in BRCA1 (Sluiter and van Rensburg, 2010). We also applied 
MLPA but did not detect a large deletion/duplication in our cohort. This may indicate that 
these types of mutations are a major contributing factor in the South African population. 
Screening large South African breast cancer cohorts are necessary in order to identify BRCA 
mutations unique to this population, especially in young TN patients. Robertson et al. (2012) 
showed that over 10% of young TN patients are likely to be BRCA1 mutations carriers 
(Robertson et al., 2012). In the TN cohort in our study, 17 % of all TN patients (n = 18) and 
22% of young patients with TN phenotype (n = 9) are BRCA1 mutation carriers.TN patients a 
priori a higher likelihood of being BRCA1/2 mutation carriers. The prevalence of BRCA1 
mutations in TNBC patients ranges between 9-37% (mean = 35%) and for BRCA2 the range 
is 1-12% (mean = 8%) (Rashid et al., 2016, Li et al., 2014, Peshkin et al., 2010). Despite the 
prevalence of Ashkenazi Jewish and Xhosa founder mutations in the South African 
population, these founder mutations are absent in our population as neither Ashkenazi nor 
Xhosa patients were included in our study. Although BRCA1/2 are the most sequenced genes 
worldwide, we identified three novel mutations, never described before, in our study cohort 
of black patients, indicating the need for large screenings of young and/or TN patients in 
South Africa widely.  
 
Our study did not identify PALB2 mutations in the selected cohort of TNBC and young breast 
cancer patients. However, previously studies have reported the presence of pathogenic 
PALB2 (2%) mutations in young white South African breast cancer patients (Sluiter et al., 
2009). These findings reinforce the need for breast cancer susceptibility screening for South 
African patients with early onset breast cancer or who are TN. Further studies are 
recommended to uncover mutations with DNA repair genes that are specific to our 
population. There is increasing evidence linking breast cancer with DNA repair genes (Chae 
et al., 2016). South African breast cancer women are an understudied population. Increasing 
mutation analysis within this population will contribute to the limited aetiology and assist in 
disease management.  
 
Patients carrying mutations in breast cancer genes in our study were also subject to 
chromosomal radiosensitivity analysis (Chapter 5). The mean age of patient positive for 
mutations in DNA repair genes (n = 10) in our study was 49 years and mutations primarily 
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occurred in white patients; 40% were confirmed TN patients. In the 10 mutation carrier 
patients analysed for chromosomal radiosensitivity, no statistical significance in MN values 
were observed when compared to the controls. In other recent studies performed, BRCA 
positive populations show elevated chromosomal radiosensitivity to IR. In the BRCA1/2 
positive study population studied by Baert et al. (2016), 72% of BRCA1 and 50% BRCA2 
healthy carriers were reported as chromosomally radiosensitive (Baert et al., 2016) (Baert et 
al., 2017). Screening TN and young South African breast cancer patients for BRCA1/2 and 
other breast cancer susceptibility genes is important as it can improve individual patient 
treatment by assessing chromosomal radiosensitivity prior to radiation therapy. Mutations in 
BRCA1/2 genes compromise DNA repair mechanisms resulting in chromosomal instability 
and chromosomal radiosensitivity. Larger studies to evaluate the effect of BRCA on 
chromosomal radiosensitivity in South African patients are further warranted.  
 
1.6. Effect of storage and anaesthetics on MN yields in breast cancer patients 
 
In our study, blood samples of patients are often transported to the labs following curative 
breast surgeries. Patients are mostly under the influence of general anaesthesia prior to 
drawing of the blood. A major challenge is the inadequate transportation of blood samples 
with lack of controlled temperature and delay in sample processing. Both factors, time and 
general anaesthesia, could affect the MN yields. In chapter 4, we investigated the influence of 
i) storage time of blood samples and ii) anaesthesia on the chromosomal radiosensitivity. In 
the first part of the study investigating storage time of blood samples, blood samples from a 
control population and patient group were collected. No differences in spontaneous MN 
values were detected in both the controls and patients following the delay in processing time. 
The radiation-induced MNi frequencies were, however, significantly increased with 
increasing storage times in patients and controls. Temperature control plays an essential role 
in blood storage. Blood samples from our study were stored at room temperature prior to 
conducting the MN assay. Belloni et al. (2010) showed the effect of temperature during blood 
storage on the yield of chromosomal aberrations using metaphase spreads. Samples prior to 
irradiation stored at 4 or 20°C with PHA, did not exhibit any chromosomal damage. When 
irradiated lymphocytes were stored for 24 and 48 hours with no PHA and at 20°C, they 
observed a significant increase in apoptosis and significant decrease in dicentrics compared 
with storage with PHA and 4°C (Belloni et al., 2010). In our study, the BN yield depression 
was noted in the patients when dose increased and after 48 hours of storage, the BN yield 
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decreased for both doses in the control group. This can be attributed to increased apoptosis 
due to storage of sample at room temperature for 48 hours as suggested by Belloni et al. 
(2010) (Belloni et al., 2010). Storage and transportation of blood samples should be 
cautiously handled by controlling temperature. If processing of samples is delayed, samples 
can then be stored at 4°C with PHA until 48 hours for reliable results (Belloni et al., 2010).         
 
Breast cancer patient undergoing surgeries are administered general anaesthetics. 
Anaesthetics are widely known to have genotoxic potential and its effects have been 
described (Chandrasekhar et al., 2006, Rozgaj and Kasuba, 2000, Lucio et al., 2017, Aldrieny 
et al., 2013). We assessed the influence of anaesthetics on the number of chromosomal 
aberrations in blood samples from patients undergoing breast surgeries (Chapter 4). Exposure 
to anaesthesia contributed to decrease in BN yield. Blood samples collected after 
administering general anaesthesia exhibit significantly enhanced spontaneous MN values. 
Our findings are in agreement with a study by Ajauro et al. (2013) where they showed that 
lymphocytes of operating room personnel exposed to anaesthetic gases exhibited significantly 
increased MN values when compared to personnel’s not exposed (Araujo et al., 2013). For 
the radiation-induced samples after anaesthetics, MN values were significantly enhanced for 
samples processed after 24 hours for both doses. The effects of radiation on lymphocytes are 
considerably more harmful and could override the effect of anaesthetics in patients 
undergoing breast surgery. Our results suggest that for radiosensitivity studies, blood samples 
should preferably be collected prior to the administration of general anaesthetics to reflect 
true radiation-induced MN values in breast cancer patients. 
 
 
 
 
 
 
 
 
 
 
 
 
102 | Page
2. Fanconi Anaemia 
 
The next aim of the study was to assess chromosomal radiosensitivity in FA patients using 
the G0 and S/G2 MN assays (Chapter 7). FA patients are known to be hypersensitive to DNA 
crosslinking agents and this trait was utilised to detect chromosomal breakage induced by 
MMC to distinguish homozygous or heterozygous mutation carriers of the FA genes. A large 
number of genes are associated with FA and new components of the FA pathway are still 
being identified; we optimised a FANC gene panel for the mutation analysis of the 22 FANC 
genes known at the start of the study using NGS in combination with MLPA was used to 
identify large deletions. Furthermore, the correlation between chromosomal radiosensitivity 
and FA mutations was investigated.  
 
Founder mutations in South Africa are particularly associated with the black South Africans 
(FANCG c.637_643delTACCGCC), Afrikaner (FANCA del E12-17; del E11-17; c.3398delA)  
and Ashkenazi (FANCC c.456+4A>T) population groups (Morgan et al., 2005, Wainstein et 
al., 2013, Feben et al., 2017a). Consequently, molecular screening for FA patients in South 
Africa is based on ethnicity. However, previous studies have shown that a subset of patients 
do not adhere to this pattern and might require further testing (Wainstein et al., 2013). The 
need for a FANC panel, therefore, was crucial in identifying and diagnosing FA patients who 
are clinically symptomatic and negative for the common mutations. Advances in genetic 
screening have paved the way for multi-gene panel tests. With the involvement of genetics in 
a number of diseases, gene panel testing is widely available (Nguyen et al., 2017, Ring et al., 
2016, Silva-Smith and Sussman, 2017, van Marcke et al., 2016, Wing et al., 2017). Our gene 
panel consisted of 20 FANC genes (Dong et al., 2015, Park et al., 2016). We optimised 
singleplex PCR for all coding exons of the FANC genes. Next, the modified Nextera XT 
(Illumina) library preparation protocol was applied as previously described (De Leeneer et 
al., 2015). To identify large genomic rearrangements in the FANC genes, MLPA was 
performed using the commercially available probemix for FANC genes (MRC-Holland) 
(Chapter 7). Lastly, all pathogenic mutations and variants identified on the Miseq platform 
were confirmed using Sanger sequencing. Following the validation, clinical diagnosis of 12 
unrelated patients and 2 siblings were molecularly confirmed using this approach. Patients 
were subjected to both the panel screening and MLPA to detect large amplification or 
deletions. 
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All South African patients (n = 13) screened in this study had clear clinical symptoms of FA 
prior to mutation analysis. The homozygous FANCG c.637_643delTACCGCC founder 
mutation was detected in 92% of the black South African patients. This is slightly higher than 
a study performed by Morgan et al. (2005) who reported 82% prevalence of the black South 
African founder mutation (Morgan et al., 2005). In addition, we identified a black patient 
compound heterozygous for the recurrent FANCG mutation and a novel missense variant 
(c.1379G>A; p.(Gly460Asp)), likely to be pathogenic. Also, others detected two FANCG 
heterozygous mutations in black South African FA population (Wainstein et al., 2013). Our 
results confirm the unlikelihood of a second common FANCG mutation in the black South 
African population. A recent study identified two black South African patients compound 
heterozygous for FANCD1/BRCA2 mutations (Feben et al., 2017b). The deleterious BRCA2 
mutation in allele 1 in both patients was c.5771_5774delTTCA; p.Ile924Argfs*38 which is 
associated with enhanced breast cancer risk (van der Merwe et al., 2012). We also identified 
this mutation in our TNBC patient cohort (Chapter 6). The second mutation in allele 2 was 
c.582G>A (p.Trp194*) which has also been was previously reported in a South African 
breast cancer cohort (Chen, 2015). All parents are mandatory heterozygous carriers and 
heterozygosity in FANC genes are shown to be associated with early onset breast cancer, 
ovarian and pancreatic cancer risk. FA carriers harbouring deleterious mutations in 
FANCD1/BRCA2 are of higher risk for these cancers. In conjunction with our results, in case 
of absence of the recurrent FANCG mutation, there is a clear need for testing black South 
African FA patients for deleterious mutations in other FANC genes. 
 
Following the identification of the FANC mutations in all 14 patients and confirmed 
heterozygosity in parents, the next aim was to investigate the chromosomal instability and 
chromosomal radiosensitivity in both patient and parent this group. The FA/BRCA pathway 
plays an integral part in maintaining chromosomal stability and is fundamental in DNA 
damage response. However, the pathway is compromised if DNA repair genes that control 
and regulate the pathway carry a defect as seen in FA patients and heterozygous carriers. The 
defect could be reflected as chromosomal instability which is a frequent trait in FA patients 
(Palovcak et al., 2017, Cerabona et al., 2014). The chromosomal instability was confirmed by 
the significantly higher spontaneous MN values in the G0 and S/G2 phases of the cell cycle 
in our study. Heterozygous carriers also displayed higher spontaneous MN values also 
probably due to defects in FANC genes.  
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Chromosomal radiosensitivity information in the FA population is also important. The 
likelihood of developing solid tumours, leukaemia or other cancers in FA patients is 
substantially high (Mathew, 2006, Velleuer and Dietrich, 2014). The cumulative risk for 
various solid tumours assessed was 700-fold increase for acute myeloid leukaemia, 600-fold 
for head and neck squamous cell carcinoma, 3000-fold for vulvar squamous cell carcinoma 
and 6000-fold for myelodysplastic syndrome (Alter, 2014). Compared to the general 
population, FA patients are reported to have a 50-fold increase in risk of solid tumours. 
(Rosenberg et al., 2003). When evaluating cancer risks in heterozygous carriers, a study by 
Berwick et al. (Berwick et al., 2007) showed increased incidence of breast cancer in FA 
carriers. Chromosomal radiosensitivity can be seen as a marker of predisposition to cancer. 
We show that FA lymphocytes also presented significantly enhanced radiation-induced MN 
values in the G0 and S/G2 phases of the cell cycle. Chromosomal radiosensitivity of FA cells 
in the G0 phases has previously been contradictory (Duckworth and Taylor, 1981). However, 
some literature data still demonstrate that FA cells are significantly more radiosensitive when 
compared to controls (Higurashi and Conen, 1971, Higurashi and Conen, 1973, Alter, 2002, 
Heddle et al., 1978). We were able to demonstrate enhanced chromosomal radiosensitivity of 
FA lymphocytes compared to FA parents and healthy individuals with significant differences 
in radiation-induced MNi in both the G0 and S/G2 phase. This is in agreement with a study 
by Bigelow et al. (Bigelow et al., 1979) who also evaluated radiosensitivity using 
lymphocytes. However, this is a much older study performed on smaller cohorts. The 
FA/BRCA genes play a fundamental role in DNA repair in the G2 phase. When comparing 
chromosomal radiosensitivity in the G0 and S/G2 phases, significant differences observed in 
the S/G2 phase for both doses were more pronounced than in the G0 phase. The enhanced 
S/G2 chromosomal radiosensitivity could be attributed to defects DNA repair pathway in FA 
patients (Sala-Trepat et al., 2000) due to mutated FANCG. The FANCG forms part of the 
core complex in the FA/BRCA pathway. Defects in the core complex could render the 
pathway as inefficient. During DNA repair, FANCG interacts with BRCA1 and BRCA2; 
FANCG directly binds to the BRC repeats on BRCA2. BRC repeats have the capability of 
binding to RAD51. The presence of a mutation in FANCG deteriorates the binding affinity of 
RAD51 contributing to the increase of breast cancer susceptibility (Hussain et al., 2003) and 
enhanced chromosomal radiosensitivity. All FA patients with FANCG deleterious mutations 
(n = 13) could exhibit chromosomal radiosensitivity due to the loss of binding affinity of 
RAD51 that impairs the FA/BRCA pathway and the HR repair mechanism. 
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Defective checkpoints are a trait that has previously been observed in FA cells (Sala-Trepat et 
al., 2000). To evaluate the G2/M checkpoint efficiency in our FA cohort, the checkpoint was 
abrogated by the addition of caffeine to the irradiated cultures in the S/G2 MN assay. The 
checkpoint efficiency is indicated by a ratio of MNi with caffeine divided by MNi without 
caffeine (MNCaf+/MNCaf-). A lower ratio indicated an impaired checkpoint. In older 
studies, FA patients’ cells treated with radiation and caffeine showed elevated chromosomal 
damage compared to healthy individuals that was quantified by metaphase spreads. Two 
heterozygous carriers were also assessed in the study and displayed increased chromosomal 
damage with caffeine treatment alone (Pincheira et al., 1988). The FA parents in our study 
showed impaired checkpoint only at 4 Gy dose of IR with significantly enhanced MNCaf+ 
values. It was suggested that the addition of caffeine to irradiated FA cells may inhibit DNA 
repair process in G2 (Sabatier and Dutrillaux, 1988). The significantly higher MNCaf+ value 
in FA patients seen in our study may be due to the inhibition of DNA damage repair and 
abrogation of the G2/M checkpoint. Although no significant differences were observed, the 
higher MNCaf+ values in the FA parents may be due to presence of a defective FANC allele 
hindering damage repair and overriding the G2/M checkpoint.  
 
The standard chromosomal breakage analysis is a preferred method to diagnose FA by 
quantifying MMC-induced chromosomal aberrations in metaphase spreads (Krynyckyi et al., 
2005). Due to the variations encountered with this technique and the labour intensity in 
scoring metaphase spreads, we have proposed an alternative method to investigate MMC-
induced MN. MMC induced DNA crosslinks in FA patients’ results in higher MN values that 
are statistically significant when compared to heterozygous carriers and controls. FA patients 
were clearly distinguishable from FA parents and controls when either a lower and higher 
concentration of MMC was used. However, due to the toxicity of MMC, the FA patients had 
low numbers of BN cells when MMC concentration was increased. We show that with the 
lower concentration of 0.02 µg/ml MMC, we could also differentiate heterozygous carriers 
from healthy controls. The heterozygous carriers had values in between patients and controls. 
Older studies conducted on lymphocytes of FA parents using DEB and MMC could not 
differentiate FA parents from controls. An older study induced chromosomal breakage using 
DEB and MMC for the identification of FA carriers were also unsuccessful with the 
overlapping of results between the FA parents and control population (Cervenka and Hirsch, 
1983, Deviren et al., 2003, Rosendorff and Bernstein, 1988, Cohen et al., 1982).  
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The chromosomal breakage analysis requires the quantification of metaphase spreads. 
Different protocols are utilised across cytogenetics laboratories that may cause variations in 
results correlated with very low yields of metaphases. Analysing metaphase spreads require 
extensive experience and results could be inconclusive results in the absence of an 
experienced analyser (Oostra et al., 2012). The chromosomal breakage analysis is highly 
labour intensive. The MMC MN assay we’ve proposed has proven to be less labour intense 
and quantifying MNi is less subjective. Another advantage of the MMC MN assay is the 
reduction in cost. It is more economical and a robust technique that allows distinguishing of 
FA patients, carriers and controls. Since, the MMC MN assay is time effective, less 
subjective and less labour intensive, it can be utilised in a clinical setting to diagnose FA 
patients particularly in South Africa. South African FA patients manifest clinically symptoms 
prior to genetic screening referrals and usually present with late stage disease with severe 
haematological presentations. Due to the subtlety of the physical defects, some patients 
clinically not diagnosed which still remains a challenge (Feben et al., 2014).  There is an 
urgent need for a quick and reliable assay for the clinical diagnosis of FA patients in South 
Africa prior to severe clinical symptoms. With further validations, the MMC MN assay is a 
promising functional assay to identify individuals with defects in FA genes.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 | Page
CONCLUSIONS 
 
As the primary aim of this research, the chromosomal instability and chromosomal 
radiosensitivity of breast cancer patients in South Africa was investigated. Breast cancer in 
South Africa is the leading cancer amongst women and has a high incidence of early-onset of 
the disease. Young African women are frequently diagnosed with TNBC. The occurrence of 
TN is often associated with BRCA1/2 mutations that play a central role in DNA repair; 
defects in DNA repair genes can lead to chromosomal instability and chromosomal 
radiosensitivity. In a selected cohort of breast cancer patients, 12% were positive for 
BRCA1/2 mutations; 3 were novel mutations identified in black South African patients. Six 
variants with unknown clinical significance were also identified in the black population; this 
highlights the need for further genetic screening in the under studied population, explicitly in 
young TN patients. Screening a larger population of TN and young patients will permit the 
identification of deleterious mutations in breast cancer susceptibility genes and contribute to 
the mutation spectrum in South African breast cancer patients.  
 
Information on breast cancer radiosensitivity is important, particularly in TN breast cancer 
patients who present with more aggressive tumours, poor prognosis and limited treatment 
options. TNBC patients are treated with IR and the information on radiosensitivity is very 
valuable. The observations of the MN assay suggest increased chromosomal instability and 
chromosomal radiosensitivity in South African breast cancer patients. The increase in 
spontaneous and radiation-induced MNi frequency was observed in young as in older 
patients. Although age influences spontaneous MN, an age effect on radiation-induced MN 
could not been shown. With a mixed ethnicity in South Africa, a correlation between 
chromosomal radiosensitivity and ethnicity was investigated and revealed differences in 
radiosensitivity in different ethnic South African groups. Overall, in the different ethnic 
groups, black and white patients were more chromosomally radiosensitive and the 
radiosensitivity was more pronounced in estrogen receptor positive patients. In the absence of 
receptors, TN patients presented with a “radioresistant phenotype”. Our results suggest that 
the healthy lymphocytes in TN patients are equipped to handle higher doses of IR, therefore, 
treatment plans could be altered with adequate doses for TNBC patients. Further validations 
of chromosomal radiosensitivity in larger TN patients population is necessary. Furthermore, 
larger cohorts are warranted to validate chromosomal instability and chromosomal 
radiosensitivity in the presence of germline mutations in DNA repair genes such as BRCA. 
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The secondary aim of the study was to investigate the chromosomal instability and 
chromosomal radiosensitivity in FA patients and parents compared to healthy individuals. Of 
all the South African FA patients recruited for the study, 92% were positive the FANCG 
founder mutations and a FANCA mutation was identified in a patient with African descent. 
The radiosensitivity data for the FA patients and parents presented here are, therefore, valid 
for the FANCG and FANCA homozygous and heterozygous carriers. Further studies are 
warranted to test FA homozygotes or compound heterozygotes of other FA genes. As a 
marker for cancer predisposition, chromosomal radiosensitivity is crucial in cancer 
prevention and monitoring. Additionally, these patients are at risk to develop secondary 
cancers as a result of radiotherapy, it is recommended that these patients are treated with 
caution. In the FA patients, chromosomal instability and chromosomal radiosensitivity was 
significantly elevated. This was observed in both the G0 and S/G2 phase of the cell cycle. As 
obligate carriers, the FA parents also exhibited chromosomal instability in G0 and S/G2 
phase. Chromosomal radiosensitivity in FA parents was not detected. Using IR, the MN assay 
proves to be beneficial for detecting FA homozygotes and heterozygotes at a group level but 
not on an individual level. On the contrary, when we induced DNA damage by MMC instead 
of IR, and using the MMC MN assay, identification of FA homozygotes and FA 
heterozygotes from controls was possible. Identification of heterozygous mutation carriers 
may be clinically relevant in the context of breast cancer prevention as heterozygous 
mutations in several FA genes were shown to be associated with an increased risk for breast 
cancer. 
 
The optimised MMC MN assay in our study has shown to be beneficial as it is less labour 
intense, more time effective and less subjective than the classic MMC chromosomal breakage 
assay. Since this technique can undeniably differentiate FANC homozygotes and 
heterozygote genotypes from healthy controls, we propose the MMC MN assay as a potential 
new functional assay supportive for the identification of individuals with a deficiency in 
genes related to the FA/BRCA pathway. 
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FUTURE PERSPECTIVES 
 
This study has highlighted the various factors that affect chromosomal radiosensitivity in 
breast cancer patients. Future experiments could continue the investigation of chromosomal 
instability and chromosomal radiosensitivity of breast cancer patients by scrutinising other 
potential factors such as the effect of ER. ER mediates its biological effects through two 
receptors – ER alpha (ERα) and ER beta (ERβ). These receptors are co-expressed in breast 
cancer cells and the ratios of expression vary. The TNBC are known to lack the expression of 
ER. However, it was recently shown that TN cells lack the expression of ERα but a portion of 
TNBC express ERβ. The lack of ER expression was suggested in our study as a factor that 
influences chromosomal radiosensitivity in TN cells. Therefore, further investigations on 
which ER subtype influences chromosomal radiosensitivity will be assessed. Overexpression 
and knockdown of the estrogen receptors in several breast cancer types by using recombinant 
DNA technology are proposed in our future studies.  
 
Our results of the S/G2 MN assay show an inclination of increased chromosomal 
radiosensitivity in luminal patients but not in TNBC patients. It would be of great interest to 
further evaluate the chromosomal radiosensitivity in the S/G2 phase of TN and luminal 
patients by increasing sample numbers. In the future, the effect of ethnicity should also be 
evaluated with larger cohorts.  
 
FA patients regularly receive blood cell transfusions due to anaemia, thrombocytopenia and 
low platelet counts. Receiving sufficient blood samples from these patients can often be a 
challenge. Using fibroblasts from skin biopsies from FA patients to investigate radiation- or 
MMC- induced DNA damage could overcome the problem of insufficient blood in FA 
patients and could exclude the interference of recent blood transfusions with the quality of 
results. Apart from biomarkers tested in our study, future work in FA patients can scrutinise 
DNA repair proteins. HR repair is crucial in the FA/BRCA pathway. RAD51 is a downstream 
effector and plays an important role in the pathway. The FANCG gene forms part of the core 
complex and mutations in this gene are frequent in the black FA patients in SA. Using 
RAD51 foci assay could allow detecting the interaction between the two genes and repair 
efficiency. RAD51 foci assay can also be used to investigate the repair kinetics in FA patients 
and parents. Other proteins involved in the FA/BRCA pathway could be investigated with 
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specific foci assays and could reveal more information on the underlying mechanism of 
radiosensitivity in the breast cancer and FA patients. 
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APPENDIX 1 
Supplementary tables for chapter 6 
Supplementary Table 1: Overview of grading and staging of breast cancer on diagnosis. 
Age 
Average 45 
Median 42 
Range 25 – 77 
Grade 
Grade 1 7% 
Grade 2 51% 
Grade 3 42% 
Stage 
Stage I 9% 
Stage II 55% 
Stage III 32% 
Stage IV 2% 
 
Supplementary Table 2: Overview of sequencing coverage per run. 
Run 
Total no. of 
amplicons 
sequenced 
No. of 
amplicons 
with 
coverage 
<28x 
No. of 
amplicons 
with coverage 
<5x 
Average 
per run 
Median 
per run 
Range 
per run 
1 4416 177 (4%) 123 (3%) 313 238 0-7000 
2 1248 38 (3%) 25 (2%) 208 185 0-1000 
3 2400 23 (1%) 20 (1%) 509 441 0-2500 
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Supplementary tables for chapter 7 
Supplementary Table 1: G0 MN assay p values 
Dose Patients vs Controls Parents vs Controls Patients vs Parents 
0Gy 0.0100* 0.2397 0.3000 
2Gy 0.0003* 0.3459 0.0219* 
4Gy 0.0025* 0.2456 0.0444* 
*Statistically significant 
 
 
Supplementary Table 2: S/G2 MN assay p values 
Dose Patients vs Controls Parents vs Controls Patients vs Parents 
0Gy <0.0001* 0.0164* 0.0108* 
2Gy C- 0.0040* 0.1996 0.0430* 
4Gy C- <0.0001* 0.0962 0.0006* 
2Gy C+ <0.0001* 0.1499 0.0051* 
4Gy C+ 0.0025* 0.0310* 0.1371 
*Statistically significant 
 
 
Supplementary Table 3: MMC MN assay p values 
Dose Patients vs Controls Parents vs Controls Patients vs Parents 
0 MMC 0.0032* 0.2858 0.0307* 
0.02 µg/ml <0.0001* 0.2013 <0.0001* 
0.1 µg/ml <0.0001* 0.0002* 0.0004* 
*Statistically significant 
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APPENDIX 2 
 
Ethics clearance certificate for breast cancer study 
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Ethics clearance certificate for Fanconi anaemia study  
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APPENDIX 3 
 
Informed consent and questionnaire for health individuals 
 
Informed consent and questionnaire for breast cancer patients 
 
Informed consent and questionnaire for Fanconi Anaemia patients/parents 
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                             Ethics Committee Chairperson: Prof Cleaton-Jones: 011 717 23 01 
 
 
INFORMED CONSENT FORM - HEALTHY DONORS 
 
Good Day, 
 
We are Dr A. Baeyens and students Flavia Francies and Olivia Herd from the Radiobiology lab based at 
WITS medical School. We are part of a collaborative study between WITS University and iThemba 
LABS to investigate the radiosensitivity of breast cancer patients. Radiosensitivity explains how well the 
radiation works on your tumour and normal organs; it means an increased susceptibility of cells, tissues or 
organs to the harmful effects of ionizing radiation. Ionizing radiation is used in radiotherapy to treat 
cancer. Information on individual radiosensitivity helps to monitor the radiotherapy treatments.  
 
We need healthy individuals, without breast cancer, as a control group for our study. Therefore we invite 
you to consider participating in a research study. Your participation in this study is entirely voluntary. If 
you decide to take part in this study, you will be asked to sign this document to confirm that you 
understand the study. You will be given a copy to keep.  
 
Should you decide not to participate in the study or if you agree and then change your mind, there will be 
no implications for you and the best treatment available for you will still be given. 
 
If you agree to participate, we kindly ask you to donate 20ml of blood once. This is not a lot of blood; it is 
only 4 teaspoons and will not harm you. We will use your blood sample to test the sensitivity to radiation.  
 
There is no direct benefit to you. But your participation in this study will contribute to the development of 
greater knowledge of radiosensitivity and may help to ameliorate the radiotherapy treatments of breast 
cancer patients. 
 
The research is completely confidential, which means that your name will not be recorded on any of our 
laboratory information. The consent forms will be locked away and only accessible by the researchers. We 
will require some personal details from you (your age, language, monthly income, do you have children, 
see questionnaire attached) and we also want to know if you are a smoker or if you have any other major 
illness, as this can have an influence on our tests. 
 
You are free to ask any questions about this study and discuss any worries you may have with the research 
staff. This study has been approved by the University of Witwatersrand, Human Research Ethics 
Committee. If you want any information regarding your rights as a research participant, or complaints 
regarding this research study, you may contact Prof. Cleaton-Jones, Chairperson of the University of the 
Witwatersrand, Human Research Ethics Committee (HREC), which is an independent committee 
established to help protect the rights of research participants at (011) 717 2301 or peter.cleaton-
jones@wits.ac.za. 
 
 
Thank you very much for your time 
 
Regards, 
Dr A. Baeyens, F. Francies, O. Herd 
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Study participant number:                                                   Date of Birth: 
 Contact no:  
 
INFORMED CONSENT: 
 
 
I hereby confirm that I have been informed about the nature, conduct, benefits of the study on 
radiosensitivity of breast cancer patients. 
 
I have also received, read and understood the above written information regarding this study. 
 
I have no further questions and declare myself prepared to participate in the study. 
 
 
PARTICIPANT: 
 
 
Name (Print): 
 
 
Signature and date: 
 
 
 
STUDY STAFF CONDUCTING CONSENT DISCUSSION: 
 
 
Name (Print): 
 
 
Signature and date: 
 
 
 
WITNESS (IF APPLICABLE): 
 
 
Name (Print): 
 
 
Signature and date: 
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RADIOSENSITIVITY STUDY ON BREAST CANCER PATIENTS 
QUESTIONNAIRE FOR PARTICIPANTS 
Age:  .....................................................................................................................................  
Home language:  ....................................................................................................................  
Ethnic group:  ........................................................................................................................  
Place of birth:  .......................................................................................................................  
What is your monthly income: - None 
 - less than R500 
 - between R500 and R1000 
 - between R1000 and R2000 
 - between R2000 and R5000 
 - more than R5000 
 - unknown 
Do you have children? How many?  .......................................................................................  
What is your highest grade completed? - Primary school 
 - High school 
 - Tertiary school 
Have you ever smoked? Do you currently smoke?  .................................................................  
Do you have any other major illness?  ....................................................................................  
Do you know your HIV status?  .............................................................................................  
Will you disclose your status to me? Are you positive or negative?  ........................................  
Are you pre- or postmenopausal?  ..........................................................................................  
Family history of cancer? 
………………………………………………………………………………………………………
… 
Participant questionnaire  Participant initials: 
  Study participant number
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                             Ethics Committee Chairperson: Prof. Cleaton-Jones: 011 717 23 01 
 
 
INFORMATION SHEET FOR HEALTHY DONORS 
 
Good Day, 
 
We are Dr. A. Baeyens and student Flavia Francies from the Radiobiology research unit of the 
Department of Radiation Sciences, WITS Medical School. We are part of a collaborative study 
between WITS University and iThemba LABS to investigate the chromosomal instability and 
radiosensitivity in Fanconi Anaemia (FA) patients. Radiosensitivity is the susceptibility of cells 
to the harmful effects of ionizing radiation. This may be due to possible defects in DNA repair. 
 
We need healthy individuals, without FA, as a control group for our study. Therefore we invite 
you to consider participating in a research study. Your participation in this study is entirely 
voluntary. If you decide to take part in this study, you will be asked to sign this document to 
confirm that you understand the study. You will be given a copy to keep.  
 
Should you decide not to participate in the study or if you agree and then change your mind, there 
will be no implications for you. If you agree to participate, we kindly ask you to donate 20ml of 
blood once. This is not a lot of blood; it is only 4 teaspoons and will not harm you. We will use 
your blood sample to test the sensitivity to radiation.  
 
There is no direct benefit to you. But your participation in this study will contribute to the 
development of greater knowledge of radiosensitivity and diagnostics in FA patients. 
 
The research is completely confidential, which means that your name will not be recorded on any 
of our laboratory information. The consent forms will be locked away and only accessible by the 
researchers. We will require some personal details from you (your age, language, monthly 
income, do you have children, see questionnaire attached) and we also want to know if you are a 
smoker or if you have any other major illness, as this can have an influence on our tests. 
 
You are free to ask any questions about this study and discuss any worries you may have with the 
research staff. This study has been approved by the University of Witwatersrand, Human 
Research Ethics Committee. If you want any information regarding your rights as a research 
participant, or complaints regarding this research study, you may contact Prof. Cleaton-
Jones, Chairperson of the University of the Witwatersrand, Human Research Ethics Committee 
(HREC), which is an independent committee established to help protect the rights of research 
participants at (011) 717 2301 or peter.cleaton-jones@wits.ac.za. 
 
 
Thank you very much for your time 
 
Regards, 
Dr A. Baeyens, F. Francies
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Study participant number:                                                   Date of Birth: 
 Contact no:  
 
INFORMED CONSENT FOR HEALTHY DONORS: 
 
 
I hereby confirm that I have been informed about the nature, conduct, benefits of the study on 
radiosensitivity of Fanconi Anaemia patients. 
 
I have also received, read and understood the above written information regarding this study. 
 
I have no further questions and declare myself prepared to participate in the study. 
 
 
PARTICIPANT: 
 
 
Name (Print): 
 
 
Signature and date: 
 
 
 
STUDY STAFF CONDUCTING CONSENT DISCUSSION: 
 
 
Name (Print): 
 
 
Signature and date: 
 
 
 
WITNESS (IF APPLICABLE): 
 
 
Name (Print): 
 
 
Signature and date: 
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QUESTIONNAIRE FOR PARTICIPANTS 
Age:  .....................................................................................................................................  
Home language:  ....................................................................................................................  
Ethnic group:  ........................................................................................................................  
Place of birth:  .......................................................................................................................  
Do you have children? How many?  .......................................................................................  
Have you ever smoked? Do you currently smoke?  .................................................................  
Do you have any other major illness?  ....................................................................................  
Do you know your HIV status?  .............................................................................................  
Will you disclose your status to me? Are you positive or negative?  ........................................  
  Participant initials: 
  Study participant number: 
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INFORMED CONSENT FORM - PATIENTS 
 
Good Day, 
 
We are Dr A. Baeyens and students Flavia Francies and Olivia from the Radiobiology research unit of the 
Department of Radiation Sciences, WITS Medical School. We are part of a collaborative study between 
WITS University and iThemba LABS to investigate the radiosensitivity of breast cancer patients. 
Radiosensitivity explains how well the radiation works on your tumour and normal organs; it means an 
increased susceptibility of cells, tissues or organs to the harmful effects of ionizing radiation. Ionizing 
radiation is used in radiotherapy to treat cancer. Information on individual radiosensitivity helps to 
monitor the radiotherapy treatments. 
 
We invite you to consider participating in our research study. Your participation in this study is entirely 
voluntary. If you decide to take part in this study, you will be asked to sign this document to confirm that 
you understand the study. You will be given a copy to keep. Should you decide not to participate in the 
study or if you agree and then change your mind, there will be no implications for you and the best 
treatment available for you will still be given. 
 
If you agree to participate, we kindly ask you to donate 20ml of blood once. This is not a lot of blood; it is 
only 4 teaspoons and will not harm you. We will use your blood sample to test the sensitivity to radiation. 
We also kindly ask you if we can use a part of your tumour tissue that will be removed by the surgeon 
during your breast operation. This part of tumour tissue we want to use will be to investigate if there is a 
link between the radiosensitivity seen in blood and in the tumour. Both your blood sample and tissue 
sample will be used to unravel the underlying mechanism of radiosensitivity.  
 
There is no direct benefit to you. But your participation in this study will contribute to the development of 
greater knowledge of radiosensitivity and may help to ameliorate the radiotherapy treatments of breast 
cancer patients. 
 
The research is completely confidential, which means that your name will not be recorded on any of our 
laboratory information. The consent forms will be locked away and will only be accessible by the 
researchers. We will require some personal details from you (your age, language, monthly income, do you 
have children, see questionnaire attached) and we also want to know if you are a smoker or if you have 
any other major illness, as this can have an influence on our tests. 
 
You are free to ask any questions about this study and discuss any worries you may have with the 
research staff. This study has been approved by the University of Witwatersrand, Human Research Ethics 
Committee. If you want any information regarding your rights as a research participant, or complaints 
regarding this research study, you may contact Prof. Cleaton-Jones, Chairperson of the University of 
the Witwatersrand, Human Research Ethics Committee (HREC), which is an independent committee 
established to help protect the rights of research participants at (011) 717 2301 or peter.cleaton-
jones@wits.ac.za. 
 
Thank you very much for your time 
Regards, 
Dr. A. Baeyens, F. Francies and O. Herd
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Study participant number:                                                   Date of Birth: 
 Contact no:  
 
INFORMED CONSENT: 
 
 
I hereby confirm that I have been informed about the nature, conduct, benefits of the study on 
radiosensitivity of breast cancer patients. 
 
I have also received, read and understood the above written information regarding this study. 
 
I have no further questions and declare myself prepared to participate in the study. 
 
 
PARTICIPANT: 
 
 
Name (Print): 
 
 
Signature and date: 
 
 
 
STUDY STAFF CONDUCTING CONSENT DISCUSSION: 
 
 
Name (Print): 
 
 
Signature and date: 
 
 
 
WITNESS (IF APPLICABLE): 
 
 
Name (Print): 
 
 
Signature and date: 
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RADIOSENSITIVITY STUDY ON BREAST CANCER PATIENTS 
QUESTIONNAIRE FOR PARTICIPANTS 
Age:  .....................................................................................................................................  
Home language:  ....................................................................................................................  
Ethnic group:  ........................................................................................................................  
Place of birth:  .......................................................................................................................  
What is your monthly income: - None 
 - less than R500 
 - between R500 and R1000 
 - between R1000 and R2000 
 - between R2000 and R5000 
 - more than R5000 
 - unknown 
Do you have children? How many?  .......................................................................................  
What is your highest grade completed? - Primary school 
 - High school 
 - Tertiary school 
Have you ever smoked? Do you currently smoke?  .................................................................  
Do you have any other major illness?  ....................................................................................  
Do you know your HIV status?  .............................................................................................  
Will you disclose your status to me? Are you positive or negative?  ........................................  
Are you pre- or postmenopausal?  ..........................................................................................  
Family history of cancer? 
………………………………………………………………………………………………………
…….. 
Participant questionnaire  Participant initials: 
  Study participant number:
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INFORMED CONSENT FORM (GENETIC COUNSELLING AND MOLECULAR 
WORK): 
 
Good Day, 
 
We are Dr A. Baeyens and students Flavia Francies and Olivia from the Radiobiology research 
unit of the Department of Radiation Sciences, WITS Medical School. We are part of a 
collaborative study between WITS University and iThemba LABS to investigate the 
radiosensitivity of breast cancer patients. Radiosensitivity explains how well the radiation works 
on your tumour and normal organs; it means an increased susceptibility of cells, tissues or organs 
to the harmful effects of ionizing radiation. Ionizing radiation is used in radiotherapy to treat 
cancer. Information on individual radiosensitivity helps to monitor the radiotherapy treatments. 
 
We invite you to consider participating in our research study. Your participation in this study is 
entirely voluntary. If you decide to take part in this study, you will be asked to sign this 
document to confirm that you understand the study. You will be given a copy to keep.  
 
Should you decide not to participate in the study or if you agree and then change your mind, 
there will be no implications for you and the best treatment available for you will still be given. 
 
If you agree to participate, we kindly ask you to donate 20ml of blood once. This is not a lot of 
blood; it is only 4 teaspoons and will not harm you. We will use your blood sample to test the 
sensitivity to radiation. We also kindly ask you if we can use a part of your tumour tissue that 
will be removed by the surgeon during your breast operation. This part of tumour tissue we want 
to use will be to investigate if there is a link between the radiosensitivity seen in blood and in the 
tumour. Both your blood sample and tissue sample will be used to unravel the underlying 
mechanism of radiosensitivity. You will also receive genetic counselling which is the process of 
evaluating family/medical history to explain what genetic factors may play in risk to develop 
cancer for you and your family. The counselors will give you advice of the consequences of the 
breast cancer and will also provide assistance in making further medical decisions such as 
frequent screenings for breast cancer. 
 
There is no direct benefit to you. But your participation in this study will contribute to the 
development of greater knowledge of radiosensitivity and may help to ameliorate the 
radiotherapy treatments of breast cancer patients. 
 
The research is completely confidential, which means that your name will not be recorded on 
any of our laboratory information. The consent forms will be locked away and will only be 
accessible by the researchers. We will require some personal details from you (your age, 
language, monthly income, do you have children, see questionnaire attached) and we also want 
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to know if you are a smoker or if you have any other major illness, as this can have an influence 
on our tests. 
 
You are free to ask any questions about this study and discuss any worries you may have with 
the research staff. This study has been approved by the University of Witwatersrand, Human 
Research Ethics Committee. If you want any information regarding your rights as a research 
participant, or complaints regarding this research study, you may contact Prof. Cleaton-
Jones, Chairperson of the University of the Witwatersrand, Human Research Ethics Committee 
(HREC), which is an independent committee established to help protect the rights of research 
participants at (011) 717 2301 or peter.cleaton-jones@wits.ac.za. 
 
Thank you very much for your time. 
 
Regards, 
Dr. A. Baeyens, F. Francies and O. Herd
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Study participant number:                                                   Date of Birth: 
 Contact no:  
 
INFORMED CONSENT (GENETIC COUNSELLING AND MOLECULAR WORK): 
 
 
I hereby confirm that I have been informed about the nature, conduct, benefits of the molecular 
study on radiosensitivity of breast cancer patients. 
 
I have also received, read and understood the above written information regarding this study. 
 
I have no further questions and declare myself prepared to participate in the study. 
 
 
PARTICIPANT: 
 
 
Name (Print): 
 
 
Signature and date: 
 
 
 
STUDY STAFF CONDUCTING CONSENT DISCUSSION: 
 
 
Name (Print): 
 
 
Signature and date: 
 
 
 
WITNESS (IF APPLICABLE): 
 
 
Name (Print): 
 
 
Signature and date:
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INFORMATION SHEET FOR FA PATIENT AND PARENTS 
 
Good Day, 
 
We are Dr. A. Baeyens and student Flavia Francies from the Radiobiology research unit of the 
Department of Radiation Sciences, WITS Medical School. We are part of a collaborative study 
between WITS University and iThemba LABS to investigate the chromosomal instability and 
radiosensitivity in Fanconi Anemia (FA) patients. Radiosensitivity is the susceptibility of cells to 
the harmful effects of ionizing radiation. This may be due to possible defects in DNA repair. 
 
We invite you to consider the participation of your child in our research study. The participation 
of your child in this study is entirely voluntary. If you decide that your child can take part in this 
study, you will be asked to sign a document to confirm that you understand the study. You will 
be given a copy to keep.  
 
Should you decide not to grant permission for your child to participate in the study or if you 
agree and then change your mind, there will be no implications for you or your child. The best 
treatment available will still be provided for your child. If you agree to grant permission for your 
child to participate, we kindly ask your child to donate 20ml of blood once. This is not a lot of 
blood; it is only 4 teaspoons and will not harm your child. We will use your child’s blood sample 
to test the sensitivity to radiation. The blood sample will be used to unravel the underlying 
mechanism of radiosensitivity in FA patients.  
 
There is no direct benefit to you or your child. But your child’s participation in this study will 
contribute to the development of greater knowledge of radiosensitivity and diagnostics in FA 
patients. The research is completely confidential, which means that your child’s name will not be 
recorded on any of our laboratory information. The consent forms will be locked away and will 
only be accessible by the researchers. We also ask permission to view your child’s medical files 
if we need to obtain any further medical information that may be relevant to our study. 
 
You are free to ask any questions about this study and discuss any worries you may have with 
the research staff. This study has been approved by the University of Witwatersrand, Human 
Research Ethics Committee. If you want any information regarding your rights as a research 
participant, or complaints regarding this research study, you may contact Prof. Cleaton-
Jones, Chairperson of the University of the Witwatersrand, Human Research Ethics Committee 
(HREC), which is an independent committee established to help protect the rights of research 
participants at (011) 717 2301 or peter.cleaton-jones@wits.ac.za. 
 
Thank you very much for your time 
 
Regards, 
Dr. A. Baeyens and F. Francies
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Study participant number: 
 
ASSENT FORM 
 
We are Dr. A. Baeyens and student Flavia Francies from WITS Medical School. We are doing a 
study to figure out if some children have Fanconi Anaemia by doing some tests. We are asking 
you to take part in the research study because you have been visiting the hospital for treatment 
for Fanconi Anaemia. 
 
 For this study, we will need some blood. You may need a needle poke, so we can test some 
of your blood. The poke for the blood test can hurt a little.  
 We will also look at your hospital file to get some information about your treatment. 
 
This study will not help you or no bad thing will happen to you. But we hope that someday this 
study will help other children who have Fanconi Anaemia like you do.  
 
 If you want to take part in this study then you can just say “Yes” or “no” if you do not wish 
to take part. 
 You do not have to be in this study if you don’t want to. We will not mind if you do not 
want to participate.  
 If you do not want to participate, you will still receive the best treatment and the doctors 
will continue to take good care of you. 
 Your parents said it is ok for you to be in this study. But you can still decide if you want to 
take part or not.  
 You can stop being part of this study at any time. 
 You can ask any questions you want to ask. If you think of a question later, you or your 
parents can contact me. 
 
If you understand everything and you want to be part of this study then write your name below. I 
will write my name too. This is to show that we both spoke about the study and you want to be 
part of it. 
 
PARTICIPANT: 
 
Name: 
 
Signature and date: 
 
STUDY STAFFF OBTAINING ASSENT: 
 
Name: 
 
Signature and date: 
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         Contact no:  
 
INFORMED CONSENT FOR FA PATIENTS AND PARENTS: 
 
 
I hereby confirm that I have been informed about the nature, conduct, benefits of the study on 
chromosomal instability and radiosensitivity of Fanconi Anaemia patients. 
 
I have also received, read and understood the above written information regarding this study. 
 
I have no further questions and hereby grant permission for my child to participate in the study. 
 
 
PARENT OR LEGAL GUARDIAN OF PARTICIPANT: 
 
 
Name (Print):  
 
 
Signature and date: 
 
 
 
STUDY STAFF CONDUCTING CONSENT DISCUSSION: 
 
 
Name (Print): 
 
 
Signature and date: 
 
 
 
WITNESS (IF APPLICABLE): 
 
 
Name (Print): 
 
 
Signature and date:
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INFORMATION SHEET FOR PARENTS OF FA PATIENTS 
 
Good Day, 
 
We are Dr. A. Baeyens and student Flavia Francies from the Radiobiology research unit of the 
Department of Radiation Sciences, WITS Medical School. We are part of a collaborative study 
between WITS University and iThemba LABS to investigate the chromosomal instability and 
radiosensitivity in Fanconi Anaemia (FA) patients. Radiosensitivity is the susceptibility of cells 
to the harmful effects of ionizing radiation. This may be due to possible defects in DNA repair. 
 
We need individuals who are asymptomatic carriers of the FA gene. Therefore we invite you to 
consider participating in a research study. Your participation in this study is entirely voluntary. If 
you decide to take part in this study, you will be asked to sign this document to confirm that you 
understand the study. You will be given a copy to keep.  
 
Should you decide not to participate in the study or if you agree and then change your mind, there 
will be no implications for you. If you agree to participate, we kindly ask you to donate 20ml of 
blood once. This is not a lot of blood; it is only 4 teaspoons and will not harm you. We will use 
your blood sample to test the sensitivity to radiation. The blood sample will be used to unravel 
the underlying mechanism of radiosensitivity in asymptomatic carriers. 
 
There is no direct benefit to you. But your participation in this study will contribute to the 
development of greater knowledge of radiosensitivity and diagnostics in FA patients. 
 
The research is completely confidential, which means that your name will not be recorded on any 
of our laboratory information. The consent forms will be locked away and only accessible by the 
researchers. We will require some personal details from you (your age, language, monthly 
income, do you have children, see questionnaire attached) and we also want to know if you are a 
smoker or if you have any other major illness, as this can have an influence on our tests. 
 
You are free to ask any questions about this study and discuss any worries you may have with the 
research staff. This study has been approved by the University of Witwatersrand, Human 
Research Ethics Committee. If you want any information regarding your rights as a research 
participant, or complaints regarding this research study, you may contact Prof. Cleaton-
Jones, Chairperson of the University of the Witwatersrand, Human Research Ethics Committee 
(HREC), which is an independent committee established to help protect the rights of research 
participants at (011) 717 2301 or peter.cleaton-jones@wits.ac.za. 
 
Thank you very much for your time 
 
Regards, 
Dr. A. Baeyens, F. Francies
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Study participant number:                                                   Date of Birth: 
 Contact no:  
 
INFORMED CONSENT FOR PARENTS OF FA PATIENTS: 
 
 
I hereby confirm that I have been informed about the nature, conduct, benefits of the study on 
radiosensitivity of Fanconi Anaemia patients. 
 
I have also received, read and understood the above written information regarding this study. 
 
I have no further questions and declare myself prepared to participate in the study. 
 
 
PARTICIPANT: 
 
 
Name (Print): 
 
 
Signature and date: 
 
 
 
STUDY STAFF CONDUCTING CONSENT DISCUSSION: 
 
 
Name (Print): 
 
 
Signature and date: 
 
 
 
WITNESS (IF APPLICABLE): 
 
 
Name (Print): 
 
 
Signature and date: 
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QUESTIONNAIRE FOR PARTICIPANTS 
Age:  .....................................................................................................................................  
Home language:  ....................................................................................................................  
Ethnic group:  ........................................................................................................................  
Place of birth:  .......................................................................................................................  
Do you have children? How many?  .......................................................................................  
Have you ever smoked? Do you currently smoke?  .................................................................  
Do you have any other major illness?  ....................................................................................  
Do you know your HIV status? Are you prepared to tell us? ...................................................  
 
 
  Participant initials: 
  Study participant number:
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GENETIC TESTING PROTOCOL: INFORMATION SHEET FOR FA PATIENTS 
AND/OR PARENTS (CARRIERS) 
 
Good Day, 
 
We are Dr. A. Baeyens and student Flavia Francies from the Radiobiology Research Unit of the 
Department of Radiation Sciences, WITS Medical School. We are part of a collaborative study 
between WITS University and iThemba LABS to investigate the chromosomal instability and 
radiosensitivity in Fanconi Anaemia (FA) patients. Radiosensitivity is the susceptibility of cells 
to the harmful effects of ionizing radiation. This may be due to possible defects in DNA repair. 
 
What is the reason for the genetic testing protocol in this research study? 
FA is an inherited condition and results from two mutations (faults) in one of the many genes 
(FA genes) associated with the diagnosis.  It is mostly inherited in an autosomal recessive 
manner, meaning that both parents to a child with FA each carry one mutation in a disease-
causing FA gene.  There are over 15 FA genes. 
 
The mutation, in a FA gene, affects the structure of chromosomes in people with FA, and 
therefore also the stability and radiosensitivity.  Different types of tests (cytogenetic) are used to 
identify these unstable chromosomes.  These results are used for diagnosis.   
 
The aim of this study is to determine the usefulness of different cytogenetic tests to identify 
chromosomal instability and radiosensitivity in FA patients, and their carrier parents.  The 
underlying genetic cause for the diagnosis will be required to investigate if there is a link 
between the specific mutations and the cytogenetic test result. The purpose of the genetic testing 
protocol is therefore to identify the underlying genetic cause for the FA diagnosis in patients and 
their carrier parents.   
 
Is participation in the genetic testing voluntary? 
Your child has been selected for the genetic testing protocol because he/she has a confirmed 
clinical diagnosis of FA, and both the underlying disease-causing gene mutations have not been 
identified.  We invite you to consider the participation of your child and yourself in our research 
study. Your/your child’s participation in the genetic testing protocol is entirely voluntary. If you 
decide that your child can take part in this study, you will be asked to sign the consent form to 
confirm that you understand the purpose for genetic testing. You will be given a copy to keep.  
 
Should you decide not to grant permission for your child for genetic testing or if you agree and 
then change your mind, there will be no implications for you or your child. The best treatment 
available will still be provided for your child. 
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What is required of your child and/or you for genetic testing? 
Your child and/or you will be asked for a blood sample of 10ml.   This is not a lot of blood; it is 
equal to about 2 teaspoons and the test is not harmful. You will not need to fast before being 
tested.  Genetic testing will be performed to identify the presence of the mutations in one of 15 
FA genes.  The testing will be performed at the Diagnostic Molecular Laboratory, University of 
Ghent, Belgium.  
 
Prior to testing you will receive genetic counselling.  A family history will be drawn up and the 
counsellor will use this and medical history to discuss the diagnosis of FA in your family, 
including the genetic cause, symptoms, progression of the disease, inheritance and genetic 
testing.  You will receive an explanation of the types of genetic tests that will be performed, and 
the associated risks and limitations.  As parents, the results from your child’s test will be used to 
identify your underlying mutation.  The benefit of testing parents is to assist with interpretation 
of results. On occasion the test result may be inconclusive.   
 
Will you get the results from the genetic test? 
A genetic counsellor will communicate the result from your genetic test to you in a separate 
session.  The counsellors will advise you of the consequences of being a carrier of the FA gene 
and the impact on future medical decisions and other family members. 
 
How will your child and/or you benefit from the genetic testing protocol? 
The benefit of the genetic testing will be that the underlying genetic cause for FA in the family is 
identified and this can be used to determine the risk of FA for other family members and in 
future children.  This information can be used in the research project to identify links between 
gene mutations and cytogenetic test results.  This research will not benefit you or your child 
directly, but will contribute to the development of greater knowledge of radiosensitive and 
diagnostics in FA patients. 
 
Are there any risks associated with the genetic testing protocol? 
The risks associated with the genetic test are in the sampling, the testing procedure and 
interpretation of the result.  These will be discussed with you and are detailed in the consent 
form. 
 
Will you receive payment to participate? 
There is no payment for participation.   
 
You are free to ask any questions about this study and genetic testing protocol and discuss any 
worries you may have with the research staff.  This study has been approved by the University of 
the Witwatersrand, Human Research Ethics Committee. If you want any information regarding 
your rights as a research participant, or complaints regarding this research study, you may 
contact Prof. Cleaton-Jones, Chairperson of the University of the Witwatersrand, Human 
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Research Ethics Committee (HREC), which is an independent committee established to help 
protect the rights of research participants at (011) 717 2301 or peter.cleaton-jones@wits.ac.za. 
 
Thank you very much for your time. 
 
Regards, 
Dr. A. Baeyens, F. Francies
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         Contact no:  
 
INFORMED CONSENT FOR GENETIC TESTING - FA PATIENTS AND/OR PARENTS 
(CARRIER)  
 
I hereby confirm that I have been informed about the nature, conduct, benefits of the study on 
chromosomal instability and radiosensitivity of Fanconi Anaemia patients. 
 
I have also received, read and understood the above written information regarding the genetic 
testing protocol. 
 
I have been informed and understand the purpose of this genetic test.  A genetic counsellor has 
discussed with me the limitations, benefits and the risks of this testing, and I have had my 
questions answered. I understand the following: 
 The test procedure is specific to the diagnosis of Fanconi Anaemia and cannot determine 
the complete genetic makeup of an individual. 
 The method and risks of the sampling procedure(s) has/have been explained to me. 
 The test may reveal previously unrecognized biological relationships, such as non-
paternity. DNA tests also may reveal a genetic condition in another family member. 
 My/my child’s DNA sample may be used to interpret that of a family member.  
 The test result may not always be definitive, and rarely are they uninformative or difficult 
to interpret. 
 There is a small potential error for all test results (generally < 1%). In addition, the 
laboratory may have difficulties analyzing the sample and a second sample may be 
requested. 
 I may withdraw my consent at any time without giving a reason and without this affecting 
my/my child’s future medical care. However, the sample remains the property of the 
pathology laboratory unless otherwise instructed by me. 
 Medical confidentiality will be respected.  
 My/my child’s result will not be released to anyone except me through my referring 
doctor and genetic counsellor (if applicable). They will only be released to other medical 
professionals or other parties with my written consent. 
 By giving written informed consent, you are giving permission for the researchers to use 
the data collected or generated in this study for scientific purposes ONLY and that all data 
will be treated confidentially. You have the right to have any questions you may have 
about the research project answered by the project head or any of the researchers involved 
in the study. 
 The DNA sample will not be stored for future use and will be destroyed in accordance 
with the Wits Research rules 
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I give my consent to have a sample taken for genetic testing on the individual named below 
for the condition, Fanconi Anaemia: 
 
PARTICIPANT: 
 
Name: 
 
Date of Birth: 
 
 
IF PARTICIPANT IS A PARENT: 
 
Patient’s name: 
 
Relation to patient: 
 
 
PARENT OR LEGAL GUARDIAN OF PARTICIPANT: 
 
Name (Print):  
 
 
Signature and date: 
 
 
STUDY STAFF CONDUCTING CONSENT DISCUSSION: 
 
Name (Print): 
 
 
Signature and date: 
 
 
WITNESS (IF APPLICABLE): 
 
Name (Print): 
 
 
Signature and date: 
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